<SEC-DOCUMENT>0001493152-24-044891.txt : 20241113
<SEC-HEADER>0001493152-24-044891.hdr.sgml : 20241113
<ACCEPTANCE-DATETIME>20241112174003
ACCESSION NUMBER:		0001493152-24-044891
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20241107
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241113
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProPhase Labs, Inc.
		CENTRAL INDEX KEY:			0000868278
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				232577138
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21617
		FILM NUMBER:		241450144

	BUSINESS ADDRESS:	
		STREET 1:		711 STEWART AVE, SUITE 200
		STREET 2:		GARDEN CITY
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			11530
		BUSINESS PHONE:		(215) 345-0919

	MAIL ADDRESS:	
		STREET 1:		711 STEWART AVE, SUITE 200
		STREET 2:		GARDEN CITY
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			11530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QUIGLEY CORP
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:PRPH="http://prophaselabs.com/20241107">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_PRPH_prophaselabs.com_20241107 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20241107_20241107 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000868278 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000004" name="dei:EntityCentralIndexKey">0000868278</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="prph-20241107.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-11-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000868278</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-07</xbrli:startDate>
        <xbrli:endDate>2024-11-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20241107__20241107_zcUCk82QoIXk"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20241107__20241107_zeRU56z2uXM4"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">November 7, 2024</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20241107__20241107_zQrqVgj1i409"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000011" name="dei:EntityRegistrantName">PROPHASE
LABS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20241107__20241107_zEck1SZOIRHe"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityFileNumber_c20241107__20241107_zXF7McMeeUP4"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000013" name="dei:EntityFileNumber">000-21617</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20241107__20241107_zRJNsa8tC8B6"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000014" name="dei:EntityTaxIdentificationNumber">23-2577138</ix:nonNumeric></span>
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 66%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20241107__20241107_zZ5tC7BnaUk2"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000015" name="dei:EntityAddressAddressLine1">711
    Stewart Avenue</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20241107__20241107_zDY798jAWO27"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 200</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_902_edei--EntityAddressCityOrTown_c20241107__20241107_zkPCsorh4gR"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000017" name="dei:EntityAddressCityOrTown">Garden City</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
<span id="xdx_90F_edei--EntityAddressStateOrProvince_c20241107__20241107_zWTXjzkGp5U"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20241107__20241107_zPafYK78FsNd"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000019" name="dei:EntityAddressPostalZipCode">11530</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive
    offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_904_edei--CityAreaCode_c20241107__20241107_zqrX7BAEQwUd"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000020" name="dei:CityAreaCode">(215)</ix:nonNumeric></span> <span id="xdx_908_edei--LocalPhoneNumber_c20241107__20241107_zE6qWd8QvMGk"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000021" name="dei:LocalPhoneNumber">345-0919</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Not
Applicable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any
of the following provisions (<i>see</i> General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20241107__20241107_zpxy1g7XngH3"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SolicitingMaterial_c20241107__20241107_zhIlu7PwPYfb"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementTenderOffer_c20241107__20241107_z2rTkXdlW8k6"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20241107__20241107_zFzsmgrtmpVd"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Registered Pursuant to Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Each Exchange on Which Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20241107__20241107_zVUwPu5tsGg3"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value
    $0.0005</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20241107__20241107_zVZEEOxHT4l"><ix:nonNumeric contextRef="AsOf2024-11-07" id="Fact000027" name="dei:TradingSymbol">PRPH</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_909_edei--SecurityExchangeName_c20241107__20241107_znY67ksS6cgf"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20241107__20241107_z2vRvcHr9Kqa"><ix:nonNumeric contextRef="AsOf2024-11-07" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
1.01. Entry into a Material Definitive Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, ProPhase Labs, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;)
with ThinkEquity LLC (the &#8220;Representative&#8221;), as the representative of the underwriters named therein (the &#8220;Underwriters&#8221;),
relating to a firm commitment underwritten public offering (the &#8220;Offering&#8221;) of 4,795,500 shares, including 625,500 shares
sold upon full exercise of the underwriter&#8217;s option to purchase additional shares (the &#8220;Shares&#8221;) of the Company&#8217;s
common stock, par value $0.0005 per share (&#8220;Common Stock&#8221;) at a price to the public of $0.72 per Share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering is being made pursuant to the Company&#8217;s registration statement on Form S-3 (File No. 333-260848), previously filed with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 5, 2021 and declared effective on November 12, 2021, including
the prospectus contained therein, a prospectus supplement dated December 29, 2021, a preliminary prospectus supplement dated November
7, 2024, and a final prospectus supplement dated November 8, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal opinion, including the related consent, of Reed Smith LLP relating to the issuance and sale of the Shares to be issued in the Offering
is filed as Exhibit 5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the Offering occurred on November 12, 2024. The net proceeds to the Company from the sale of the Shares, after deducting the
underwriting discounts and commissions and other estimated offering expenses payable by the Company, is expected to be approximately
$3 million. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
closing of the Offering, the Company issued the Representative warrants (the &#8220;Representative&#8217;s Warrants&#8221;) as compensation
to purchase up to 5% of the aggregate number of shares of common stock. The Representative&#8217;s Warrants will be exercisable at a
per share exercise price of $0.90. The Representative&#8217;s Warrants are exercisable, in whole or in part, during the four and one-half
year period commencing 180 days from the commencement of sales of the shares of common stock in this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and covenants made by the Company. It also provides for customary
indemnification by each of the Company and the Underwriters, severally and not jointly, for losses or damages arising out of or in connection
with the Offering, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination
provisions. In addition, pursuant to the terms of the Underwriting Agreement, each of the Company&#8217;s directors, executive officers
and holders of 5% or more of the Shares have entered into &#8220;lock-up&#8221; agreements with the Representative that generally prohibit,
without the prior written consent of the Representative and subject to certain exceptions, the sale, transfer or other disposition of
securities of the Company for a period of 120 days (with respect to the Company&#8217;s directors and executive officers) and 90 days
(with respect to the holders of 5% or more of the Shares) from November 7, 2024. Further, pursuant to the terms of the Underwriting Agreement,
the Company has agreed for a period of three months from November 7, 2024, subject to certain exceptions, not to (i) offer, pledge, sell,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of the Company or any securities
convertible into or exercisable or exchangeable for shares of capital stock of the Company; (ii) file any registration statement; (iii)
complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank, or (iv) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital
stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Underwriting Agreement and the Representative Warrants do not purport to be complete and is qualified in
its entirety by reference to the copy of the Underwriting Agreement and the form of Representative Warrant, which are filed herewith
as Exhibits 1.1 and 4.1, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as
of specific dates, were solely for the benefit of the parties to the Underwriting Agreement and may be subject to limitations agreed
upon by the contracting parties. Accordingly, the Underwriting Agreement is incorporated herein by reference only to provide investors
with information regarding the terms of the Underwriting Agreement, and not to provide investors with any other factual information regarding
the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s periodic reports and other
filings with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Press
Releases</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, the Company issued a press release announcing the launch of the Offering. A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 12, 2024, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached
as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Underwriting Agreement dated November 7, 2024 between ProPhase Labs, Inc. and ThinkEquity LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Form
    of Representative Warrant (included in Exhibit 1.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Reed Smith LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Reed Smith LLP (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release issued by ProPhase Labs, Inc., dated November 7, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-2.htm">Press Release issued by ProPhase Labs, Inc., dated November 12, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ProPhase Labs, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Ted Karkus</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ted Karkus </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman of the Board and Chief Executive Officer</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
November 12, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LtoGRe2jpYpYRYqIr9FuJdhmyyb+HclbGlvEZWFZZr4ZIUKxpIWukeE4L3LYY9PWyiEUWCGjOaN3pKt1Av4WeNHWsTKue39gSp5Bz4wHcnTyQme9a4tlAnE8jKZDOYJoksgZ7DYi+OopmUqXaJxWNShTwo6pZY1O8atP2KsnGWpeXdUB2WoyPm4Q9fIbZBRL2NJdPYivFvI8FUHYTSCWTLfWu7KnQ/MlIaux8XW2p/8bfAAM70qX -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">Exhibit 1.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNDERWRITING
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">between</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPHASE
LABS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
LLC</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
Representative of the Several Underwriters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPHASE
LABS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>UNDERWRITING
AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
7, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
Representative of the several Underwriters named on Schedule 1 attached hereto</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17
State Street, 41<SUP>st</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, ProPhase Labs, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and
affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined)
as being subsidiaries or affiliates of Prophase Labs, Inc., the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;)
with ThinkEquity LLC (hereinafter referred to as &ldquo;you&rdquo; (including its correlatives) or the &ldquo;<B>Representative</B>&rdquo;),
and with the other underwriters named on <U>Schedule 1</U> hereto for which the Representative is acting as representative (the Representative
and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo; or, individually, an &ldquo;<B>Underwriter</B>&rdquo;)
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">1.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Purchase and Sale of Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1
<I><U>Firm Securities</U></I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.1
<U>Nature and Purchase of Firm Securities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the several Underwriters, an aggregate of 4,170,000 shares (the &ldquo;<B>Firm Shares</B>&rdquo;) of the
Company&rsquo;s common stock, par value $0.0005 per share (the &ldquo;<B>Common Stock</B>&rdquo;) and no pre-funded warrants (each, a
&ldquo;<B>Firm Pre-Funded Warrant</B>&rdquo;, and in the aggregate, the &ldquo;<B>Firm Pre-Funded Warrants</B>&rdquo;) to purchase one
share of Common Stock at an exercise price of $0.001 per share (the &ldquo;<B>Pre-Funded Warrant Shares</B>&rdquo;) until such time as
the Pre-Funded Warrants are exercised in full, subject to adjustment as provided in the Firm Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares and Firm Pre-Funded Warrants
set forth opposite their respective names on <U>Schedule 1</U> attached hereto and made a part hereof at a purchase price of $0.66960
per Firm Share (93.0% of the per Firm Share offering price), and $N/A per Firm Pre-Funded Warrant (93.0% of the per Firm Share offering
price less $0.001). The Firm Shares and the Firm Pre-Funded Warrants (collectively, the &ldquo;<B>Firm Securities</B>&rdquo;) are to
be offered initially to the public at the offering price set forth on the cover page of the Prospectus (as defined in Section 2.1.1 hereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.2
<U>Shares Payment and Delivery</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Delivery and payment for the Firm Securities shall be made at 10:00 a.m., Eastern time, on the Business Day (or, if the Firm Securities
are priced, as contemplated by Rule 15c6-1(c) under the Exchange Act, after 4:30 p.m., Eastern time, the second (2nd)) Business Day following
the date hereof, or at such earlier time as shall be agreed upon by the Representative and the Company, at the offices of Loeb &amp;
Loeb LLP, 345 Park Avenue, New York, NY 10154 (&ldquo;<B>Representative Counsel</B>&rdquo;), or at such other place (or remotely by facsimile
or other electronic transmission) as shall be agreed upon by the Representative and the Company. The hour and date of delivery and payment
for the Firm Securities is called the &ldquo;<B>Closing Date</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Payment for the Firm Securities shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order
of the Company upon delivery of the certificates (in form and substance satisfactory to the Underwriters) representing the Firm Securities
(or through the facilities of the Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;)) for the account of the Underwriters. The Firm
Securities shall be registered in such name or names and in such authorized denominations as the Representative may request in writing
at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Securities
except upon tender of payment by the Representative for all of the Firm Securities. The term &ldquo;<B>Business Day</B>&rdquo; means
any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law
to close in New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2
<U>Over-allotment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.1
<U>Option Securities</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Securities,
the Company hereby grants to the Underwriters an option to purchase up to 625,500 additional shares of Common Stock and/or additional
Pre-Funded Warrants to purchase up to N/A additional shares of Common Stock, together representing an aggregate of fifteen percent (15%)
of the Firm Securities sold in the offering, from the Company (the &ldquo;<B>Over-allotment Option</B>&rdquo;). Such 625,500 additional
shares of Common Stock, the net proceeds of which will be deposited with the Company&rsquo;s account, are hereinafter referred to as
&ldquo;<B>Option Shares</B>.&rdquo; Such additional Pre-Funded Warrants to purchase N/A shares of Common Stock, the net proceeds of which
will be deposited with the Company&rsquo;s account, are hereinafter referred to as &ldquo;<B>Option Pre-Funded Warrants</B>.&rdquo; The
Firm Pre-Funded Warrants and the Option Pre-Funded Warrants may be referred to herein collectively as the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;).
The Option Shares and Option Pre-Funded Warrants may be referred to herein collectively as the &ldquo;<B>Option Securities</B>.&rdquo;
The purchase price to be paid per Option Share and per Option Pre-Funded Warrant, respectively, shall be equal to the price per Firm
Share and per Firm Pre-Funded Warrant in Section 1.1.1 hereof. The Firm Securities, the Option Securities and the Underlying Shares (defined
below) are hereinafter referred to together as the &ldquo;<B>Public Securities.&rdquo;</B> The Public Securities shall be issued directly
by the Company and shall have the rights and privileges described in the Registration Statement, the Disclosure Package and the Prospectus.
The offering and sale of the Public Securities is hereinafter referred to as the &ldquo;<B>Offering</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.2
<U>Exercise of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative
as to all (at any time) or any part (from time to time) of the Option Securities within 45 days after the date hereof. The Underwriters
shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option. The Over-allotment
Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in
writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares and/or Option Pre-Funded
Warrants to be purchased and the date and time for delivery of and payment for the Option Shares and/or Option Pre-Funded Warrants (the
&ldquo;<B>Option Closing Date</B>&rdquo;), which shall not be later than one (1) full Business Day after the date of the notice or such
other time as shall be agreed upon by the Company and the Representative, at the offices of Representative Counselor at such other place
(including remotely by facsimile or other electronic transmission) as shall be agreed upon by the Company and the Representative. If
such delivery and payment for the Option Securities does not occur on the Closing Date, the Option Closing Date will be as set forth
in the notice. Upon exercise of the Over-allotment Option with respect to all or any portion of the Option Securities, subject to the
terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Option Securities
specified in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall purchase that portion of the total
number of Option Securities then being purchased as set forth in <U>Schedule 1</U> opposite the name of such Underwriter bears to the
total number of Firm Securities, subject, in each case, to such adjustments as the Representative, in its sole discretion, shall determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.3
<U>Payment and Delivery</U>. Payment for the Option Securities shall be made on the Option Closing Date by wire transfer in Federal (same
day) funds, payable to the order of the Company upon delivery to the Representative of certificates (in form and substance satisfactory
to the Underwriters) representing the Option Shares and/or Option Pre-Funded Warrants (or through the facilities of DTC) for the account
of the Underwriters. The Option Securities shall be registered in such name or names and in such authorized denominations as the Representative
may request in writing at least two (2) full Business Days prior to the Option Closing Date. The Company shall not be obligated to sell
or deliver the Option Securities except upon tender of payment by the Representative for applicable Option Securities. The Option Closing
Date may be simultaneous with, but not earlier than, the Closing Date; and in the event that such time and date are simultaneous with
the Closing Date, the term &ldquo;<B>Closing Date</B>&rdquo; shall refer to the time and date of delivery of the Firm Securities and
the Option Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3
<U>Representative&rsquo;s Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.1
<U>Purchase Warrants</U>. The Company hereby agrees to issue and sell to the Representative (and/or its designees) on the Closing Date
an option (&ldquo;<B>Representative&rsquo;s Warrant</B>&rdquo;) for the purchase of an aggregate number of shares of Common Stock representing
5% of the Firm Securities for an aggregate purchase price of $100.00 pursuant to the terms of the Representative&rsquo;s Warrant Agreement,
in the form attached hereto as Exhibit A (the &ldquo;<B>Representative&rsquo;s Warrant Agreement</B>&rdquo;). In the event that the Representative
exercises the Over-allotment Option, the Company agrees to issue and sell to the Representative (and/or its designees) on each Option
Closing Date an additional Representative&rsquo;s Warrant for the purchase of an aggregate number of shares of Common Stock equal to
5% of the Option Securities sold on such Option Closing Date. The Representative&rsquo;s Warrants shall be exercisable, in whole or in
part, commencing on the Closing Date and expiring on the five-year anniversary of the Closing Date at an initial exercise price per share
of Common Stock of $0.90, which is equal to 125% of the initial public offering price of the Firm Shares. The Representative&rsquo;s
Warrants and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the &ldquo;<B>Representative&rsquo;s
Securities</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3.2
<U>Delivery.</U> Delivery of the Representative&rsquo;s Warrant shall be made on the Closing Date and any Option Closing Date and shall
be issued in the name or names and in such authorized denominations as the Representative may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations and Warranties of the Company</U>.
The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below), as of the Closing Date and as of
the Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
<U>Filing of Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1
<U>Pursuant to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;)
a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-260848), including any related prospectus or prospectuses, for
the registration of the Public Securities under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), which
registration statement was prepared by the Company in all material respects in conformity with the requirements of the Securities Act
and the rules and regulations of the Commission under the Securities Act (the &ldquo;<B>Securities Act Regulations</B>&rdquo;) and contains
and will contain all material statements that are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations. Except as the context may otherwise require, such registration statement on file with the Commission at any given time,
including any amendments thereto to such time, exhibits and schedules thereto at such time, documents filed as a part thereof or incorporated
pursuant to Item 12 of Form S-3 under the Securities Act at such time and the documents and information otherwise deemed to be a part
thereof or included therein pursuant to Rule 430B of the Securities Act Regulations (the &ldquo;<B>Rule 430B Information</B>&rdquo;)
or otherwise pursuant to the Securities Act Regulations at such time, is referred to herein as the &ldquo;<B>Registration Statement</B>.&rdquo;
The Registration Statement at the time it originally became effective is referred to herein as the &ldquo;<B>Initial Registration Statement</B>.&rdquo;
If the Company files any registration statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the
term &ldquo;Registration Statement&rdquo; shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement
was declared effective by the Commission on November 12, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
prospectus in the form in which it was filed with the Commission in connection with the Initial Registration Statement is herein called
the &ldquo;<B>Base Prospectus</B>.&rdquo; Each preliminary prospectus supplement to the Base Prospectus (including the Base Prospectus
as so supplemented) that described the Public Securities and the Offering and omitted the Rule 430B Information and that was used prior
to the filing of the final prospectus supplement referred to in the following paragraph is herein called a &ldquo;<B>Preliminary Prospectus</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly
after the execution and delivery of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement
to the Base Prospectus relating to the Public Securities and the Offering in accordance with the provisions of Rule 430B and Rule 424(b)
of the Securities Act Regulations. Such final prospectus supplement (including the Base Prospectus as so supplemented), in the form filed
with the Commission pursuant to Rule 424(b) under the Securities Act is herein called the &ldquo;<B>Prospectus</B>.&rdquo; Any reference
herein to the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated
by reference therein pursuant to Item 12 of Form S-3 under the Securities Act as of the date of such prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Time</B>&rdquo; means 7:15 p.m., Eastern time, on November 7, 2024, on the data of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Disclosure
Package</B>&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Preliminary Prospectus
dated November 7, 2024 and the information included on <U>Schedule 2-A</U> hereto, all considered together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Free Writing Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act
Regulations (&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule
405 of the Securities Act Regulations) relating to the Public Securities that is (i) required to be filed with the Commission by the
Company, (ii) a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required
to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a
description of the Public Securities or of the Offering that does not reflect the final terms, in each case in the form filed or required
to be filed with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule
433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
General Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to
prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433) (the &ldquo;<B>Bona
Fide Electronic Roadshow</B>&rdquo;), as evidenced by its being specified in <U>Schedule 2-B</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Issuer
Limited Use Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2
<U>Pursuant to the Exchange Act</U>. The Company has filed with the Commission a Form 8-A (File No. 000-21617) providing for the registration
pursuant to Section 12(g) under the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), of the shares
of Common Stock. The registration of the shares of Common Stock and related Form 8-A have been declared effective under the Exchange
Act on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the shares of Common Stock under the Exchange Act, nor has the Company received any notification that the Commission is contemplating
terminating such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Stock Exchange Listing</U>. The shares of Common Stock have been approved for listing on The NASDAQ Capital Market (the &ldquo;<B>Exchange</B>&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, delisting the shares of Common Stock from the Exchange,
nor has the Company received any notification that the Exchange is contemplating terminating such listing except as described in the
Registration Statement, the Disclosure Package and the Prospectus. The Company has submitted the Listing of Additional Shares Notification
Form with the Exchange with respect to the Offering of the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3
<U>No Stop Orders, etc</U>. Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory authority has issued any
order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus or has instituted
or, to the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company has complied
with each request (if any) from the Commission for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4
<U>Disclosures in Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1
<U>Compliance with Securities Act and 10b-5 Representation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective (including each deemed effective
date with respect to the Underwriters pursuant to Rule 430B or otherwise under the Securities Act) complied and will comply in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. The conditions for use of Form S-3, set forth
in the General Instructions thereto, have been satisfied. Each Preliminary Prospectus and the Prospectus, at the time each was or will
be filed with the Commission, complied and will comply in all material respects with the requirements of the Securities Act and the Securities
Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the Prospectus
was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the
extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Neither the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or
at any Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits or
will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided,
however, that this representation and warranty shall not apply to the Underwriters&rsquo; Information (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), did not, does not and
will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and any Issuer Limited Use Free Writing Prospectus hereto
does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus or the Prospectus, and each
such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus as of the Applicable Time,
did not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation and
warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information furnished
to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Disclosure
Package or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided
by or on behalf of any Underwriter consists solely of the following statements concerning the Underwriters contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus (the &ldquo;<B>Underwriters&rsquo; Information</B>&rdquo;): (i) the second sentence of the subsection entitled
&ldquo;Discounts and Commissions&rdquo; related to concessions; (ii) the first three paragraphs under the subsection entitled &ldquo;Price
Stabilization, Short Positions and Penalty Bids&rdquo;; and (iii) the subsection entitled &ldquo;Electronic Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time
of any filing with the Commission pursuant to Rule 424(b), at the Closing Date or at any Option Closing Date (if any), included, includes
or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>,
that this representation and warranty shall not apply to the Underwriters&rsquo; Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The documents incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, when they became effective
or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or
the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and none of such documents contained any
untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated
by reference in the Registration Statement, the Disclosure Package and the Prospectus, when such documents become effective or are filed
with the Commission, as the case may be, will conform in all material respects to the requirements of the Securities Act or the Exchange
Act, as applicable, and the rules and regulations of the Commission thereunder, and will not contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2
<U>Disclosure of Agreements</U>. The agreements and documents described in the Registration Statement, the Disclosure Package and the
Prospectus conform in all material respects to the descriptions thereof contained or incorporated by reference therein and there are
no agreements or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration
Statement, the Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement or
to be incorporated by reference in the Registration Statement, the Disclosure Package or the Prospectus, that have not been so described
or filed or incorporated by reference. Each agreement or other instrument (however characterized or described) to which the Company is
a party or by which it is or may be bound or affected and (i) that is referred to or incorporated by reference in the Registration Statement,
the Disclosure Package and the Prospectus, or (ii) is material to the Company&rsquo;s business, has been duly authorized and validly
executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company&rsquo;s
knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency,
reorganization or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution
provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive
and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, none of such agreements
or instruments has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in
default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default thereunder. To the Company&rsquo;s knowledge, performance by the Company of the material provisions
of such agreements or instruments will not result in a violation of any existing applicable law, rule, regulation, judgment, order or
decree of any governmental or regulatory agency, body, authority, or court, domestic or foreign, having jurisdiction over the Company
or any of its assets or businesses (each, a &ldquo;<B>Governmental Entity</B>&rdquo;), including, without limitation, those relating
to environmental laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3
<U>Prior Securities Transactions</U>. Since January 18, 2021, no securities of the Company have been sold by the Company or by or on
behalf of, or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as
disclosed in the Registration Statement, the Disclosure Package and the Preliminary Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.4
<U>Regulations</U>. The disclosures in the Registration Statement, the Disclosure Package and the Prospectus concerning the effects of
federal, state, local and all foreign regulation on the Offering and the Company&rsquo;s business as currently contemplated are correct
in all material respects and no other such regulations are required to be disclosed in the Registration Statement, the Disclosure Package
and the Prospectus that are not so disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.5
<U>No Other Distribution of Offering Materials</U>. The Company has not, directly or indirectly, distributed and will not distribute
any offering material in connection with the Offering other than any Preliminary Prospectus, the Disclosure Package, the Prospectus and
other materials, if any, permitted under the Securities Act and consistent with Section 3.2 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5
<U>Changes After Dates in Registration Statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.1
<U>No Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Disclosure
Package and the Prospectus, except as otherwise specifically stated therein: (i) there has been no material adverse change in the financial
position or results of operations of the Company, nor any change or development that, singularly or in the aggregate, would involve a
material adverse change or a prospective material adverse change, in or affecting the condition (financial or otherwise), results of
operations, stockholder&rsquo;s equity, business, general affairs, management, assets, properties or prospects of the Company (a &ldquo;<B>Material
Adverse Change</B>&rdquo;); (ii) there have been no material transactions entered into by the Company, other than as contemplated pursuant
to this Agreement; (iii) no officer or director of the Company has resigned from any position with the Company; and (iv) the Company
has not sustained any material loss or interference with its business or properties from fire, explosion, flood, earthquake, hurricane,
accident or other calamity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5.2
<U>Recent Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration
Statement, the Disclosure Package and the Prospectus, the Company has not: (i) issued any securities or incurred any liability or obligation,
direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect to its
capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6
<U>Disclosures in Commission Filings</U>. Since January 1, 2021, (i) none of the Company&rsquo;s filings with the Commission contained
any untrue statement of a material fact or omitted to state any material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; and (ii) the Company has made all filings with the Commission
required under the Exchange Act and the rules and regulations of the Commission promulgated thereunder (the &ldquo;<B>Exchange Act Regulations</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7
<U>Independent Accountants</U>. To the knowledge of the Company, Morison Cogen LLP (&ldquo;<B>Morison Cogen</B>&rdquo;), whose report
is filed with the Commission and included or incorporated by reference in the Registration Statement, the Disclosure Package and the
Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations
and the Public Company Accounting Oversight Board. Morison Cogen may be referred to herein as the &ldquo;<B>Prior Auditor.</B>&rdquo;
To the knowledge of the Company, Fruci &amp; Associates II, PLLC ( <B>the &ldquo;Auditor&rdquo;</B>&ldquo;), who serves as the Company&rsquo;s
current auditor is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations
and the Public Company Accounting Oversight Board. Neither the Prior Auditor nor the Auditor has, during the periods covered by the financial
statements included or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus, provided to
the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8
<U>Financial Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules included or incorporated
by reference in the Registration Statement, the Disclosure Package and the Prospectus, fairly present in all material respects the financial
position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial statements
have been prepared in conformity with U.S. generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;), consistently applied
throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that
are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules included
or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated
therein. No other historical or pro forma financial statements or supporting schedules are required to be included or incorporated by
reference in the Registration Statement, the Disclosure Package or the Prospectus by the Securities Act or the Securities Act Regulations.
The pro forma financial information and the related notes, if any, included or incorporated by reference in the Registration Statement,
the Disclosure Package and the Prospectus have been properly compiled and prepared in accordance with the applicable requirements of
the Securities Act, the Securities Act Regulations, the Exchange Act or the Exchange Act Regulations and present fairly in all material
respects the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein
are appropriate to give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration
Statement, the Disclosure Package or the Prospectus, or incorporated or deemed incorporated by reference therein, regarding &ldquo;non-GAAP
financial measures&rdquo; (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation G
of the Exchange Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement,
the Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations (including
contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material
current or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of operations, liquidity,
capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus, (a) neither the Company nor any of its direct and indirect subsidiaries, including each entity
disclosed or described in the Registration Statement, the Disclosure Package and the Prospectus as being a subsidiary of the Company
(each, a &ldquo;<B>Subsidiary</B>&rdquo; and, collectively, the &ldquo;<B>Subsidiaries</B>&rdquo;), has incurred any material liabilities
or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the
Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has
not been any change in the capital stock of the Company or any of its Subsidiaries, or, other than in the course of business or any grants
under any stock compensation plan, and (d) there has not been any Material Adverse Change in the Company&rsquo;s long-term or short-term
debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9
<U>Authorized Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Registration Statement, the Disclosure
Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions
stated in the Registration Statement, the Disclosure Package and the Prospectus, the Company will have on the Closing Date the adjusted
stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Disclosure Package
and the Prospectus, on the date hereof, as of the Applicable Time and on the Closing Date and any Option Closing Date, there will be
no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares of Common Stock of the
Company or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts or commitments to issue
or sell shares of Common Stock or any such options, warrants, rights or convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10
<U>Valid Issuance of Securities, etc</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10.1
<U>Outstanding Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by
this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights
of rescission, rights of first refusal or rights of participation or similar rights with respect thereto or put rights, and are not subject
to personal liability by reason of being such holders; and none of such securities were issued in violation of the preemptive rights,
rights of first refusal or rights of participation or similar rights of any holders of any security of the Company or similar contractual
rights granted by the Company. The authorized shares of Common Stock conform in all material respects to all statements relating thereto
contained in the Registration Statement, the Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of
Common Stock were at all relevant times either registered under the Securities Act and the applicable state securities or &ldquo;blue
sky&rdquo; laws or, based in part on the representations and warranties of the purchasers of such Shares, exempt from such registration
requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10.2
<U>Securities Sold Pursuant to this Agreement</U>. The Public Securities and the Representative&rsquo;s Securities have been duly authorized
for issuance and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not
and will not be subject to personal liability by reason of being such holders; the Public Securities and the Representative&rsquo;s Securities
are not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights
granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public Securities
the Representative&rsquo;s Securities have been duly and validly taken. The Public Securities the Representative&rsquo;s Securities conform
in all material respects to all statements with respect thereto contained in the Registration Statement, the Disclosure Package and the
Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Pre-Funded Warrants has been duly
and validly taken; the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and the Representative&rsquo;s Warrant
(the &ldquo;Underlying Shares&rdquo;) have been duly authorized and reserved for issuance by all necessary corporate action on the part
of the Company and when paid for and issued, such Underlying Shares will be validly issued, fully paid and non-assessable; the holders
thereof are not and will not be subject to personal liability by reason of being such holders; and such shares of Common Stock are not
and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11
<U>Registration Rights of Third Parties</U>. No holders of any securities of the Company or any rights exercisable for or convertible
or exchangeable into securities of the Company have the right to require the Company to register any such securities of the Company under
the Securities Act or to include any such securities in a registration statement to be filed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12
<U>Validity and Binding Effect of Agreements</U>. This Agreement. the Pre-Funded Warrants and the Representative&rsquo;s Warrant Agreement
has been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements
of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be
limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally; (ii) as enforceability
of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.13
<U>No Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Pre-Funded Warrants, the Representative&rsquo;s
Warrant Agreement and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and
the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse
of time or both: (i) result in a material breach of, or constitute a material default under, or result in the creation, modification,
termination or imposition of any lien, charge, mortgage, pledge, security, interest, claim, equity, trust or other encumbrance, preferential
arrangement, or restriction of any kind whatsoever upon any portion of any property or assets of the Company pursuant to the terms of
any indenture, mortgage, deed of trust, note, lease, loan agreement or any other agreement or instrument, license or permit, to which
the Company is a party or as to which any of its properties or any of its assets are bound; (ii) result in any violation of the provisions
of the Company&rsquo;s Certificate of Incorporation (as the same may be amended or restated from time to time, the &ldquo;<B>Charter</B>&rdquo;)
or the by-laws of the Company (as the same may be amended or restated from time to time); or (iii) result in a material violation of
any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof (including,
without limitation, those promulgated by the Food and Drug Administration of the U.S. Department of Health and Human Services (the &ldquo;<B>FDA</B>&rdquo;)
or by any foreign, federal, state or local regulatory authority performing functions similar to those performed by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14
<U>No Defaults; Violations</U>. No material default by the Company exists in the due performance and observance of any term, covenant
or condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement
or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party
or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is not in violation
of any term or provision of its Charter or by-laws, or in material violation of any franchise, license, permit, applicable law, rule,
regulation, judgment or decree of any Governmental Entity applicable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15
<U>Corporate Power; Licenses; Consents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15.1
<U>Conduct of Business</U>. The Company has all requisite corporate power and authority, and has all necessary consents, authorizations,
approvals, registrations, orders, licenses, certificates, qualifications, registrations and permits of and from all governmental regulatory
officials and bodies that it needs as of the date hereof to conduct its business purpose as described in the Registration Statement,
the Disclosure Package and the Prospectus; except where the failure to be so qualified or to be in good standing would not result in
a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.15.2
<U>Transactions Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement, the Pre-Funded
Warrants and the Representative&rsquo;s Warrant Agreement and to carry out the provisions and conditions hereof, and all consents, authorizations,
approvals, registrations, orders, licenses, certificates, qualifications and permits required in connection therewith have been obtained.
No consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance,
sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this Agreement, the
Pre-Funded Warrants and the Representative&rsquo;s Warrant Agreement and as contemplated by the Registration Statement, the Disclosure
Package and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations of the
Exchange and the Financial Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.16
<U>D&amp;O Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the questionnaires (the &ldquo;<B>Questionnaires</B>&rdquo;)
completed by each of the Company&rsquo;s directors and officers immediately prior to the Offering (the &ldquo;<B>Insiders</B>&rdquo;),
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal stockholders as described in the
Registration Statement, the Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in Section 2.27 below)
provided to the Underwriters, is true and correct in all material respects and the Company has not become aware of any information which
would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17
<U>Litigation; Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or
governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s
knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the Disclosure Package and the
Prospectus, or in connection with the Company&rsquo;s listing application for the listing of the Public Securities on the Exchange, and
which is required to be disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18
<U>Good Standing</U>. The Company has been duly incorporated and is validly existing as a corporation and is in good standing under the
laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing in each other jurisdiction
in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to be so
qualified or in good standing, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse
Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.19
<U>Insurance</U>. The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering
such risks which the Company believes are adequate, including, but not limited to, directors and officers insurance coverage at least
equal to $5,000,000 and all such insurance is in full force and effect. The Company has no reason to believe that it will not be able
(i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions
as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse
Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20
<U>Transactions Affecting Disclosure to FINRA</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20.1
<U>Finder&rsquo;s Fees</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, there are no
claims, payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee
by the Company or any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements or understandings
of the Company or, to the Company&rsquo;s knowledge, any of its stockholders that may affect the Underwriters&rsquo; compensation, as
determined by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20.2
<U>Payments Within 12 Months</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company
has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s fee, consulting
fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or
provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct or indirect affiliation or
association with any FINRA member, within the twelve months prior to the date of this Agreement, other than the payment to the Underwriters
as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20.3
<U>Use of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20.4
<U>FINRA Affiliation</U>. There is no (i) officer or director of the Company, (ii) beneficial owner of 10% or more of any class of the
Company&rsquo;s securities or (iii) beneficial owner of the Company&rsquo;s unregistered equity securities which were acquired during
the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person of a FINRA
member participating in the Offering (as determined in accordance with the rules and regulations of FINRA). Except as disclosed in the
Registration Statement, the Disclosure Package and the Prospectus, the Company (i) does not have any material lending or other relationship
with any bank or lending affiliate of any Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Public
Securities to repay any outstanding debt owed to any affiliate of any Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.20.5
<U>Information</U>. All information provided by the Company in its, and to the Company&rsquo;s knowledge, all information provided by
the Company&rsquo;s officers and directors in their FINRA questionnaire to Representative Counsel specifically for use by Representative
Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete in all
material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.21
<U>Foreign Corrupt Practices Act</U>. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers
in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of
any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office (domestic
or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist it in connection
with any actual or proposed transaction) that (a) might subject the Company to any damage or penalty in any civil, criminal or governmental
litigation or proceeding, (b) if not given in the past, might have had a Material Adverse Change; or (c) if not continued in the future,
might adversely affect the assets, business, operations or prospects of the Company, or (d) violated or is in violation of any provision
of the Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;FCPA&rdquo;) or any applicable non-U.S. anti-bribery statute or
regulation; (i) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment; or (ii) received notice of any
investigation, proceeding or inquiry by any Governmental Entity regarding any of the matters in caused (i) or (ii) above; and the Company
has conducted its business in compliance with the FCPA in all material respects, and has instituted and maintains policies and procedures
designed to ensure and which are reasonable expected to ensure, that eh Company will continue to comply in all material respects with
the FCPA. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company
to comply in all material respects with FCPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.22
<U>Compliance with OFAC</U>. None of the Company nor any of its Subsidiaries or, to the Company&rsquo;s knowledge, any director, officer,
agent, employee or affiliate of the Company or any of its Subsidiaries or any other person acting on behalf of the Company and its Subsidiaries,
is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
(&ldquo;<B>OFAC</B>&rdquo;), and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute
or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing
the activities of any person currently subject to any U.S. sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.23
<U>Forward-Looking Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) contained in either the Registration Statement, Disclosure Package or Prospectus has been made or reaffirmed
without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.24
<U>Money Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;<B>Money Laundering Laws</B>&rdquo;);
and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws
is pending or, to the best knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.25
<U>Regulatory</U>. (a) All preclinical studies and clinical trials conducted by or on behalf of the Company that are material to the
Company and its Subsidiaries, taken as a whole are or have been adequately described in the Registration Statement, the Disclosure Package
and the Prospectus in all material respects. The preclinical studies and clinical trials conducted by or on behalf of the Company and
its Subsidiaries that are described in the Registration Statement, the Disclosure Package and the Prospectus or the results of which
are referred to in the Registration Statement, the Disclosure Package and the Prospectus were and, if still ongoing, to the Company&rsquo;s
knowledge, are being conducted in material compliance with all laws and regulations applicable thereto in the jurisdictions in which
they are being conducted and in material compliance with all laws and regulations applicable to preclinical studies and clinical trials
from which data will be submitted to support marketing approval. The descriptions in the Registration Statement, the Disclosure Package
and the Prospectus of the results of such studies are accurate and complete in all material respects and fairly present the data derived
from such studies, and the Company has no knowledge of, or reason to believe that, any large well-controlled clinical study the aggregate
results of which are inconsistent with or otherwise call into question the results of any clinical study conducted by or on behalf of
the Company that are described in the Registration Statement, the Disclosure Package and the Prospectus or the results of which are referred
to in the Registration Statement, the Disclosure Package and the Prospectus. Except as disclosed in the Registration Statement, the Disclosure
Package and the Prospectus, the Company has not received any written notices or statements from the FDA, the European Medicines Agency
(&ldquo;<B>EMA</B>&rdquo;) or any other governmental agency or authority imposing, requiring, requesting or suggesting a clinical hold,
termination, suspension or material modification for or of any preclinical studies and clinical trials that are described in the Registration
Statement, the Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Disclosure
Package and the Prospectus. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company
has not received any written notices or statements from the FDA, the EMA or any other governmental agency, and otherwise has no knowledge
of, or reason to believe that, (i) any investigational new drug application for any potential product of the Company is or has been rejected
or placed on clinical hold; and (ii) any license, approval, permit or authorization to conduct any clinical trial of any potential product
of the Company has been, will be or may be suspended, revoked, modified or limited. Neither Company nor any of its subsidiaries has failed
to file any material filing, declaration, listing, registration, notification, report or submission that is required to be so filed with
(i) the FDA or (ii), to the Company&rsquo;s knowledge, any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA, any filing, declaration, listing, registration, report or submission that is required
to be so filed. All such filings were in material compliance with applicable laws when filed and no deficiencies have been asserted by
any applicable regulatory authority (including, without limitation, the FDA or any foreign, federal, state or local governmental or regulatory
authority performing functions similar to those performed by the FDA) with respect to any such filings, declarations, listings, registrations,
reports or submissions. To the knowledge of the Company, there are no facts that would be reasonably likely to result in any warning,
untitled or notice of violation letter or Form FDA-483 from the FDA. The Company is not aware of any studies, tests or trials the results
of which the Company believes reasonably call into question (i) the study, test or trial results of any of its products, (ii) the efficacy
or safety of any of its products or (iii) any of the Company&rsquo;s filings with any Governmental Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Regulatory Filings and Permits</U>. The Company and its Subsidiaries have such permits, licenses, clearances, registrations, listings,
exemptions, patents, franchises, certificates of need and other approvals, consents and other authorizations (&ldquo;<B>Permits</B>&rdquo;)
issued by the appropriate domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the
business of the Company in compliance with all applicable laws, including, without limitation, any Investigational New Drug Application
(an &ldquo;<B>IND</B>&rdquo;), Investigational Device Exemption (&ldquo;<B>IDE</B>&rdquo;), Biologics License Application (&ldquo;<B>BLA</B>&rdquo;)
and/or New Drug Application (an &ldquo;<B>NDA</B>&rdquo;), as required by FDA, the Drug Enforcement Administration (the &ldquo;<B>DEA</B>&rdquo;),
or any other Permits issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of
pharmaceuticals such as those being developed by the Company and its Subsidiaries (collectively, the &ldquo;<B>Regulatory Permits</B>&rdquo;),
except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect;
the Company is in compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits
are valid and in full force and effect; the Company has not received any notice of proceedings relating to the revocation, termination,
modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable
decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect. The Company has not failed to submit
to the FDA any IND, BLA or NDA necessary to conduct the business of the Company, any such filings that were required to be made were
in material compliance with applicable laws when filed, and no material deficiencies have been asserted by the FDA with respect to any
such filings or submissions that were made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Compliance with Health Care Laws</U>. Each of the Company and its Subsidiaries is, and at all times in the past five (5) years has
been, in compliance in all material respects with all applicable Health Care Laws, and has not engaged in activities which are, as applicable,
cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or
federal health care program. For purposes of this Agreement, &ldquo;<B>Health Care Laws</B>&rdquo; means: (i) the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.), the Public Health Service Act (42 U.S.C. &sect;&sect; 201 et seq.), and the regulations
promulgated thereunder; (ii) all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws,
including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Physician Payment Sunshine Act
(42 U.S.C. &sect; 1320a-7h), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C.
&sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and
287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;)
(42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), the civil monetary penalties law (42 U.S.C. &sect;
1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.),
the new drug cap and negotiation requirements of the Inflation Reduction Act of 2022 (42 U.S.C. &sect; 1395w, 42 U.S.C. &sect; 1320f),
and the regulations promulgated pursuant to such statutes; (iii) Medicare (Title XVIII of the Social Security Act); (iv) Medicaid (Title
XIX of the Social Security Act); (v) the Controlled Substances Act (21 U.S.C. &sect;&sect; 801 et seq.) and the regulations promulgated
thereunder; (vi) the Clinical Laboratory Improvement Amendments of 1998 (42 U.S.C. &sect; 263a) and state and local laboratory laws;
and (vii) any and all other applicable health care laws and regulations. Neither the Company nor, to the knowledge of the Company, any
subsidiary has received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is
in material violation of any Health Care Laws, and, to the Company&rsquo;s knowledge, no such claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action is threatened. Neither the Company nor, to the knowledge of the Company, any
subsidiary is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution
agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any
governmental or regulatory authority. Additionally, neither the Company, its Subsidiaries nor any of its respective employees, officers
or directors are, or in the last five (5) years has been, excluded, suspended or debarred from participation in any U.S. federal health
care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding,
or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.26
<U>Officers&rsquo; Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to the Representative
or to Representative Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters covered
thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.27
<U>Lock-Up Agreements. Schedule 3</U> hereto contains a complete and accurate list of the Company&rsquo;s officers, directors and each
owner of 5% or more of the Company&rsquo;s outstanding shares of Common Stock (or securities convertible into or exercisable for shares
of Common Stock) (collectively, the &ldquo;<B>Lock-Up Parties</B>&rdquo;). The Company has caused each of the Lock-Up Parties to deliver
to the Representative an executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit B</U> (the <B>&ldquo;Lock-Up Agreement</B>&rdquo;),
prior to the execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.28
<U>Subsidiaries</U>. All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the
place of organization or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease
of property or the conduct of business requires such qualification, except where the failure to qualify would not have a Material Adverse
Change. The Company&rsquo;s ownership and control of each Subsidiary is as described in the Registration Statement, the Disclosure Package
and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29
<U>Related Party Transactions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29.1
<U>Business Relationships</U>. There are no business relationships or related party transactions involving the Company or any other person
required to be described in the Registration Statement, the Disclosure Package and the Prospectus that have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29.2
<U>No Relationships with Customers and Suppliers</U>. No relationship, direct or indirect, exists between or among the Company on the
one hand, and the directors, officers, 5% or greater stockholders, customers or suppliers of the Company or any of the Company&rsquo;s
affiliates on the other hand, which is required to be described in the Disclosure Package and the Prospectus or a document incorporated
by reference therein and which is not so described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.29.3
<U>No Unconsolidated Entities</U>. There are no transactions, arrangements or other relationships between and/or among the Company, any
of its affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated entity, including, but not limited
to, any structure finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company&rsquo;s
liquidity or the availability of or requirements for its capital resources required to be described in the Disclosure Package and the
Prospectus or a document incorporated by reference therein which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.30
<U>Board of Directors</U>. The Board of Directors of the Company is comprised of the persons disclosed in the Registration Statement,
the Disclosure Package and the Prospectus. The qualifications of the persons serving as board members and the overall composition of
the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder
(the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) applicable to the Company and the listing rules of the Exchange. At least one member of
the Audit Committee of the Board of Directors of the Company qualifies as an &ldquo;audit committee financial expert,&rdquo; as such
term is defined under Regulation S-K and the listing rules of the Exchange. In addition, at least a majority of the persons serving on
the Board of Directors qualify as &ldquo;independent,&rdquo; as defined under the listing rules of the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31
<U>Sarbanes-Oxley Compliance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31.1
<U>Disclosure Controls</U>. The Company has developed and currently maintains disclosure controls and procedures that will comply with
Rule 13a-15 or 15d-15 under the Exchange Act Regulations, and such controls and procedures are effective to ensure that all material
information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company&rsquo;s
Exchange Act filings and other public disclosure documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31.2
<U>Compliance</U>. The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions
of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure
the Company&rsquo;s future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material
provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.32
<U>Accounting Controls</U>. The Company and its Subsidiaries maintain systems of &ldquo;internal control over financial reporting&rdquo;
(as defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and
have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons
performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset
accountability; (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company
is not aware of any material weaknesses in its internal controls. The Company&rsquo;s Prior Auditor, Auditor and the Audit Committee
of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design
or operation of internal controls over financial reporting which are known to the Company&rsquo;s management and that have adversely
affected or are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial
information; and (ii) any fraud known to the Company&rsquo;s management, whether or not material, that involves management or other employees
who have a significant role in the Company&rsquo;s internal controls over financial reporting. Since the date of the latest audited financial
statements included in the Disclosure Package, there has been no change in the Company&rsquo;s internal control over financial reporting
that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting,
except as described in the Registration Statement, the Disclosure Package and the Prospectus..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.33
<U>No Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds
thereof as described in the Registration Statement, the Disclosure Package and the Prospectus, will not be, required to register as an
&ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.34
<U>No Labor Disputes</U>. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of
the Company, is imminent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.35
<U>Intellectual Property Rights</U>. The Company and each of its Subsidiaries owns or possesses or has valid, to the Company&rsquo;s
knowledge, rights to use all material patents, patent applications, trademarks, service marks, trade names, trademark registrations,
service mark registrations, copyrights, trade secrets or know-how and licenses (collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;)
necessary for the conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration
Statement, the Disclosure Package and the Prospectus, except where the failure to own or possess such rights would not, individually
or in the aggregate, result in a Material Adverse Change. To the knowledge of the Company, no conduct by the Company or any of its Subsidiaries
necessary for the conduct of its business as currently carried on and as described in the Registration Statement, the Disclosure Package
and the Prospectus will involve or give rise to any infringement of, or license or similar fees (other than license or similar fees described
or contemplated in the Registration Statement, the Disclosure Package and the Prospectus) for any Intellectual Property Rights of others.
Neither the Company nor any of its Subsidiaries has received any notice alleging any infringement of, license or similar fees for, or
conflict with, any asserted Intellectual Property Rights of others. To the knowledge of the Company, there is no infringement, misappropriation
or violation by third parties of any of the Intellectual Property Rights owned by, or licensed to, the Company. There is no pending or,
to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the rights of the Company in or to
any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim.
The Intellectual Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed
to the Company have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is
no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity, inventorship,
or scope of any such Intellectual Property Rights that would reasonably be expected to result in a Material Adverse Change, and the Company
is unaware of any facts which would form a reasonable basis for any such claim. There is no pending, or to the Company&rsquo;s knowledge,
threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual
Property Rights or other proprietary rights of others, the Company has not received any written notice of such claim and the Company
is unaware of any other facts which would form a reasonable basis for any such claim. To the Company&rsquo;s knowledge, no employee of
the Company is in or has ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement,
invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant
to or with a former employer where the basis of such violation relates to such employee&rsquo;s employment with the Company, or actions
undertaken by the employee while employed with the Company and could reasonably be expected to result, individually or in the aggregate,
in a Material Adverse Change. To the Company&rsquo;s knowledge, all material technical information developed by and belonging to the
Company which has not been patented or disclosed in a filed patent application has been kept confidential. The Company is not a party
to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any other person or entity that
are required to be set forth in the Registration Statement, the Disclosure Package and the Prospectus and are not described therein.
The Registration Statement, the Disclosure Package and the Prospectus contain in all material respects the same description of the matters
set forth in the preceding sentence. None of the technology employed by the Company has been obtained or is being used by the Company
in violation of any contractual obligation binding on the Company or any of its Subsidiaries or, to the Company&rsquo;s knowledge, any
of its officers, directors or employees, or otherwise in violation of the rights of any persons. To the Company&rsquo;s knowledge, all
licenses to the Intellectual Property Rights described in the Registration Statement, the Disclosure Package and the Prospectus are in
full force and effect in all material respects and are enforceable by the Company and, to the Company&rsquo;s knowledge, the other parties
thereto, in accordance with their terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or
similar laws affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution provision may
be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms
of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor
may be brought. None of such agreements or instruments has been assigned by the Company, and the Company, has no knowledge, that any
other party is in default thereunder and no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute
a default thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.36
<U>Clinical Studies</U>. All preclinical and clinical studies conducted by or on behalf of the Company Parties that are material to an
understanding of the Company&rsquo;s business and an investment in the Company Parties, are or have been adequately described in the
Registration Statement, the Disclosure Package and the Prospectus in all material respects. To the Company&rsquo;s knowledge, after reasonable
inquiry, the clinical and preclinical studies conducted by or on behalf of the Company Parties that are described in the Registration
Statement, the Disclosure Package and Prospectus or the results of which are referred to in the Registration Statement, the Disclosure
Package and the Prospectus were and, if still ongoing, are being conducted in material compliance with all laws and regulations applicable
thereto in the jurisdictions in which they are being conducted and with all laws and regulations applicable to preclinical and clinical
studies from which data will be submitted to support marketing approval. The descriptions in the Registration Statement, the Disclosure
Package and the Prospectus of the results of such studies are accurate and complete in all material respects and fairly present the data
derived from such studies, and Company has no knowledge of any large well-controlled clinical study the aggregate results of which are
inconsistent with or otherwise call into question the results of any clinical study conducted by or on behalf of the Company that are
described in the Registration Statement, the Disclosure Package and the Prospectus. Except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus, the Company has not received any written notices or statements from the FDA, the European
Medicines Agency (&ldquo;EMA&rdquo;) or any other Governmental Entity imposing, requiring, requesting or suggesting a clinical hold,
termination, suspension or material modification for or of any clinical or preclinical studies that are described in the Registration
Statement, the Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Disclosure
Package and the Prospectus, the Company Parties have not received any written notices or statements from the FDA, the EMA or any other
Governmental Entity, and otherwise has no knowledge or reason to believe, that (i) any investigational new drug application for potential
product of the Company is or has been rejected or determined to be non-approvable or conditionally approvable; and (ii) any license,
approval, permit or authorization to conduct any clinical trial of any potential product of the Company has been, will be or may be suspended,
revoked, modified or limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37
<U>Taxes</U>. Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing
authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries
has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed
against the Company or such respective Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed
with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods
to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters, (i) no issues
have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from
the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have
been given by or requested from the Company or its Subsidiaries. The term &ldquo;<B>taxes</B>&rdquo; means all federal, state, local,
foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service,
service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties
or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or
additional amounts with respect thereto. The term &ldquo;<B>returns</B>&rdquo; means all returns, declarations, reports, statements and
other documents required to be filed in respect to taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.38
<U>ERISA Compliance</U>. The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security
Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;<B>ERISA</B>&rdquo;)) established
or maintained by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects with
ERISA. &ldquo;<B>ERISA Affiliate</B>&rdquo; means, with respect to the Company, any member of any group of organizations described in
Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder
(the &ldquo;<B>Code</B>&rdquo;) of which the Company is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred
or is reasonably expected to occur with respect to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company or
any of its ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates,
if such &ldquo;employee benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as
defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to incur any material liability
under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections
412, 4971, 4975 or 4980B of the Code. Each &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its
ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to the knowledge of the Company,
nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.39
<U>Compliance with Laws</U>. The Company: (i) is and has been for the past five years in material compliance with all statutes, rules,
regulations, ordinances, judgments, orders and decrees of all Governmental Entities applicable to the ownership, testing, development,
manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export
storage or disposal of any product manufactured or distributed by the Company (&ldquo;<B>Applicable Laws</B>&rdquo;), including but not
limited to all Health Care Laws, except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Change; (ii) is and has been for the past five years in material compliance with (A) all laws applicable to the collection, storage,
use, access, disclosure, processing, security, transfer, privacy and protection of Personal Information (defined below) and all regulations
or guidance thereunder, including, but not limited to the Federal Trade Commission Act (&ldquo;<B>FTC Act</B>&rdquo;), California Consumer
Privacy Act (&ldquo;<B>CCPA</B>&rdquo;) and all amendments thereto, including the California Privacy Rights Act (&ldquo;<B>CPRA</B>&rdquo;),
the Colorado Privacy Act (&ldquo;<B>CPA</B>&rdquo;), the Connecticut Data Privacy Act (&ldquo;<B>CTDPA</B>&rdquo;), the Utah Consumer
Privacy Act (&ldquo;<B>UCPA</B>&rdquo;), the Virginia Consumer Data Protection Act (&ldquo;<B>VCDPA</B>&rdquo;), the California Genetic
Information Privacy Act (&ldquo;<B>GIPA</B>&rdquo;), and various other state laws applicable to the collection of Personal Information
in the U.S., Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (&ldquo;<B>GDPR</B>&rdquo;), the
United Kingdom Data Protection Act 2018 (&ldquo;<B>UK GDPR</B>&rdquo;), and any and all similar laws relating to privacy, security, telemarketing
or text messaging, data protection, data availability and destruction, and data breaches, including security incident notification in
any applicable jurisdiction (collectively &ldquo;<B>Data Protection Laws</B>&rdquo;), (B) its own external or internal written privacy
or information security policies, (C) the requirements of any contract, agreement, instrument or arrangement to which the Company is
bound related to the processing of Personal Information or the security of its internal systems, and (D) industry standards and self-regulatory
guidelines to which the Company purport to comply; (iii) has not received any warning letter, untitled letter or other correspondence
or written notice from any other Governmental Entity alleging or asserting noncompliance with any Applicable Laws or any licenses, consents,
certificates, approvals, clearances, authorizations, permits, orders and supplements or amendments thereto required by any such Applicable
Laws (&ldquo;<B>Authorizations</B>&rdquo;); (iv) possesses all material Authorizations and such Authorizations are valid and in full
force and effect and the Company is not in material violation of any term of any such Authorizations; (v) has not received written notice
of any claim, action, suit, litigation, proceeding, hearing, enforcement, investigation, inquiry, arbitration or other action from any
Governmental Entity or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations
and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action; (vi) has not received written notice that any Governmental
Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that
any such governmental authority is considering such action; (vii) has filed, obtained, maintained or submitted all material reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws
or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or
amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission);
and (viii) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued,
any recall, market withdrawal or replacement, safety alert, post-sale warning, &ldquo;dear doctor&rdquo; letter, or other notice or action
relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company&rsquo;s
knowledge, no third party has initiated, conducted or intends to initiate any such notice or action. &ldquo;<B>Personal Information</B>&rdquo;
as used herein means information relating to (a) an identified or identifiable natural person and, (b) an identified or identifiable
legal entity (where such information is protected similarly as personal data or personally identifiable information under applicable
Data Protection Laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.40
<U>Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the time of effectiveness
of the Registration Statement and any amendment thereto, at the earliest time thereafter that the Company or another offering participant
made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Public Securities and at
the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405, without taking account of
any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.41
<U>Environmental Laws</U>. The Company and its Subsidiaries are in compliance with all foreign, federal, state and local rules, laws
and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health
and safety or the environment which are applicable to their businesses (&ldquo;<B>Environmental Laws</B>&rdquo;), except where the failure
to comply would not, singularly or in the aggregate, result in a Material Adverse Change. There has been no storage, generation, transportation,
handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other hazardous substances
by, due to, or caused by the Company or any of its Subsidiaries (or, to the Company&rsquo;s knowledge, any other entity for whose acts
or omissions the Company or any of its Subsidiaries is or may otherwise be liable) upon any of the property now or previously owned or
leased by the Company or any of its Subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule, regulation,
order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation,
order, judgment, decree or permit, give rise to any liability; and there has been no disposal, discharge, emission or other release of
any kind onto such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances
with respect to which the Company has knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.42
<U>Real Property</U>. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus, the Company and each
of its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real
or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case free and clear
of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, materially affect the value
of such property and do not interfere with the use made and proposed to be made of such property by the Company or any of its Subsidiaries;
and all of the leases and subleases material to the business of the Company and its subsidiaries, considered as one enterprise, and under
which the Company or any of its subsidiaries holds properties described in the Registration Statement, the Disclosure Package and the
Prospectus, are in full force and effect, and neither the Company nor any Subsidiary has received any notice of any material claim of
any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases
mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or
subleased premises under any such lease or sublease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.43
<U>Contracts Affecting Capital</U>. There are no transactions, arrangements or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company&rsquo;s or any of its Subsidiaries&rsquo; liquidity or the availability of or requirements for their capital resources
required to be described or incorporated by reference in the Registration Statement, the Disclosure Package and the Prospectus which
have not been described or incorporated by reference as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.44
<U>Loans to Directors or Officers</U>. There are no outstanding loans, advances (except normal advances for business expenses in the
ordinary course of business) or guarantees or indebtedness by the Company or its Subsidiaries to or for the benefit of any of the officers
or directors of the Company, its Subsidiaries or any of their respective family members, except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.45
<U>Reserved</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.46
<U>Smaller Reporting Company</U>. As of the time of filing of the Registration Statement, the Company was, and currently is, a &ldquo;smaller
reporting company,&rdquo; as defined in Rule 12b-2 of the Exchange Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.47
<U>Industry Data</U>. The statistical and market-related data included in each of the Registration Statement, the Disclosure Package
and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate
or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.48
<U>Margin Securities</U>. The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board of
Governors of the Federal Reserve System (the &ldquo;<B>Federal Reserve Board</B>&rdquo;), and none of the proceeds of Offering will be
used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring
any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause any
of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings of Regulation T, U or X of the Federal
Reserve Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.49
<U>Exchange Act Reports</U>. The Company has filed in a timely manner all reports required to be filed pursuant to Sections 13(a), 13(e),
14 and 15(d) of the Exchange Act during the preceding 12 months (except to the extent that Section 15(d) requires reports to be filed
pursuant to Sections 13(d) and 13(g) of the Exchange Act, which shall be governed by the next clause of this sentence); and the Company
has filed in a timely manner all reports required to be filed pursuant to Sections 13(d) and 13(g) of the Exchange Act since January
1, 2021, except where the failure to timely file could not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.50
<U>Minute Books</U>. The minute books of the Company and each Subsidiary have been made available to the Underwriters and Representative
counsel, and such books (i) contain a complete summary of all meetings and actions of the board of directors (including each board committee)
and stockholders of the Company and each Subsidiary (or analogous governing bodies and interest holders, as applicable), and each of
its Subsidiaries since the time of its incorporation or organization through the date of the latest meeting and action, and (ii) accurately
in all material respects reflect all transactions referred to in such minutes. There are no material transactions, agreements, dispositions
or other actions of the Company and each Subsidiary that are not properly approved and/or accurately and fairly recorded in the minute
books of the Company or its Subsidiary, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.51
<U>Integration</U>. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering
to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such
securities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.52
<U>No Stabilization</U>. Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent
of the Representative) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might
reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of
the price of any security of the Company to facilitate the sale or resale of the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.53
<U>Electronic Road Show</U>. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) of
the Securities Act Regulations such that no filing of any &ldquo;road show&rdquo; (as defined in Rule 433(h) of the Securities Act Regulations)
is required in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.54
<U>Confidentiality and Non-Competition</U>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant of the
Company is subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any employer
or prior employer that could reasonably be expected to materially affect his ability to be and act in his respective capacity of the
Company or be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants of the Company</U>. The Company covenants
and agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Amendments to Registration Statement</U>. The Company shall deliver to the Representative, prior to filing, any amendment or supplement
to the Registration Statement, Preliminary Prospectus, Disclosure Package or Prospectus proposed to be filed after the date hereof and
not file any such amendment or supplement to which the Representative shall reasonably object in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Federal Securities Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.1
<U>Compliance</U>. The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 424(b) and Rule 430B of the Securities
Act Regulations, and will notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment
to the Registration Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus
shall have been filed and when any post-effective amendment to the Registration Statement shall become effective; (ii) of the receipt
of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment
or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus or for additional information; (iv) of the issuance
by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of
any order preventing or suspending the use of any Preliminary Prospectus, the Disclosure Package or the Prospectus, or of the suspension
of the qualification of the Public Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings
for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement;
and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of
the Public Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations, in the manner
and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it deems necessary
to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission
and, in the event that it was not, it will promptly file such prospectus. The Company shall use its best efforts to prevent the issuance
of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible
moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.2
<U>Continued Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the
Exchange Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement
and in the Registration Statement, the Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public
Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;<B>Rule 172</B>&rdquo;), would
be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the
Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the
Disclosure Package or the Prospectus in order that the Disclosure Package or the Prospectus, as the case may be, will not include any
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading
in the light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend
or supplement the Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities
Act or the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event; (B) prepare any amendment
or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Disclosure Package
or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative
with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement; <I>provided</I>, <I>however</I>,
that the Company shall not file or use any such amendment or supplement to which the Representative or counsel for the Underwriters shall
reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters
may reasonably request. The Company has given the Representative notice of any filings made pursuant to the Exchange Act or the Exchange
Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative notice of its intention to make
any such filing from the Applicable Time until the later of the Closing Date and the exercise in full or expiration of the Over-allotment
Option specified in Section 1.2 hereof and will furnish the Representative with copies of the related document(s) a reasonable amount
of time prior to such proposed filing, as the case may be, and will not file or use any such document to which the Representative or
counsel for the Underwriters shall reasonably object.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.3
<U>Exchange Act Registration</U>. For a period of three (3) years after the date of this Agreement, the Company shall use its best efforts
to maintain the registration of the shares of Common Stock under the Exchange Act. The Company shall not voluntarily deregister the shares
of Common Stock under the Exchange Act without the prior written consent of the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2.4
<U>Free Writing Prospectuses</U>. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall
not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or
retained by the Company under Rule 433; <I>provided</I>, <I>however</I>, that the Representative shall be deemed to have consented to
each Issuer General Use Free Writing Prospectus hereto and any &ldquo;road show that is a written communication&rdquo; within the meaning
of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that it has treated or agrees that it will
treat each such free writing prospectus consented to, or deemed consented to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo;
as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including
timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would
conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material
fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement,
at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<U>Delivery to the Underwriters of Registration Statements</U>. The Company has delivered or made available or shall deliver or make
available to the Representative and counsel for the Representative, without charge upon request, signed copies of the Registration Statement
as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates
of experts, and will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed
and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment
thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant
to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<U>Delivery to the Underwriters of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to
each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company
hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded by Rule
172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented)
as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will
be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
<U>Effectiveness and Events Requiring Notice to the Representative</U>. The Company shall use its best efforts to cause the Registration
Statement to remain effective with a current prospectus until the later of (i) at least nine months after the Applicable Time and (ii)
through and including the expiration date of the Pre-Funded Warrants (or the date that all of the Pre-Funded Warrants have been exercised,
if earlier), and shall notify the Representative immediately and confirm the notice in writing: (i) of the issuance by the Commission
of any stop order or of the initiation, or the threatening, of any proceeding for that purpose; (ii) of the issuance by any state securities
commission of any proceedings for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction
or of the initiation, or, to the Company&rsquo;s knowledge, the threatening, of any proceeding for that purpose; (iii) of the mailing
and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus; (iv) of the receipt
of any comments or request for any additional information from the Commission; and (v) of the happening of any event during the period
described in this Section 3.5 that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement,
the Disclosure Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration Statement in order
to make the statements therein not misleading, or (b) in the Disclosure Package or the Prospectus in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission shall
enter a stop order or suspend such qualification at any time, the Company shall make every reasonable effort to obtain promptly the lifting
of such order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6
<U>Review of Financial Statements.</U> For a period of three years after the date of this Agreement, the Company, at its expense, shall
cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial statements
for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7
<U>Listing</U>. The Company shall use its reasonable best efforts to maintain the listing of the shares of Common Stock (including the
Public Securities) on the Exchange for at least three years from the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8
<U>Financial Public Relations Firm</U>. The Company has retained an investor relations firm reasonably acceptable to the Representative
and the Company, which shall initially be Renmark Financial Communications Inc., which firm shall be experienced in assisting issuers
in public relations with their security holders, and shall retain such firm or another firm reasonably acceptable to the Representative
for a period of not less than two years after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9
<U>Reports to the Representative</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.1
<U>Periodic Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish or make available
to the Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes
generally to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report
the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every
press release and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy
of each Form 8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities
Act; (v) a copy of each report or other communication furnished to stockholders and (vi) such additional documents and information with
respect to the Company and the affairs of any future subsidiaries of the Company as the Representative may from time to time reasonably
request; <I>provided</I>, <I>however</I>, the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality
agreement which is reasonably acceptable to the Representative and Representative Counsel in connection with the Representative&rsquo;s
receipt of such information. Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered
to the Representative pursuant to this Section 3.9.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.2
<U>Transfer Agent; Transfer Sheets</U>. For a period of three (3) years after the date of this Agreement, the Company shall retain a
transfer agent and registrar acceptable to the Representative (the &ldquo;<B>Transfer Agent</B>&rdquo;) and shall furnish to the Representative
at the Company&rsquo;s sole cost and expense such transfer sheets of the Company&rsquo;s securities as the Representative may reasonably
request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. American Stock Transfer &amp; Trust
Company, LLC. is acceptable to the Representative to act as Transfer Agent for the shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9.3
<U>Trading Reports</U>. During such time as the Public Securities are listed on the Exchange, the Company shall provide, if available
and upon request, to the Representative, at the Company&rsquo;s expense, such reports published by Exchange relating to price trading
of the Public Securities, as the Representative shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10
<U>Payment of Expenses</U>. The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the
extent not paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement,
including, but not limited to: (i) all filing fees and communication expenses relating to the registration of Public Securities to be
issued and sold in the Offering with the Commission; (ii) all filing fees associated with the review of the Offering by FINRA; (iii)
all fees and expenses relating to the listing of such Common Stock and the shares of Common Stock underlying the Pre-Funded Warrants
on the Exchange, including any fees charged by The Depository Trust Company (DTC) for new securities; (iv) all fees, expenses and disbursements
relating to background checks of the Company&rsquo;s officers and directors in an amount not to exceed $15,000 in the aggregate; (v)
all fees, expenses and disbursements relating to the registration, qualification or exemption of the Public Securities under the &ldquo;blue
sky&rdquo; securities laws of such states, if applicable, and the securities laws of such foreign jurisdictions, as applicable, as the
Representative may reasonably designate; (vi) the costs of all mailing and printing of the underwriting documents (including, without
limitation, this Agreement, any blue sky surveys and, if appropriate, any agreement among underwriters, selected dealers&rsquo; agreement,
underwriters&rsquo; questionnaire and power of attorney), Registration Statements, Prospectuses, the Pre-Funded Warrants and all amendments,
supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative may reasonably deem necessary;
(vii) the costs and expenses of the public relations firm referred to in Section 3.8 hereof; (viii) the costs of preparing, printing
and delivering certificates representing the Public Securities; (ix) fees and expenses of the Transfer Agent for the shares of Common
Stock; (x) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriters; (xi)
to the extent approved by the Company in writing, the costs associated with post-Closing advertising of the Offering in the national
editions of The Wall Street Journal and The New York Times; (xii) the costs associated with one set of bound volumes of the public offering
materials as well as commemorative mementos and lucite tombstones, each of which the Company or its designee will provide within a reasonable
time after the Closing in such quantities as the Representative may reasonably request; (xiii) the fees and expenses of the Company&rsquo;s
accountants; (xiv) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives; (xv) the reasonable
and documented fees and expenses of Underwriter&rsquo;s legal counsel not to exceed $125,000; (xvi) the $12,000 cost associated with
the Representative&rsquo;s use of Ipreo&rsquo;s book building, prospectus tracking and compliance software for the Offering; and (xvii)
$10,000 for data services and communications expenses; (xviii) up to $25,000 of the Representative&rsquo;s actual accountable &ldquo;road
show,&rdquo; market making and trading, and clearing firm settlement expenses for the Offering. The Representative may deduct from the
net proceeds of the Offering payable to the Company on the Closing Date, or the Option Closing Date, if any, the expenses set forth herein
to be paid by the Company (less any amounts previously advanced) to the Underwriters, provided, however, that in the event that the Offering
is terminated, the Company agrees to reimburse the Underwriters pursuant to Section 8.3 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11
<U>Non-accountable Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section 3.10, on the
Closing Date it shall pay to the Representative, by deduction from the net proceeds of the Offering contemplated herein, a non-accountable
expense allowance equal to one percent (1.0%) of the gross proceeds received by the Company from the sale of the Public Securities (as such term is defined in Section 8.3 hereof), provided, however, that in the event that the Offering is terminated, the
Company agrees to reimburse the Underwriters pursuant to Section 8.3 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12
<U>Application of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent
with the application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Disclosure
Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13
<U>Delivery of Earnings Statements to Security Holders</U>. The Company shall make generally available to its security holders as soon
as practicable, but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement,
an earnings statement (which need not be certified by independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act)
covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.14
<U>Stabilization</U>. Neither the Company nor, to its knowledge, any of its employees, directors or stockholders (without the consent
of the Representative) has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might
reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of
the price of any security of the Company to facilitate the sale or resale of the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.15
<U>Internal Controls</U>. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances
that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded
as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability for assets;
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded
accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any
differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16
<U>Accountants</U>. As of the date of this Agreement, the Company shall continue to retain a nationally recognized independent registered
public accounting firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that
Morison Cogen is acceptable to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.17
<U>FINRA</U>. The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware
that (i) any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company&rsquo;s securities
or (iii) any beneficial owner of the Company&rsquo;s unregistered equity securities which were acquired during the 180 days immediately
preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in
the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.18
<U>No Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility to the Company is solely
contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary
capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other
transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.19
<U>Restriction on Continuous Offerings</U>. Notwithstanding the restrictions contained in Section 3.20, the Company, on behalf of itself
and any successor entity, agrees that, without the prior written consent of the Representative, it will not, for a period of twelve (12)
months after the date of this Agreement, directly or indirectly in any &ldquo;at-the-market&rdquo;, continuous equity or variable rate
transaction, other than pursuant to the Company&rsquo;s Sales Agreement with the Representative, dated December 28, 2021, offer to sell,
sell, contract to sell, grant any option to sell or otherwise dispose of shares of capital stock of the Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.20
<U>Company Lock-Up Agreements</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written
consent of the Representative, neither the Company nor any of the Company&rsquo;s successors will for a period of three months after
the date of this Agreement (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (i) offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or
dispose of, directly or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable
for shares of capital stock of the Company; (ii) file or cause to be filed any registration statement with the Commission relating to
the offering of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares
of capital stock of the Company (other than a registration statement on Form S-8 and any amendments thereto and a registration statement
on Form S-3 as contemplated by Rule 415(a)(6) under the Securities Act in a form substantially similar to the Initial Registration Statement);
or (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank or
(iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of capital stock of the Company, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by
delivery of shares of capital stock of the Company or such other securities, in cash or otherwise. In addition, the Company agrees that
for a period of twelve (12) months after the closing of this Offering that the Company will not directly or indirectly, in any &ldquo;at
the market&rdquo;, continuous equity or variable rate transaction, other than pursuant to the Sales Agreement between the Company and
the Representative dated December 28, 2021, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any
shares of its capital stock or any securities convertible into, exercisable or exchangeable for shares of its capital stock without the
express written consent of the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions contained in this Section 3.20 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance
by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on
the date hereof, which is disclosed in the Registration Statement, Disclosure Package and Prospectus, provided that such options, warrants,
and securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities or to extend the term of such securities, (iii) the issuance by the Company
of stock options, shares of capital stock of the Company or other awards under any equity compensation plan of the Company or pursuant
to any inducement award, provided that in each of (ii) and (iii) above, the underlying shares shall be restricted from sale during the
entire Lock-Up Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.21
<U>Release of D&amp;O Lock-up Period</U>. If the Representative, in its sole discretion, agrees to release or waive the restrictions
set forth in the Lock-Up Agreements described in Section 2.27 hereof for an officer or director of the Company and provide the Company
with notice of the impending release or waiver at least three Business Days before the effective date of the release or waiver, the Company
agrees to announce the impending release or waiver by a press release substantially in the form of <U>Exhibit C</U> hereto through a
major news service at least two Business Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.22
<U>Blue Sky Qualifications</U>. The Company shall use its best efforts, in cooperation with the Underwriters, if necessary, to qualify
the Public Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or
foreign) as the Representative may designate and to maintain such qualifications in effect so long as required to complete the distribution
of the Public Securities; <I>provided</I>, <I>however</I>, that the Company shall not be obligated to file any general consent to service
of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or
to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.23
<U>Reporting Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the
exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations. Additionally,
the Company shall report the use of proceeds from the issuance of the Public Securities as may be required under Rule 463 under the Securities
Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.24
<U>Press Releases</U>. Prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other
communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise,
or earnings, business affairs or business prospects (except for routine oral marketing communications in the ordinary course of business
and consistent with the past practices of the Company and of which the Representative is notified), without the prior written consent
of the Representative, which consent shall not be unreasonably withheld, unless in the judgment of the Company and its counsel, and after
notification to the Representative, such press release or communication is required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.25
<U>Sarbanes-Oxley</U>. Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company shall
at all times comply in all material respects with all applicable provisions of the Sarbanes-Oxley Act in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.26
<U>Reservation of Common Stock</U>. As of the date hereof, the Company has irrevocably reserved, and the Company shall continue to reserve
and keep available at all times, free of pre-emptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue the Underlying Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">4.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions of Underwriters&rsquo; Obligations</U>.
The obligations of the Underwriters to purchase and pay for the Public Securities, as provided herein, shall be subject to (i) the continuing
accuracy of the representations and warranties of the Company as of the date hereof and as of each of the Closing Date and the Option
Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the
performance by the Company of its obligations hereunder; and (iv) the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Regulatory Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1
<U>Commission Actions; Required Filings</U>. At each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment thereto has been issued under the Securities Act, no order preventing or
suspending the use of any Preliminary Prospectus or the Prospectus has been issued and no proceedings for any of those purposes have
been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated by the Commission. The Company has complied with each
request (if any) from the Commission for additional information. A prospectus containing the Rule 430B Information shall have been filed
with the Commission in the manner and within the time frame required by Rule 424(b) under the Securities Act Regulations (without reliance
on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the
Commission in accordance with the requirements of Rule 430B under the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2
<U>FINRA Clearance</U>. On or before the date of this Agreement, FINRA shall have raised no objections as to the amount of compensation
allowable or payable to the Underwriters as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.3
<U>Exchange Stock Market Clearance</U>. On the Closing Date, the Company&rsquo;s shares of Common Stock, including the Firm Shares, the
Option Shares and the Underlying Shares upon exercise of the Firm Pre-Funded Warrants shall have been approved for listing on the Exchange,
subject only to official notice of issuance. On the first Option Closing Date (if any), the Company&rsquo;s shares of Common Stock (including
the shares of Common Stock underlying the Option Shares and the Underlying Shares issuable upon the exercise of the Option Pre-Funded
Warrants) shall have been approved for listing on the Exchange, subject only to official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Company Counsel Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1
<U>Closing Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion of Reed Smith
LLP, counsel to the Company, and a written statement providing certain &ldquo;10b-5&rdquo; negative assurances, dated the Closing Date
and addressed to the Representative, in the form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2
<U>Opinion of Special Intellectual Property Counsel for the Company</U>. On the Closing Date, the Representative shall have received
the opinion of Reed Smith LLP, as special intellectual property counsel for the Company, and a written statement providing certain &ldquo;10b-5&rdquo;
negative assurances, dated the Closing Date and addressed to the Representative, in the form and substance reasonably satisfactory to
the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3
<U>Opinion of Special Regulatory Counsel for the Company</U>. On the Closing Date, the Representative shall have received the opinion
of Reed Smith LLP, special regulatory counsel (including FDA-related matters) for the Company, and a written statement providing certain
&ldquo;10b-5&rdquo; negative assurances, dated the Closing Date and addressed to the Representative, in the form and substance reasonably
satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.4
<U>Option Closing Date Opinions of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable
opinions of each counsel listed in Sections 4.2.1, 4.2.2 and 4.2.3, dated the Option Closing Date, addressed to the Representative and
in form and substance reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the statements made by
such counsels in their respective opinions delivered on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.5
<U>Reliance</U>. In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other than the
laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified
in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other
counsel reasonably acceptable to the Representative, familiar with the applicable laws; and (ii) as to matters of fact, to the extent
they deem proper, on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions
having custody of documents respecting the corporate existence or good standing of the Company; <I>provided</I> that copies of any such
statements or certificates shall be delivered to Representative Counsel if requested. The opinions listed in Sections 4.2.1, 4.2.2 and
4.2.3, and any opinion relied upon by any such counsel, shall include a statement to the effect that it may be relied upon by Representative
Counsel in its opinion delivered to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Comfort Letters</U>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1
<U>Cold Comfort Letter</U>. At the time this Agreement is executed, the Representative shall have received a cold comfort letter from
the Prior Auditor containing statements and information of the type customarily included in accountants&rsquo; comfort letters with respect
to the financial statements and certain financial information contained or incorporated by reference or deemed incorporated by reference
in the Registration Statement, the Disclosure Package and the Prospectus, addressed to the Representative and in form and substance satisfactory
in all respects to the Representative, dated as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2
<U>Bring-down Comfort Letter</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received
from the Prior Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Prior
Auditor reaffirms the statements made in its letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall
be a date not more than three (3) business days prior to the Closing Date or the Option Closing Date, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>Officers&rsquo; Certificates</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1
<U>Officers&rsquo; Certificate</U>. The Company shall have furnished to the Representative a certificate, dated the Closing Date and
any Option Closing Date (if such date is other than the Closing Date), of its Chief Executive Officer and its Chief Financial Officer
stating that (i) such officers have carefully examined the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus
and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of
the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not include any untrue statement of a material
fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
and the Disclosure Package, as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than
the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date if such date
is other than the Closing Date), and the Prospectus and each amendment or supplement thereto, as of the respective date thereof and as
of the Closing Date, did not include any untrue statement of a material fact and did not omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances in which they were made, not misleading, (ii) since the effective date
of the Registration Statement, no event has occurred which should have been set forth in a supplement or amendment to the Registration
Statement, the Disclosure Package or the Prospectus, (iii) to their knowledge after reasonable investigation, as of the Closing Date
(or any Option Closing Date if such date is other than the Closing Date), the representations and warranties of the Company in this Agreement
are true and correct in all material respects (except for those representations and warranties qualified as to materiality, which shall
be true and correct in all respects, and except for those representations and warranties which may refer to facts existing at a specific
date, which shall be true and correct as of such date) and the Company has complied with all agreements and satisfied all conditions
on its part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing Date if such date is other
than the Closing Date), and (iv) there has not been, subsequent to the date of the most recent audited financial statements included
or incorporated by reference in the Disclosure Package, any material adverse change in the financial position or results of operations
of the Company, or any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective
material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects
of the Company, except as set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2
<U>Secretary&rsquo;s Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have
received a certificate of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Date, as the case
may be, respectively, certifying: (i) that each of the Charter and Bylaws is true and complete, has not been modified and is in full
force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors relating to the Offering are in full force and
effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel
and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents referred to in such certificate shall
be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.3
<U>Chief Financial Officer&rsquo;s Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative
shall, upon its request, have received a certificate of the Chief Financial Officer of the Company, dated the Closing Date or the Option
Date, as the case may be, respectively, with respect to the accuracy of certain information contained in the Registration Statement,
the Disclosure Package and the Prospectus, in a form reasonably acceptable to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5
<U>No Material Changes</U>. Prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been
no Material Adverse Change or development involving a prospective Material Adverse Change from the latest dates as of which such condition
is set forth in the Registration Statement and no change in the capital stock or debt of the Company, the Disclosure Package and the
Prospectus; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any
Insider before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision,
ruling or finding would result in a Material Adverse Change, except as set forth in the Registration Statement, the Disclosure Package
and the Prospectus; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated
or threatened by the Commission; (iv) no action shall have been taken and no law, statute, rule, regulation or order shall have been
enacted, adopted or issued by any Governmental Entity which would prevent the issuance or sale of the Public Securities or materially
and adversely affect or potentially materially and adversely affect the business or operations of the Company; (v) no injunction, restraining
order or order of any other nature by any federal or state court of competent jurisdiction shall have been issued which would prevent
the issuance or sale of the Public Securities or materially and adversely affect or potentially materially and adversely affect the business
or operations of the Company and (vi) the Registration Statement, the Disclosure Package and the Prospectus and any amendments or supplements
thereto shall contain all material statements which are required to be stated therein in accordance with the Securities Act and the Securities
Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations,
and neither the Registration Statement, the Disclosure Package, the Prospectus nor any amendment or supplement thereto shall contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6
<U>Corporate Proceedings</U>. All corporate proceedings and other legal matters incident to the authorization, form and validity of each
of this Agreement, the Public Securities, the Registration Statement, the Disclosure Package and the Prospectus and all other legal matters
relating to this Agreement and the transactions contemplated hereby and thereby shall be reasonably satisfactory in all material respects
to counsel for the Underwriters, and the Company shall have furnished to such counsel all documents and information that they may reasonably
request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7
<U>Delivery of Agreements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7.1
<U>Lock-Up Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies
of the Lock-Up Agreements from each of the persons listed in <U>Schedule 3</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7.2
<U>Pre-Funded Warrants</U>. On the Closing Date and at each Option Closing Date (if any), the Company shall have delivered to the Representative
executed copies of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8
<U>Additional Documents</U>. At the Closing Date and at each Option Closing Date (if any) Representative Counsel shall have been furnished
with such documents and opinions as they may require for the purpose of enabling Representative Counsel to deliver an opinion to the
Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities as herein
contemplated shall be satisfactory in form and substance to the Representative and Representative Counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Indemnification of the Underwriters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.1
<U>General</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates
and each of its and their respective directors, officers, members, employees, representatives, partners, stockholders, affiliates, counsel
and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act (collectively the &ldquo;<B>Underwriter Indemnified Parties</B>,&rdquo; and each an &ldquo;<B>Underwriter Indemnified
Party</B>&rdquo;), against any and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all
legal or other expenses reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened,
or any claim whatsoever, whether arising out of any action between any of the Underwriter Indemnified Parties and the Company or between
any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they or any of them may become subject under the
Securities Act, the Exchange Act or any other statute or at common law or otherwise or under the laws of foreign countries (a &ldquo;<B>Claim</B>&rdquo;),(i)
arising out of or based upon any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration Statement,
the Disclosure Package, any Preliminary Prospectus, the Prospectus or in any Issuer Free Writing Prospectus (as from time to time each
may be amended and supplemented); (B) any materials or information provided to investors by, or with the approval of, the Company in
connection with the marketing of the Offering, including any &ldquo;road show&rdquo; or investor presentations made to investors by the
Company (whether in person or electronically); (C) any application or other document or written communication (in this Section 5, collectively
called &ldquo;<B>application</B>&rdquo;) executed by the Company or based upon written information furnished by the Company in any jurisdiction
in order to qualify the Public Securities under the securities laws thereof or filed with the Commission, any state securities commission
or agency, the Exchange or any other national securities exchange; or the omission or alleged omission therefrom of a material fact required
to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading,
unless such statement or omission was made in reliance upon, and in conformity with, the Underwriters&rsquo; Information, or (ii) otherwise
arising in connection with or allegedly in connection with the Offering. The Company also agrees that it will reimburse each Underwriter
Indemnified Party for all documented fees and expenses (including but not limited to any and all documented legal or other expenses reasonably
incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising
out of any action between any of the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties
and any third party, or otherwise) (collectively, the &ldquo;<B>Expenses</B>&rdquo;), and further agrees wherever and whenever possible
to advance payment of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing, pursuing or defending
any Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.2
<U>Procedure</U>. If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against
the Company pursuant to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution
of such action and the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the
approval of such Underwriter Indemnified Party) and payment of actual expenses if an Underwriter Indemnified Party requests that the
Company do so. Such Underwriter Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees
and expenses of such counsel shall be at the expense of the Company, and shall be advanced by the Company. The Company shall not be liable
for any settlement of any action effected without its consent (which shall not be unreasonably withheld). In addition, the Company shall
not, without the prior written consent of the Underwriters, settle, compromise or consent to the entry of any judgment in or otherwise
seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may
be sought hereunder (whether or not such Underwriter Indemnified Party is a party thereto) unless such settlement, compromise, consent
or termination (i) includes an unconditional release of each Underwriter Indemnified Party, acceptable to such Underwriter Indemnified
Party, from all liabilities, expenses and claims arising out of such action for which indemnification or contribution may be sought and
(ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any Underwriter
Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Indemnification of the Company</U>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company,
its directors, its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the
foregoing indemnity from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions
made in the Registration Statement, any Preliminary Prospectus, the Disclosure Package or Prospectus or any amendment or supplement thereto
or in any application, in reliance upon, and in strict conformity with, the Underwriters&rsquo; Information. In case any action shall
be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration Statement, the
Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and in respect of which indemnity may be
sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company and each other
person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of Section 5.1.2. The Company
agrees promptly to notify the Representative of the commencement of any litigation or proceedings against the Company or any of its officers,
directors or any person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act, in connection with the issuance and sale of the Public Securities or in connection with the Registration Statement, the
Disclosure Package, the Prospectus or any Issuer Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.1
<U>Contribution Rights</U>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient
to hold harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect
thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount
paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in
such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters,
on the other, from the Offering of the Public Securities, or (ii) if the allocation provided by clause (i) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also
the relative fault of the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that
resulted in such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall
be deemed to be in the same proportion as the total net proceeds from the Offering of the Public Securities purchased under this Agreement
(before deducting expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand,
and the total underwriting discounts and commissions received by the Underwriters with respect to the shares of the Common Stock purchased
under this Agreement, as set forth in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined
by reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material
fact relates to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access
to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would
not be just and equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters
were treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action
in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess
of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Offering of
the Public Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.2
<U>Contribution Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice
of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made
against another party (&ldquo;contributing party&rdquo;), notify the contributing party of the commencement thereof, but the failure
to so notify the contributing party will not relieve it from any liability which it may have to any other party other than for contribution
hereunder. In case any such action, suit or proceeding is brought against any party, and such party notifies a contributing party or
its representative of the commencement thereof within the aforesaid 15 days, the contributing party will be entitled to participate therein
with the notifying party and any other contributing party similarly notified. Any such contributing party shall not be liable to any
party seeking contribution on account of any settlement of any claim, action or proceeding affected by such party seeking contribution
on account of any settlement of any claim, action or proceeding affected by such party seeking contribution without the written consent
of such contributing party. The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted
by law, any right to contribution under the Securities Act, the Exchange Act or otherwise available. Each Underwriter&rsquo;s obligations
to contribute pursuant to this Section 5.3 are several and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">6.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Default by an Underwriter</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Default Not Exceeding 10% of Firm Securities or Option Securities</U>. If any Underwriter or Underwriters shall default in its or
their obligations to purchase the Firm Securities or the Option Securities, if the Over-allotment Option is exercised hereunder, and
if the number of the Firm Securities or Option Securities with respect to which such default relates does not exceed in the aggregate
10% of the number of Firm Securities or Option Securities that all Underwriters have agreed to purchase hereunder, then such Firm Securities
or Option Securities to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective
commitments hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Default Exceeding 10% of Firm Securities or Option Securities</U>. In the event that the default addressed in Section 6.1 relates
to more than 10% of the Firm Securities or Option Securities, the Representative may in its discretion arrange for the Representative
or for another party or parties to purchase such Firm Securities or Option Securities to which such default relates on the terms contained
herein. If, within one (1) Business Day after such default relating to more than 10% of the Firm Securities or Option Securities, the
Representative does not arrange for the purchase of such Firm Securities or Option Securities, then the Company shall be entitled to
a further period of one (1) Business Day within which to procure another party or parties satisfactory to the Representative to purchase
said Firm Securities or Option Securities on such terms. In the event that neither the Representative nor the Company arrange for the
purchase of the Firm Securities or Option Securities to which a default relates as provided in this Section 6, this Agreement will automatically
be terminated by the Representative or the Company without liability on the part of the Company (except as provided in Sections 3.9 and
5 hereof) or the several Underwriters (except as provided in Section 5 hereof); <I>provided</I>, <I>however</I>, that if such default
occurs with respect to the Option Securities, this Agreement will not terminate as to the Firm Securities; and <I>provided</I>, <I>further</I>,
that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for
damages occasioned by its default hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Postponement of Closing Date</U>. In the event that the Firm Securities or Option Securities to which the default relates are to be
purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, the Representative or
the Company shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding
five (5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Disclosure
Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration
Statement, the Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary.
The term &ldquo;<B>Underwriter</B>&rdquo; as used in this Agreement shall include any party substituted under this Section 6 with like
effect as if it had originally been a party to this Agreement with respect to such shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">7.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Additional Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Board Composition and Board Designations</U>. The Company shall ensure that: (i) the qualifications of the persons serving as members
of the Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with the Exchange Act and with
the listing rules of the Exchange or any other national securities exchange, as the case may be, in the event the Company seeks to have
any of its securities listed on another exchange or quoted on an automated quotation system, and (ii) if applicable, at least one member
of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined
under Regulation S-K and the listing rules of the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Prohibition on Press Releases and Public Announcements</U>. The Company shall not issue press releases or engage in any other publicity,
without the Representative&rsquo;s prior written consent, for a period ending at 5:00 p.m., Eastern time, on the first (1<SUP>st</SUP>)
Business Day following the forty-fifth (45<SUP>th</SUP>) day after the Closing Date, other than normal and customary releases issued
in the ordinary course of the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Right of First Refusal</U>. Provided that the Firm Securities are sold in accordance with the terms of this Agreement, the Representative
shall have an irrevocable right of first refusal (the &ldquo;<B>Right of First Refusal</B>&rdquo;), for a period of twelve (12) months
after the date the Offering is completed, to act as sole investment banker, sole book-runner and/or sole placement agent and/or Merger
&amp; Acquisition, advisor, at the Representative&rsquo;s sole discretion, for each and every future public and private equity offering,
including all equity linked financings that are not done with Avenue Capital, or CJEF Singapore as well as acquisition or disposition
of business units, entering into a merger, consolidation or other business combination, share purchase or capital exchange, asset sale
or acquisition, tender offer, recapitalization, reorganization, consolidation, amalgamation, or similar business combination that are
not done with Exact Sciences or Guardent Health, (each, a &ldquo;<B>Subject Transaction</B>&rdquo;) during such twelve (12) month period
for the Company or any successor to or any subsidiary of the Company on terms and conditions customary to the Representative for such
Subject Transaction. For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment banker,
book-runner, financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written consent of the
Representative. The Representative shall also have the sole right to determine whether or not any other broker dealer shall have the
right to participate in any Subject Transaction and the economic terms of any such participation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall notify the Representative of its intention to pursue a Subject Transaction, including the material terms thereof, by providing
written notice thereof by registered mail or overnight courier service addressed to the Representative. If the Representative fails to
exercise its Right of First Refusal with respect to any Subject Transaction within ten (10) Business Days after the mailing of such written
notice, then the Representative shall have no further claim or right with respect to the Subject Transaction. The Representative may
elect, in its sole and absolute discretion, not to exercise its Right of First Refusal with respect to any Subject Transaction; provided
that any such election by the Representative shall not adversely affect the Representative&rsquo;s Right of First Refusal with respect
to any other Subject Transaction during the twelve (12) month period agreed to above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">8.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Effective Date of this Agreement and Termination
Thereof</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1
<U>Effective Date</U>. This Agreement shall become effective when both the Company and the Representative have executed the same and
delivered counterparts of such signatures to the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2
<U>Termination</U>. The Representative shall have the right to terminate this Agreement at any time prior to any Closing Date, (i) if
any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially
disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock Exchange or the Nasdaq Stock Market
LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges
for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having jurisdiction;
or (iii) if the United States shall have become involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium
has been declared by a New York State or federal authority; or (v) if a moratorium on foreign exchange trading has been declared which
materially adversely impacts the United States securities markets; or (vi) if the Company shall have sustained a material loss by fire,
flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have
been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Securities or Option Securities; or
(vii) if the Company is in material breach of any of its representations, warranties or covenants hereunder; or (viii) if the Representative
shall have become aware after the date hereof of such a Material Adverse Change or such adverse material change in general market conditions
as in the Representative&rsquo;s judgment would make it impracticable to proceed with the offering, sale and/or delivery of the Public
Securities or to enforce contracts made by the Underwriters for the sale of the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3
<U>Expenses</U>. Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant
to Section 6.2 above, in the event that this Agreement shall not be carried out for any reason whatsoever, within the time specified
herein or any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual
and accountable out-of-pocket expenses related to the transactions contemplated herein then due and payable (including the fees and disbursements
of Representative&rsquo;s Counsel) up to $200,000, and upon demand the Company shall pay the full amount thereof to the Representative
on behalf of the Underwriters; provided, however, that such expense cap in no way limits or impairs the indemnification and contribution
provisions of this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to the Company
to the extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4
<U>Survival of Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any
termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in
full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this
Agreement or any part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5
<U>Representations, Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter,
its officers or directors or any person controlling the Company or (ii) delivery of and payment for the Public Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">9.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1
<U>Notices</U>. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed
(registered or certified mail, return receipt requested), personally delivered or sent by electronic mail transmission and confirmed
and shall be deemed given when so delivered and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Representative:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
LLC<BR>
17 State Street, 41<SUP>st</SUP> Floor<BR>
New York, New York 10004<BR>
Attention: Head of Investment Banking<BR>
e-mail: Notices@think-equity.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loeb
&amp; Loeb LLP<BR>
345 Park Avenue<BR>
New York, New York 10154<BR>
Attn: Mitchell S. Nussbaum, Esq.<BR>
Email: mnussbaum@loeb.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs. Inc<BR>
711 Stewart Ave., Suite 200<BR>
Garden City, NY 11530<BR>
Attention:<BR>
Email:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reed
Smith LLP<BR>
599 Lexington Avenue<BR>
New York, New York 10022<BR>
Attention: Herbert F. Kozlov<BR>
Email: hkozlov@reedsmith.com</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2
<U>Research Analyst Independence</U>. The Company acknowledges that each Underwriter&rsquo;s research analysts and research departments
are required to be independent from its investment banking division and are subject to certain regulations and internal policies, and
that such Underwriter&rsquo;s research analysts may hold views and make statements or investment recommendations and/or publish research
reports with respect to the Company and/or the Offering that differ from the views of their investment banking division. The Company
acknowledges that each Underwriter is a full service securities firm and as such from time to time, subject to applicable securities
laws, rules and regulations, may effect transactions for its own account or the account of its customers and hold long or short positions
in debt or equity securities of the Company; <I>provided</I>, <I>however</I>, that nothing in this Section 9.2 shall relieve the Underwriter
of any responsibility or liability it may otherwise bear in connection with activities in violation of applicable securities laws, rules
or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3
<U>Headings</U>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4
<U>Amendment</U>. This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5
<U>Entire Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. Notwithstanding
anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms and conditions of that
certain engagement letter between the Company and ThinkEquity LLC dated October 21, 2024, shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6
<U>Binding Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative, the Underwriters,
the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors, legal
representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim
under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo;
shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7
<U>Governing Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that
any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in
the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably
submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting
a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in
Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies)
all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or incurred in connection with the
preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates)
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8
<U>Execution in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties hereto in
separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered
to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission shall
constitute valid and sufficient delivery thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9
<U>Waiver, etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not
be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision
hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPHASE
    LABS, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Ted Karkus</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ted
    Karkus</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed
                                            as of the date first written above mentioned, on behalf of itself and as Representative of
                                            the several Underwriters named on <U>Schedule 1</U> hereto:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THINKEQUITY
                                            LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Kevin Mangan</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Mangan</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Director, Head of Equity Syndicate</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
1</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriter</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Number of Firm Shares to be Purchased</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Number of Firm Pre-Funded Warrants to be Purchased</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Number of Option Shares and/or Option Pre-Funded Warrants to be Purchased if the Over-Allotment Option is Fully Exercised</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ThinkEquity LLC</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,170,000</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,795,500</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,170,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,795,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Sch.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
2-A</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
Information</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Firm Shares: 4,170,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Firm Pre-Funded Warrants: 0</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Option Shares and/or Option Pre-Funded Warrants: 625,500 Option Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Offering Price per Share: $0.72</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
Offering Price per Pre-Funded Warrant: Not applicable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
Discount per Share: $0.0504</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
Discount per Pre-Funded Warrant: Not applicable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
non-accountable expense allowance per Share: $0.0072</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
non-accountable expense allowance per Pre-Funded Warrant: Not applicable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
to Company per Share (before expenses): $0.6696</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
to Company per Pre-Funded Warrants (before expenses): Not applicable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Sch. 2-A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
2-B</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer
General Use Free Writing Prospectuses</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer
Free Writing Prospectus filed on November 7, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Sch. 2-B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SCHEDULE
3</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
of Lock-Up Parties</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ted
Karkus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jed
A. Latkin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis
Gleckel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warren
Hirsch</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
Bisesar</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Sch. 3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXHIBIT
A</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Representative&rsquo;s Warrant Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PURCHASE WARRANT IS VOID AFTER 5:00 P.M., EASTERN TIME, [___________________]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<B>DATE
THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING</B>].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WARRANT
TO PURCHASE COMMON STOCK</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROPHASE
LABS, INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: _______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
Exercise Date: ______, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
WARRANT TO PURCHASE COMMON STOCK (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after ____, 2024 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and, in accordance with FINRA Rule 5110(g)(8)(A),
prior to at 5:00 p.m. (New York time) on ___________, 2029 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from ProPhase Labs, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares of Common Stock,
par value $0.0005 per share, of the Company (the &ldquo;<U>Warrant Shares</U>&rdquo;), as subject to adjustment hereunder. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or its subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred share, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; means the date of the commencement of sales of the securities in the Public Offering pursuant to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the New York Stock Exchange is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as applicable, (c) if Common Stock
is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock are then reported in the &ldquo;Pink Sheets&rdquo;
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of the Common Stock as determined
by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly
executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within one (1) Trading Day following the
date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice
of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased
all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this
Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one (1) Business Day of receipt
of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of the Common Stock under this Warrant shall be <B>$_______</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. In lieu of exercising this Warrant by delivering the aggregate Exercise Price by wire transfer or cashier&rsquo;s
check, at the election of the Holder this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a &ldquo;cashless
    exercise,&rdquo; as set forth in the applicable Notice of Exercise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
    exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a &ldquo;cashless exercise,&rdquo; the parties acknowledge and agree that in accordance with Section
3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the
holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to
take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
its transfer agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder prior to the Warrant Share Delivery Date (as
defined below), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is one (1) Trading Day after the delivery to the Company of the Notice
of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). If the Warrant Shares can be delivered via DWAC, the transfer
agent shall have received from the Company, at the expense of the Company, any legal opinions or other documentation required by it to
deliver such Warrant Shares without legend (subject to receipt by the Company of reasonable back up documentation from the Holder, including
with respect to affiliate status) and, if applicable and requested by the Company prior to the Warrant Share Delivery Date, the transfer
agent shall have received from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder to provide
a confirmation as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant Shares upon a cashless
exercise of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be
deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder
of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise
Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi) prior
to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date, the Company shall pay to the Holder, in
cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the
Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading
Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading Day following such Warrant Share Delivery
Date until such Warrant Shares are delivered or Holder rescinds such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause its transfer agent to deliver to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; <U>provided</U>, <U>however</U>,
that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently
with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder&rsquo;s
right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such
restored right).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares pursuant to an exercise on
or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market
transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price
at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the
portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to
pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of
the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to
pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant
as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all transfer agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">viii.
<U>Signature</U>. This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the Holder
in order to exercise this Purchase Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise
this Purchase Warrant. No additional legal opinion, other information or instructions shall be required of the Holder to exercise this
Purchase Warrant. The Company shall honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant
in accordance with the terms, conditions and time periods set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
(i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in
the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company&rsquo;s
transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company
shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares
of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of the number of shares of the
Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of
this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st
</SUP>day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be
defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary
or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise Price
of this Warrant will not be adjusted in the event that the Company or any Subsidiary thereof, as applicable, sells or grants any option
to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option
to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the Exercise
Price then in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
[RESERVED]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the
Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other
than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way
of return of capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder
has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock,
(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each
a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number
of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable by holders of Common Stock as a result of such Fundamental
Transaction for each share of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without
regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and
approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity
(or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the
number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified,
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock
of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such notice or any defect
therein shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice
provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of
the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.
Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly
assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Registration Rights</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Demand Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.1.
<U>Grant of Right</U>. The Company, upon written demand (a &ldquo;<U>Demand Notice</U>&rdquo;) of the Holder(s) of at least 51% of the
Warrants and/or the underlying Warrant Shares (&ldquo;<U>Majority Holders</U>&rdquo;), agrees to register, on one occasion, all or any
portion of the Warrant Shares underlying the Warrants (collectively, the &ldquo;<U>Registrable Securities</U>&rdquo;). On such occasion,
the Company will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt
of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter, subject
to compliance with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice
if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant
to Section 5.2 hereof and either: (i) the Holder has elected to participate in the offering covered by such registration statement or
(ii) if such registration statement relates to an underwritten primary offering of securities of the Company, until the offering covered
by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated. The demand for registration
may be made at any time during a period of four (4) years beginning on the Initial Exercise Date. The Company covenants and agrees to
give written notice of its receipt of any Demand Notice by any Holder(s) to all other registered Holders of the Warrants and/or the Registrable
Securities within ten (10) days after the date of the receipt of any such Demand Notice. Any such registration statement as referenced
above, a &ldquo;<U>Registration Statement</U>.&rdquo; Notwithstanding anything else herein to the contrary, as to any particular Registrable
Security, such securities shall cease to be Registrable Securities upon the earliest to occur of: (i) a Registration Statement with respect
to the sale of such securities shall have become effective under the Securities Act and such securities shall have been sold, transferred,
disposed of or exchanged in accordance with such Registration Statement by the applicable holder; (B) (i) such securities shall have
been otherwise transferred, (ii) new certificates for such securities not bearing (or book entry positions not subject to) a legend restricting
further transfer shall have been delivered by the Company and (iii) subsequent public distribution of such securities shall not require
registration under the Securities Act; (C) such securities shall have ceased to be outstanding; (D) such securities may be sold without
registration pursuant to Rule 144 or any successor rule promulgated under the Securities Act (but with no volume or other restrictions
or limitations including as to manner or timing of sale); and (E) such securities have been sold to, or through, a broker, dealer or
underwriter in a public distribution or other public securities transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.2
<U>Terms</U>. The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section
5.1.1, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts to cause
the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such States as are reasonably
requested by the Holder(s); provided, however, that in no event shall the Company be required to register the Registrable Securities
in a State in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State
or submit to general service of process in such State, or (ii) the principal shareholders of the Company to be obligated to escrow their
shares of capital stock of the Company. The Company shall cause any registration statement filed pursuant to the demand right granted
under Section 5.1.1 to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the
Registrable Securities covered by such registration statement are first given the opportunity to sell all of such securities. The Holders
shall only use the prospectuses provided by the Company to sell the Warrant Shares covered by such registration statement, and will immediately
cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due
to a material misstatement or omission. Notwithstanding the provisions of this Section 5.1.2, the Holder shall be entitled to a demand
registration under this Section 5.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary
of the date of the Underwriting Agreement (as defined below) in accordance with FINRA Rule 5110(g)(8)(C).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>5.2
</U>&ldquo;<U>Piggy-Back&rdquo; Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.1
Grant of Right. In addition to the demand right of registration described in Section 5.1 hereof, the Holder shall have the right, for
a period of no more than five (5) years from the Initial Exercise Date in accordance with FINRA Rule 5110(g)(8)(D), to include the Registrable
Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated
by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely
in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall,
in its reasonable discretion, impose a limitation on the number of shares of Common Stock which may be included in the Registration Statement
because, in such underwriter(s)&rsquo; judgment, marketing or other factors dictate such limitation is necessary to facilitate public
distribution, then the Company shall be obligated to include in such Registration Statement only such limited portion of the Registrable
Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of
Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number
of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable
Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such
securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.2
Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5.2.1 hereof,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent
them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish
the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date
of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed
by the Company during the two (2) year period following the Initial Exercise Date until such time as all of the Registrable Securities
have been sold by the Holder. The holders of the Registrable Securities shall exercise the &ldquo;piggy-back&rdquo; rights provided for
herein by giving written notice within ten (10) days of the receipt of the Company&rsquo;s notice of its intention to file a registration
statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration
under this Section 5.2.2; provided, however, that such registration rights shall terminate on the second anniversary of the Initial Exercise
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>5.3
General Terms</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.1
<U>Indemnification</U>. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration
statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section
20 (a) of the Exchange Act against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and
other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become
subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent
and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriters contained in Section
5.1 of the Underwriting Agreement between the Underwriters and the Company, dated as of [___], 20[XX]. The Holder(s) of the Registrable
Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify
the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys&rsquo; fees and other expenses
reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the
Securities Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their successors
or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the provisions
contained in Section 5.2 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.2
<U>Exercise of Warrants</U>. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants
prior to or after the initial filing of any registration statement or the effectiveness thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.3
<U>Documents Delivered to Holders</U>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to
each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel
to the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten public offering,
an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a &ldquo;cold comfort&rdquo; letter
dated the effective date of such registration statement (and, if such registration includes an underwritten public offering, a letter
dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has
issued a report on the Company&rsquo;s financial statements included in such registration statement, in each case covering substantially
the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants&rsquo;
letter, with respect to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer&rsquo;s
counsel and in accountants&rsquo; letters delivered to underwriters in underwritten public offerings of securities. The Company shall
also deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to
the managing underwriter, if any, copies of all correspondence between the Commission and the Company, its counsel or auditors and all
memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each Holder
and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted from the
registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation
shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and
independent auditors, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.4
<U>Underwriting Agreement</U>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected
by any Holders whose Registrable Securities are being registered pursuant to this Section 5, which managing underwriter shall be reasonably
satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such
managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily
contained in agreements of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating
to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties
and covenants of the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such
Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except
as they may relate to such Holders, their Warrant Shares and their intended methods of distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.5
<U>Documents to be Delivered by Holder(s</U>). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to
the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security
holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3.6 <U>Damages</U>.
Should the registration or the effectiveness thereof required by Sections 5.1 and 5.2 hereof be delayed by the Company or the
Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief
available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the
threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and
without the necessity of posting bond or other security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
6</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares, and
in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall
not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company
will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or
stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
in accordance with the provisions of the Underwriting Agreement, dated November __, 2024, by and between the Company and ThinkEquity
LLC as representatives of the underwriters set forth therein (the &ldquo;Underwriting Agreement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall
be delivered in accordance with the notice provisions of the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>PROPHASE
    LABS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
OF EXERCISE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TO:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prophase
    Labs, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify">[&nbsp;&nbsp;]
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&nbsp;&nbsp;]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. If the Warrant is being exercised via cash exercise, the undersigned is an &ldquo;accredited investor&rdquo;
as defined in Regulation D promulgated under the Securities Act of 1933, as amended</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: _______________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: ________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ________________________________________</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(To
assign the foregoing warrant, execute<BR>
this form and supply required information.<BR>
Do not use this form to exercise the warrant.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________________________
whose address is</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________________________________________.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
______________, _______</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Signature: _____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
Address: _____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement
or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXHIBIT
B</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Lock-Up Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
LLC<BR>
17 State Street, 41<SUP>st</SUP> Fl<BR>
New York, NY 10004</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that ThinkEquity LLC (the &ldquo;<B>Representative</B>&rdquo;) proposes to enter into an Underwriting Agreement
(the &ldquo;<B>Underwriting Agreement</B>&rdquo;) with ProPhase Labs, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;),
providing for the public offering (the &ldquo;<B>Public Offering</B>&rdquo;) of shares of common stock, par value $0.0005 per share,
of the Company (the &ldquo;<B>Shares</B>&rdquo;) and/or pre-funded warrants ro purchase Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
induce the Representative to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without
the prior written consent of the Representative, the undersigned will not, during the period commencing on the date hereof and ending
120 days for officers and directors of the Company after the date of the final prospectus (the &ldquo;<B>Prospectus</B>&rdquo;) relating
to the Public Offering (the &ldquo;<B>Lock-Up Period</B>&rdquo;), (1) offer, pledge, sell, contract to sell, grant, lend, or otherwise
transfer or dispose of, directly or indirectly, any Shares or any securities convertible into or exercisable or exchangeable for Shares,
whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power
of disposition (collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;); (2) enter into any swap or other arrangement that transfers
to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction
described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for
or exercise any right with respect to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any
offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities.
Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior
written consent of the Representative in connection with (a) transactions relating to Lock-Up Securities acquired in open market transactions
after the completion of the Public Offering; <U>provided</U> that no filing under Section 16(a) of the Securities Exchange Act of 1934,
as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), shall be required or shall be voluntarily made in connection with subsequent sales
of Lock-Up Securities acquired in such open market transactions; (b) transfers of Lock-Up Securities as a <I>bona fide</I> gift, by will
or intestacy or to a family member or trust for the benefit of a family member (for purposes of this lock-up agreement, &ldquo;family
member&rdquo; means any relationship by blood, marriage or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities
to a charity or educational institution; (d) if the undersigned, directly or indirectly, controls a corporation, partnership, limited
liability company or other business entity, any transfers of Lock-Up Securities to any shareholder, partner or member of, or owner of
similar equity interests in, the undersigned, as the case may be (<U>provided</U> that in the case of any transfer pursuant to the foregoing
clauses (b), (c) or (d), (i) any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and deliver
to the Representative a lock-up agreement substantially in the form of this lock-up agreement and (iii) no filing under Section 16(a)
of the Exchange Act shall be required or shall be voluntarily made); (e) the receipt by the undersigned from the Company of Shares upon
the exercise of options to purchase Shares issued under an equity incentive plan of the Company or an employment arrangement described
in the Prospectus and the transfer of Shares or any securities convertible into Shares to the Company upon the exercise of options to
purchase Shares, in each case on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis or to cover tax obligations of the undersigned
in connection with such exercise; (f) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer
of Lock-Up Securities, provided that (i) such plan does not provide for the transfer of Lock-Up Securities during the Lock-Up Period
and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf
of the undersigned or the Company regarding the establishment of such plan, such public announcement or filing shall include a statement
to the effect that no transfer of Lock-Up Securities may be made under such plan during the Lock-Up Period; (g) the transfer of Lock-Up
Securities that occurs by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement,
provided that the transferee agrees to sign and deliver a lock-up agreement substantially in the form of this lock-up agreement for the
balance of the Lock-Up Period, and provided further, that any filing under Section 13 or Section 16(a) of the Exchange Act that is required
to be made during the Lock-Up Period as a result of such transfer shall include a statement that such transfer has occurred by operation
of law; and (h) the transfer of Lock-Up Securities pursuant to a <I>bona fide</I> third party tender offer, merger, consolidation or
other similar transaction made to all holders of the Shares involving a change of control (as defined below) of the Company after the
closing of the Public Offering and approved by the Company&rsquo;s board of directors; provided that in the event that the tender offer,
merger, consolidation or other such transaction is not completed, the Lock-Up Securities owned by the undersigned shall remain subject
to the restrictions contained in this lock-up agreement. For purposes of clause (h) above, &ldquo;<B>change of control</B>&rdquo; shall
mean the consummation of any <I>bona fide</I> third party tender offer, merger, amalgamation, consolidation or other similar transaction
the result of which is that any &ldquo;<B>person</B>&rdquo; (as defined in Section 13(d)(3) of the Exchange Act), or group of persons,
becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total voting power of the voting
stock of the Company. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer
agent and registrar against the transfer of the undersigned&rsquo;s Lock-Up Securities except in compliance with this lock-up agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up
agreement during the period from the date hereof to and including the 34<SUP>th</SUP> day following the expiration of the initial Lock-Up
Period, the undersigned will give notice thereof to the Company and will not consummate any such transaction or take any such action
unless it has received written confirmation from the Company that the Lock-Up Period (as may have been extended pursuant to the previous
paragraph) has expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the undersigned is an officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally
applicable to any issuer-directed or &ldquo;friends and family&rdquo; Shares that the undersigned may purchase in the Public Offering;
(ii) the Representative agrees that, at least three (3) business days before the effective date of any release or waiver of the foregoing
restrictions in connection with a transfer of Lock-Up Securities, the Representative will promptly notify the Company of the impending
release or waiver; and (iii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press
release through a major news service at least two (2) business days before the effective date of the release or waiver. Any release or
waiver granted by the Representative hereunder to any such officer or director shall only be effective two (2) business days after the
publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely
to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound by the same
terms described in this lock-up agreement to the extent and for the duration that such terms remain in effect at the time of such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
provision in this agreement shall be deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities
exercisable or exchangeable for or convertible into Shares, as applicable; <U>provided</U> that the undersigned does not transfer the
Shares acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise permitted pursuant to the terms
of this lock-up agreement. In addition, no provision herein shall be deemed to restrict or prohibit the entry into or modification of
a so-called &ldquo;10b5-1&rdquo; plan at any time (other than the entry into or modification of such a plan in such a manner as to cause
the sale of any Lock-Up Securities within the Lock-Up Period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the Company and the Representative are relying upon this lock-up agreement in proceeding toward consummation
of the Public Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the
undersigned&rsquo;s heirs, legal representatives, successors and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that, if the Underwriting Agreement is not executed by [&#9679;], 20[XX], or if the Underwriting Agreement (other
than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Shares
to be sold thereunder, then this lock-up agreement shall be void and of no further force or effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not the Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only
be made pursuant to an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%"></TD>
  <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Very <FONT STYLE="font-size: 10pt">truly
  yours,</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U><BR>
  </U>(Name - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
  (Signature)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Name of Signatory, in the case of entities
  - Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><BR>
</U>(Title of Signatory, in the case of entities - Please Print)</FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><BR></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EXHIBIT
C</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Press Release</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPHASE
LABS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Date]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs, Inc. (the &ldquo;Company&rdquo;) announced today that ThinkEquity LLC, acting as representative for the underwriters in the Company&rsquo;s
recent public offering of _______ shares of the Company&rsquo;s common stock, is [waiving] [releasing] a lock-up restriction with respect
to _________ shares of the Company&rsquo;s common stock held by [certain officers or directors] [an officer or director] of the Company.
The [waiver] [release] will take effect on _________, 20___, and the shares may be sold on or after such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release is not an offer or sale of the securities in the United States or in any other jurisdiction where such offer or sale is
prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration
under the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 67; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">Ex. C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="width: 150px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reed Smith LLP</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">599 Lexington Avenue<BR> New York, NY 10022-7650</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel +1 212 521 5400</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax +1 212 521 5450</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reedsmith.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
12, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase Labs, Inc.<BR> 711 Stewart Ave., Suite 200</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Garden City, NY 11530</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to ProPhase Labs, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the offer
and sale by the Company of 4,795,500 shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.0005
(the &ldquo;<U>Common Stock</U>&rdquo;) and warrants (the &ldquo;<U>Representative&rsquo;s Warrants</U>&rdquo;) to purchase up to 239,775
shares of Common Stock (the &ldquo;<U>Representative&rsquo;s Warrant Shares</U>&rdquo;), issued to the representative of the underwriters
(the &ldquo;<U>Representative</U>&rdquo;) pursuant to the underwriting agreement dated as of November 7, 2024, between the Company and
ThinkEquity LLC as the representative of the several underwriters named therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
such capacity, we have reviewed copies of the registration statement on Form S-3 (File No. 333-260848) filed by the Company under the
Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
on November 5, 2021 (such registration statement, including the documents incorporated therein, the &ldquo;<U>Registration Statement</U>&rdquo;),
and the base prospectus dated November 12, 2021 forming a part of the Registration Statement with respect to the offering from time to
time of the securities described therein with an aggregate initial offering price not to exceed $300,000,000, which was included as part
of the Registration Statement at the time it became effective (the &ldquo;<U>Base Prospectus</U>&rdquo;) and the final prospectus supplement,
dated November 8, 2024, relating to the offer and sale of the Shares, the Representative&rsquo;s Warrants and underlying Representative&rsquo;s
Warrant Shares and, if applicable, the Pre-Funded Warrants in the form first filed by the Company pursuant to Rule 424(b) under the Securities
Act with the Commission (the &ldquo;<U>Final Prospectus Supplement</U>&rdquo; and, the Base Prospectus, as amended and supplemented by
the Final Prospectus Supplement, including the documents incorporated by reference therein, the &ldquo;<U>Prospectus</U>&rdquo;). This
opinion letter is furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K, 17 C.F.R. &sect; 229.601(b)(5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have reviewed originals or copies of the Registration Statement, the Prospectus, the Underwriting Agreement, the Pre-Funded Warrant Agreement,
the Representative&rsquo;s Warrant Agreement, the certificate of incorporation and bylaws of the Company, as amended through the date
hereof, certain resolutions of the Board of Directors of the Company, and such other corporate records, agreements and documents of the
Company, certificates or comparable documents of public officials and officers of the Company and have made such other investigations
as we have deemed necessary as a basis for the opinion set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0">ProPhase Labs, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">November 12, 2024</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></TD><TD STYLE="width: 50%; text-align: right"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="width: 150px"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
rendering the opinion set forth below, we have assumed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    genuineness of all signatures;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    legal capacity of natural persons;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    authenticity of all documents submitted to us as originals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    conformity to original documents of all documents submitted to us as duplicates or conformed copies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    to matters of fact, the truthfulness of the representations made in certificates or comparable documents of public officials and
    officers of the Company; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    respect to the issuance of the Shares, the amount of valid consideration paid in respect of such Shares will equal or exceed the
    par value of such Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not independently established the validity of the foregoing assumptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing, and subject to the qualifications, assumptions and limitations stated herein, we are of the opinion that (i) the
Shares have been duly authorized by all necessary corporate action on the part of the Company under the DGCL and, when issued and sold
pursuant to the Underwriting Agreement, will be validly issued, fully paid and nonassessable, (ii) the Pre-Funded Warrants as described
in the Prospectus have been duly authorized by all requisite corporate action on the part of the Company under the General Corporation
Law of the State of Delaware (the &ldquo;DGCL&rdquo;) and, when the Pre-Funded Warrants have been duly executed by the Company and delivered
to and paid for by as contemplated by the Underwriting Agreement, will be valid and legally binding obligations of the Company, enforceable
against the Company in accordance with their terms, (iii) the Pre-Funded Warrant Shares have been duly authorized by all requisite corporate
action on the part of the Company under the DGCL and when issued and delivered by the Company against payment therefor in accordance
with the terms of such Pre-Funded Warrants, will be duly authorized, validly issued, fully paid and non-assessable, (iv) the Representative&rsquo;s
Warrants as described in the Prospectus have been duly authorized by all requisite corporate action on the part of the Company under
the DGCL and, when the Representative&rsquo;s Warrants have been duly executed by the Company and delivered to and paid for as contemplated
by the Underwriting Agreement, will be valid and legally binding obligations of the Company, enforceable against the Company in accordance
with their terms, and (v) the Representative&rsquo;s Warrant Shares have been duly authorized by all requisite corporate action on the
part of the Company under the DGCL and when issued and delivered by the Company against payment therefor in accordance with the terms
of such Representative&rsquo;s Warrants, will be duly authorized, validly issued, fully paid and non-assessable .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinion is limited to the DGCL, and we do not express any opinion herein concerning any other law. This opinion letter speaks only as
of its date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0">ProPhase Labs, Inc.</P><P STYLE="margin-top: 0; margin-bottom: 0">November 12, 2024</P><P STYLE="margin-top: 0; margin-bottom: 0">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></TD><TD STYLE="width: 50%; text-align: right"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="width: 150px"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K being filed on the
date hereof and incorporated by reference into the Registration Statement and to the use of our name under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus. In giving such consent, we do not hereby admit that we are within the category of persons whose consent is required
under Section 7 of the Securities Act, and the rules and regulations of the Commission promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Reed Smith</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REED
    SMITH LLP</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT="" style="width:150px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ProPhase
Labs Announces Pricing of Public Offering of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GARDEN
CITY, NY, November 7, 2024 (GLOBE NEWSWIRE) </B>&mdash; ProPhase Labs, Inc. (NASDAQ: PRPH) (&ldquo;ProPhase&rdquo; or the &ldquo;Company&rdquo;),
a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000
shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of
approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are being offered by the
Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 625,500 shares of common
stock at the public offering price less discounts, to cover over-allotments. The offering is expected to close on November 12, 2024,
subject to satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital
expenditures, product development and commercialization expenditures, and acquisitions of companies, businesses, technologies and products
within and outside the diagnostic services, genomics and consumer products industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
is acting as sole book-running manager for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-260848), including a base prospectus,
filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on November 5, 2021 and declared effective on November
12, 2021. The offering will be made only by means of a written prospectus. A prospectus supplement and accompanying prospectus describing
the terms of the offering will be filed with the SEC on its website at <U>www.sec.gov</U>. Copies of the prospectus supplement and the
accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street,
41<SUP>st </SUP>Floor, New York, New York 10004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means
of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
ProPhase Labs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs, Inc. (Nasdaq: PRPH) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with
bold action and the power of insight. We believe we are revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions,
while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving
cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action.
Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We
develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to
executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs&rsquo; subsidiaries and their
strategic synergies highlight our potential for long-term value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, visit <FONT STYLE="background-color: white"><U>www.ProPhaseLabs.com</U></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains &ldquo;forward-looking statements&rdquo; as defined by the Private Securities Litigation Reform Act of 1995 that
involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo; &ldquo;might,&rdquo;
&ldquo;will,&rdquo; &ldquo;objective,&rdquo; &ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;would,&rdquo;
&ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;design,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo;
&ldquo;plan&rdquo; or the negative of these terms and similar expressions intended to identify forward-looking statements. These statements
include statements related to the expected completion of the offering described herein and the intended use of proceeds. The Company
cautions readers that forward-looking statements are based on management&rsquo;s expectations and assumptions as of the date of this
release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited
to, risks related to prevailing market conditions, the impact of general economic, industry or political conditions in the United States,
and the Company&rsquo;s ability to satisfy customary closing conditions associated with the offering. Management believes that these
forward-looking statements are reasonable as and when made. The Company undertakes no obligation to update forward-looking statements
except as required by applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Relations and Institutional Investor Contact: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">267-880-1111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>investorrelations@prophaselabs.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Retail
Investor Relations Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renmark
Financial Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Boidman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">514-939-3989</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Jboidman@renmarkfinancial.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>ProPhase
Labs Announces Closing of Public Offering of Common Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GARDEN
CITY, NY, November 12, 2024 (GLOBE NEWSWIRE)</B> &mdash; ProPhase Labs, Inc. (NASDAQ: PRPH) (&ldquo;ProPhase&rdquo; or the &ldquo;Company&rdquo;),
a next-generation biotech, genomics and diagnostics company, today announced the closing of its previously announced underwritten public
offering of 4,795,500 shares of its common stock, including 625,500 shares sold upon full exercise of the underwriter&rsquo;s option
to purchase additional shares. Each share of common stock was sold at a public offering price of $0.72 per share, for gross proceeds
of approximately $3.45 million, before deducting underwriting discounts and offering expenses. All of the shares were sold by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital
expenditures, product development and commercialization expenditures, and acquisitions of companies, businesses, technologies and products
within and outside the diagnostic services, genomics and consumer products industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ThinkEquity
acted as sole book-running manager for the offering. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-260848), including a base prospectus,
filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on November 5, 2021 and declared effective on November
12, 2021. The final prospectus supplement relating to the offering was filed with the SEC on November 8, 2024 and is available on the
SEC&rsquo;s website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the
offering may be obtained from ThinkEquity, 17 State Street, 41<SUP>st</SUP> Floor, New York, New York 10004.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
ProPhase Labs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs, Inc. (Nasdaq: PRPH) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with
bold action and the power of insight. We believe we are revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions,
while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving
cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action.
Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We
develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to
executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs&rsquo; subsidiaries and their
strategic synergies highlight our potential for long-term value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, visit www.ProPhaseLabs.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains &ldquo;forward-looking statements&rdquo; as defined by the Private Securities Litigation Reform Act of 1995 that
involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo; &ldquo;might,&rdquo;
&ldquo;will,&rdquo; &ldquo;objective,&rdquo; &ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;would,&rdquo;
&ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;design,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo;
&ldquo;plan&rdquo; or the negative of these terms and similar expressions intended to identify forward-looking statements. These statements
include statements related to the intended use of proceeds. ProPhase cautions readers that forward-looking statements are based on management&rsquo;s
expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause
actual results to differ materially, including, but not limited to, risks related to prevailing market conditions, the impact of general
economic, industry or political conditions in the United States, and ProPhase&rsquo;s ability to satisfy customary closing conditions
associated with the offering. Management believes that these forward-looking are reasonable as and when made. Forward-looking statements
reflect its analysis only on their stated date, and ProPhase undertakes no obligation to update or revise these statements except as
may be required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Relations and Institutional Investor Contact: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ProPhase
Labs, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">267-880-1111</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">investorrelations@prophaselabs.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Retail
Investor Relations Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renmark
Financial Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Boidman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">514-939-3989</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jboidman@renmarkfinancial.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '<"K<# 2(  A$! Q$!_\0
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MO#\Z^9CXSN!_RT/YTG_":7/_ #T/YT ?37_"3V7]X?G1_P )/9?WA^=?,O\
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MZY4B@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHI('&17@_@[Q#+=2(&<FO:M+D,D"D^E &A1110 4444 %%%% !1110 4444
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XX_X1V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?X?C]]'7T1HW_'JGTH U:*** "BBB@ HHHH **** "BBB@ HHILCB-"S' %
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MQ/\ "9[?H_\ Q[K]*U:RM'_X]U^E:M=:/B:GQ,****9F%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )@>@HP/04M%
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MO9/!W^K2M*>YYN9? >C0_P"K%24R+_5BGUU'R3"BBB@04444 %%%% !1110
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M,]O.BLYQGUKZ'\.:W'>VR#<"<4 =)1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I10>E '
M>,O]4]?/?B7_ (^'^M?0GC+_ %3U\]^)?^/A_K0!S4?6I:BCZU+0 4444 %5
MI/\ 6#ZU9JM)_K!]: /3_A__ *Z.OHC1O^/5/I7SO\/_ /71U]$:-_QZI]*
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M%=J.@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML![5T4T?,9G/F=B]1116QXH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4R1!(A!I]% 'F7C:P"QN0*\;ND*W+#WKZ"\8V_F6[<=J\.U6U
M,=RQQWKFJ+4^JRRI>%F4!TH;H:3OBE;I61ZXMC_Q]#ZU[)X._P!6E>-V/_'T
M/K7LG@[_ %:5I3W/,S+X#T>+_5BGTR+_ %8I]=1\DPHHHH$%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKL****9 4444 %%%%  >E<QXD_X]V^E=.>E<QXD_X]V^E3+8WP_QH\,\1?\
M'RWUK'BZ5L>(O^/EOK6/%TKD>Y]M2_AHDHHHI%A0>E%!Z4 ,3_6"NX\,?ZQ*
MX=/]8*[CPQ_K$JH[G-B_@/8]%_U ^E:U9.B_Z@?2M:NM;'QE7XF%%%%,S"BB
MB@ HHHH **** "BBB@ HHHH **** "N8\1_ZIJZ>N8\1_P"J:IEL;X?XT>,>
M(/\ 7-]:YM?O&ND\0?ZYOK7-K]XUR2W/M*'P$E%%%(U"BBB@"&3[PKL?"/\
MKD^M<=)]X5V/A'_7)]:J.YCB?X3/;M'_ ./=?I6K65H__'NOTK5KK1\34^)A
M1113,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ./\ %O\ J'^E?//BO_7O]:^AO%O^H?Z5\\^*_P#7
MO]: .,7[YJ:H5^^:FH **** "BBB@"%_O"NN\+?\?"?6N1?[PKKO"W_'PGUH
M ^A?"'^I2NVKB?"'^I2NVH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?6O9/!W^K2M*>YYF9? >CQ?ZL4^F1?ZL4^NH^284444""BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D*JW4 TM% $$MG!*.4%
M49-&@)^X*U:*5BU.2V9C?V)#G[@_*K$6DP)R4'Y5HT46&ZDGU(DMH8_NH*E
M Z444R+W"BBB@04444 %%%% !1110 'I7,>)/^/=OI73GI7,>)/^/=OI4RV-
M\/\ &CPSQ%_Q\M]:QXNE;'B+_CY;ZUCQ=*Y'N?;4OX:)****184'I10>E #$
M_P!8*[CPQ_K$KAT_U@KN/#'^L2JCN<V+^ ]CT7_4#Z5K5DZ+_J!]*UJZUL?&
M5?B84444S,**** "BBB@ HHHH **** "BBB@ HHHH *YCQ'_ *IJZ>N8\1_Z
MIJF6QOA_C1XQX@_US?6N;7[QKI/$'^N;ZUS:_>-<DMS[2A\!)1112-0HHHH
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M/X@>4QVR?K0![(;B%>LB_G5.XU>VAX\P5X%=_$R4$@2G\ZR)_B)-*3^\/YT
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M77>%O^/A/K0!]"^$/]2E=M7$^$/]2E=M0 4444 %%%% !1110 4444 %%%%
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M-M#;(_TKS;6?"MS;NQ"'% '/VMTT/1C6Q;^))K;&'/YUA26[6[8<$4S8'Z4
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M>-?&;2O(D<A_.@!?&?C1F=UCD/X&O+;S69KMVW,3FH;N^DNY&+$G)JLL8S0
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MIO8U:*16#*".E+5',%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU^;-='7B_@[6BC(K-7KEC=K<0J0<G%=4)71\AC*#I3+E%%%6<(4444 %%%%
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MS)0!Z1X/T7[+ C[<<5W@Z"JMA;+;VJ*!VJW0 4444 %%%% !6?J6I1V,+,S
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M[P3BOD59WAE!4XYKUCX?Z^\4D:N_IWH ^CQR,T5FZ7J"7<"8;/%:5 !1110
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MUJS5:3_6#ZT >G_#_P#UT=?1&C?\>J?2OG?X?_ZZ.OHC1O\ CU3Z4 :M%%%
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MTQ)SS0!6 9I2QJQ2 4M !1110 R0X%7M(M_M4ZKC/-9MQG972^"8#-?H".]
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M4AAD4M5K&3S+<-5F@ HHHH PM>U(64+G.,"OGOQUK'VN:0!N]>H?$74S;Q2
M-7SSJE^;FY?)SS0!F*"92:GIBK@YI] !1110 56N!EA5@TT)O<4 >A?#BV\R
MZCR.XKZ6TRW$-E'QVKP/X;6VV>,X[BOH6W&+>,?[- $M%%% !1110 4444 %
M%%% !1110 4444 ,E_U3?2O+/&T3%'.*]5894BN$\86H:W<X[4 ?-.NJ5N&S
MZUE1=*W?%*>7=/\ 6L&'I0!+1110 4444 1*/WP->B>#K\PS(,UY[C#9K?\
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MB;IU^M 'K_P^M"CQG'I7M\/$*?2O*_ \(54./2O58_\ 5K]* '4444 %%%%
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M?,)%>#ZA (IVP.]?1GCB#?&YQ7@&NQ[)W^M &(IS3ZCCZU)0 4444 %5I/\
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M=HHW#-;QDF?.XC"3I/;0W:*:CAU# \4ZK.(**** "BBB@ HHHH **** .?\
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ME]QZ\@NO^/D_6O7_ !E]QZ\@NO\ CY/UKEJ;GU^7?PQ1TI:0=*6LST HHHH
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M@KN/#'^L2JCN<V+^ ]CT7_4#Z5K5DZ+_ *@?2M:NM;'QE7XF%%%%,S"BBB@
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M_P ]?UH ]GHKQC_A:Z?\]?UH_P"%KI_SU_6@#V>BO&/^%KI_SU_6C_A:Z?\
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M** "BBB@ HHHH **** "BBB@ H/2BB@#AO%\&^%SCM7SSXIB\NX?ZU]->)8
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M_6O</B!/L209]:\"U67?._UH RD'S&I:8G6GT %%%% !112$T +VJO,EP?\
M5Y_"K<*[Y *[KP[X7_M +E,Y]J /,_*OO]NCRK[_ &Z]^_X5ROE@^7^E1_\
M"NQ_SS_2@#P7RK[_ &Z/*OO]NO>O^%=C_GG^E'_"NQ_SS_2@#P7RK[_;H\J^
M_P!NO>O^%=C_ )Y_I1_PKL?\\_TH \%\J^_VZ/*OO]NO>O\ A78_YY_I1_PK
ML?\ //\ 2@#P7RK[_;H\J^_VZ]Z_X5V/^>?Z4?\ "NQ_SS_2@#P7RK[_ &Z/
M*OO]NO>O^%=C_GG^E'_"NQ_SS_2@#P7RK[_;H\J^_P!NO>O^%=C_ )Y_I1_P
MKL?\\_TH \&$5]GG?4RPW/<&O<_^%=C_ )Y_I1_PKP?\\_TH \.\B?\ NFCR
M)_[IKW'_ (5X/^>?Z4?\*\'_ #S_ $H \.\B?^Z:/(G_ +IKW'_A7@_YY_I1
M_P *\'_//]* /#O(G_NFCR)_[IKW'_A7@_YY_I1_PKP?\\_TH \)G@GV?=-;
M?@R&8:FA*G&ZO6)/AT"N/+_2KVB> A:72OY>,'TH ]/\) C1TSZ"MZL_2+;[
M+9K'CI6A0!%<2".)B?2O$_B1<ATD&?6O6];G,-NV/2O!/'-Z9'<9H \FN.;M
MOK4PZ5'*,W!/O4HZ4 %%%% !1110 4UPQ'RTCMMK4T>T^URA<9R: ,)X[PGY
M=U,\J^_VZ]FTSP0+F(-Y><^U:H^'8Q_J_P!* /!/*OO]NCRK[_;KWK_A78_Y
MY_I1_P *['_//]* /!?*OO\ ;H\J^_VZ]Z_X5V/^>?Z4?\*['_//]* /!?*O
MO]NCRK[_ &Z]Z_X5V/\ GG^E'_"NQ_SS_2@#P7RK[_;H\J^_VZ]Z_P"%=C_G
MG^E'_"NQ_P \_P!* /!?*OO]NCRK[_;KWK_A78_YY_I1_P *['_//]* /!?*
MOO\ ;H\J^_VZ]Z_X5V/^>?Z4?\*['_//]* /!?*OO]NE6*]SSNKWG_A78_YY
M_I1_PKL?\\_TH \-6"X[J:7R)_[IKW'_ (5X/^>?Z4?\*\'_ #S_ $H \.\B
M?^Z:/(G_ +IKW'_A7@_YY_I1_P *\'_//]* /#O(G_NFCR)_[IKW'_A7@_YY
M_I1_PKP?\\_TH \.,$^/NFF003^>/E/6O=/^%=C_ )Y_I34^'8#@^7^E '/>
M"8YA*F0:^@] !^RC/I7$:'X3%FRG9C'M7H>GP>1"%Q0!<KD/',^W377/8UUS
M'"DUYWX[G/V:0>U 'S7XF);4G/\ M51A^X*NZ^<WSGWJG']R@!]%%% !1110
M U_NU-IW_'POUJ%_NU+IW_'P/K0![7X&QF/\*]KT_P#X]5KQ+P-UC_"O;-/_
M ./5: +=%%% !1110 4444 %%%% !1110 4444 %%%% &'X@_P"/1_I7S?X[
M_P"/A_K7TKKL9>S?'I7S;X^0K</GUH \]A^\:L57A/S&K% !1110 56D_P!8
M/K5FJTG^L'UH ]/^'_\ KHZ^B-&_X]4^E?._P_\ ]='7T1HW_'JGTH U:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0J",$ TM% &9?Z5
M%<J<(.:Y:^\&+.20GZ5WE%2XIF]/$3I[,\?O_ _E D)^E<EJ.@26Y.$/Y5]#
MSVZ3(0RBL*]\-1W)/RCFH=/L>G0S*2^,^=9K2>-C\IJ()(.H->X7W@9"A8(/
MRKC]4\*-"3M3]*R<&CUZ684YZ' CCK2Y%:-]I$\3'"FLPVLR-R#46.Z,HR5T
MQ]%-P5ZTNX4ABT49HH **** "BBB@ HHHH *0CBEHH C^93D5LZ)JDD%PN6.
M,UDD9%-0F)MPIIV%**G&S/?_  UK2S0*I;G%=A&X= 17@'A?7&CG12W&:]MT
M:]2YM%.[G%=,)7/DL=AG2E<U****T/-"BBB@ HHHH Y_Q!_Q[M]*\,\3_P#'
MPWUKW/Q!_P >[?2O#/$__'PWUK"H?0Y5N<_%4M115+6!] ]PHHHH$%1C_6"I
M*C'^L% T=CX:_P!8M>RZ#_J5^E>->&O]8M>RZ#_J5^E=%,^;S/<W****V/""
MBBB@ HHHH **** "BBB@ I&^Z:6D;[IH XKQ7_J'^E>(:S_Q]-]:]O\ %?\
MJ'^E>(:S_P ?3?6N>H?4Y7\)3C^Z*?3(_NBGUB>PPHHHH$(>E%O_ *X?6@]*
M+?\ UP^M ^AZ+X5^\E>N:9_Q[CZ5Y'X5^\E>N:9_Q[CZ5TTSY3,?B+U%%%:G
MDA1110 4444 %%%% !1110 5%/\ ZLU+44_^K- UN>9^,ON/7D%U_P ?)^M>
MO^,ON/7D%U_Q\GZURU-SZ_+OX8HZ4M(.E+69Z 4444 -?I5C3_\ 7"J[]*L:
M?_KA0@E\)ZQX4_@KTNW_ -0M>:>%/X*]+M_]0M=<-CX_'?&2T4459YX4444
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M7\!['HO^H'TK6K)T7_4#Z5K5UK8^,J_$PHHHIF84444 %%%% !1110 4444
M%%%% !1110 5S'B/_5-73US'B/\ U35,MC?#_&CQCQ!_KF^M<VOWC72>(/\
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M $KYY\5_Z]_K7T-XM_U#_2OGGQ7_ *]_K0!QB_?-35"OWS4U !1110 4444
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MW3]* /%_B7/L\SGUKPBYE\R=OK7LWQ4D*M)^->&JY:X;ZT 3@4ZBB@ HHHH
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M'^%> :7_ ,?"_6O?_AY]R/\ "@#U:BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D?&DICM&Q_=KYP\2W+/=."
M>]?1GCC_ (\W_P!VOFSQ'_Q]O]: .=/WZ?3#]ZGT %%%% !1110!!<=*['P,
MVV\C^M<=/TKK/!9Q=I]: /I_PU+NLD'M6_7+^%F_T1/I744 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5;\XM6KQ
M7QS*?WE>U:A_QZM7B7CGK)0!XOJ1S<'ZU"GW:FU'_CX/UJ%/NT .HHHH ***
M* &O]VIM-&ZX4#UJ"3[E6M#&Z]4'UH ]J\#6K?NSCTKVBP7;;*#7G/@2V7R(
MSCM7IL2A8P!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@".X_X]Y/\
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M?E7E/B#PO) [,J''TKGE"Q]'A<?&KI(XP-FEI9X6MVVD4P-Q69Z>^PZBBB@
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M?<>O(+K_ (^3]:Y:FY]?EW\,4=*6D'2EK,] **** &OTJQI_^N%5WZ58T_\
MUPH02^$]8\*?P5Z7;_ZA:\T\*?P5Z7;_ .H6NN&Q\?COC):***L\\**** "B
MBB@ K.UG_CR;Z5HUG:S_ ,>3?2DRZ?Q(\0\4?\?#_6N0?[U=?XH_X^'^M<@_
MWJY);GVN&^! .E+2#I2U)T!1110 UONU-IG_ !]+]:A;[M3:9_Q]+]: E\+/
M:O"'^J2N^C^X*X'PA_JDKOH_N"NN&Q\7C/XC'44459QA1110 4444 !Z5S'B
M3_CW;Z5TYZ5S'B3_ (]V^E3+8WP_QH\,\1?\?+?6L>+I6QXB_P"/EOK6/%TK
MD>Y]M2_AHDHHHI%A0>E%!Z4 ,3_6"NX\,?ZQ*X=/]8*[CPQ_K$JH[G-B_@/8
M]%_U ^E:U9.B_P"H'TK6KK6Q\95^)A1113,PHHHH **** "BBB@ HHHH ***
M* "BBB@ KF/$?^J:NGKF/$?^J:IEL;X?XT>,>(/]<WUKFU^\:Z3Q!_KF^M<V
MOWC7)+<^TH? 24444C4**** (9/O"NQ\(_ZY/K7'2?>%=CX1_P!<GUJH[F.)
M_A,]NT?_ (]U^E:M96C_ /'NOTK5KK1\34^)A1113,PHHHH **** "BBB@ H
MHHH *ANO^/9_I4U0W7_'L_TH&MSQWQC_ *U_K7G<WWS7HGC'_6O]:\[F^^:Y
M)[GV6"_AH8M+2+2U!VA1110 AZ5';?\ 'XOUJ0]*CMO^/Q?K0/HSW3P!_J$^
ME=_7 > /]0GTKOZ[(;'Q6-_C,****HXPHHHH **** "BBB@#C_%O^H?Z5\\^
M*_\ 7O\ 6OH;Q;_J'^E?//BO_7O]: .,7[YJ:H5^^:FH **** "BBB@"%_O"
MNN\+?\?"?6N1?[PKKO"W_'PGUH ^A?"'^I2NVKB?"'^I2NVH **** "HYXA-
M&4-244 >7^-_#*20.ZISCTKY[US3'M;MAM( -?8FJV*WEL5(R<5XCXW\*>6T
MCJGZ4 >+J<#!I]/O;=X)RI&,&HP>* %HHHH **** "FNN13J* 'VETUI(&4X
MKUWP'XG;?&C/Q]:\:E7/2MC0M4:QG4YQS0!]AZ?>I=6Z$$$XJ[7E?@?Q,+I$
M1G_6O4HW#H&!R"* '4444 %%%% !1110 4444 %(WW3]*6D;[I^E '@?Q6^_
M)^->'1_\?#?6O<_BJI+2?C7AJ*1<-]: +5%%% !1110 4QNM/I"* +VF'%PO
MUKW_ .'; I'^%?.EO/Y5POUKWSX97/F>6,^E 'LU% Z44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <CXU0M:-_N
MU\W^)8BMT_UKZ;\4Q^9:M]*^>?%UN$G<X[T <$?O4^HW_P!::D'2@ HHHH *
M*** ()^E=9X+_P"/M/K7)S]*ZSP7_P ?:?6@#Z5\+?\ 'HGTKJ:Y;PM_QZ)]
M*ZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"K?_ /'JU>*>.5/[RO;[I=\)%>2>.K+$<AQ0!X#J7%P?K4*?=JQK
M V73#WJO']V@!U%%% !1110 R3[E6M"XO5^M5G^[4^D'9=*?>@#Z0\"2?Z/'
MSVKTR,Y05X]X%O?W<8S7KEJ^^ &@">BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@".X_X]Y/\ =-?-OQ1_X^9/J:^DKC_CWD_W37S;\4?^/F3ZF@#R>W^^
M:MU4M_OFK= !1110 56D_P!8/K5FJTG^L'UH ]/^'_\ KHZ^B-&_X]4^E?._
MP_\ ]='7T1HW_'JGTH U:*** "BBB@ HHHH @NO]4:\I\:H"'KU:Z_U1KRKQ
MIT>LY['I9?\ Q#R&:%?M9..]=AX<N!#*@!KE9Q_I)/O5_3KLQ7"C/>N9:,^L
MK1YX6/H3P[<>;"O/:NAKB?!-QYT*<]J[:NN.Q\3B8\M1H****HYPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!" PP163J^D0W=NV%&<5K
MT$9ZT6*C)Q=T>&^)?##0NSJG'TKA;B%H)"I%?2VKZ5'>0'Y1G%>1>*/#36SN
MX3]*YYPL?2X''*:Y9'!@\4M-F#12E2*4=*Q/:%HHHH$%%%% "&G1MM84AJ-V
MVT#W/1/!]QF9!FO9[,YM4/M7@O@R?-T@]Z]XL#FSC^E=-/8^6S2-IEFBBBM3
MQPHHHH Y_P 0?\>[?2O#/$__ !\-]:]S\0?\>[?2O#/$_P#Q\-]:PJ'T.5;G
M/Q5+4452U@?0/<****!!48_U@J2HQ_K!0-'8^&O]8M>RZ#_J5^E>->&O]8M>
MRZ#_ *E?I713/F\SW-RBBBMCP@HHHH **** "BBB@ HHHH *1ONFEI&^Z: .
M*\5_ZA_I7B&L_P#'TWUKV_Q7_J'^E>(:S_Q]-]:YZA]3E?PE./[HI],C^Z*?
M6)[#"BBB@0AZ46_^N'UH/2BW_P!</K0/H>B^%?O)7KFF?\>X^E>1^%?O)7KF
MF?\ 'N/I733/E,Q^(O4445J>2%%%% !1110 4444 %%%% !44_\ JS4M13_Z
MLT#6YYGXR^X]>077_'R?K7K_ (R^X]>077_'R?K7+4W/K\N_ABCI2T@Z4M9G
MH!1110 U^E6-/_UPJN_2K&G_ .N%""7PGK'A3^"O2[?_ %"UYIX4_@KTNW_U
M"UUPV/C\=\9+1115GGA1110 4444 %9VL_\ 'DWTK1K.UG_CR;Z4F73^)'B'
MBC_CX?ZUR#_>KK_%'_'P_P!:Y!_O5R2W/M<-\" =*6D'2EJ3H"BBB@!K?=J;
M3/\ CZ7ZU"WW:FTS_CZ7ZT!+X6>U>$/]4E=]']P5P/A#_5)7?1_<%=<-CXO&
M?Q&.HHHJSC"BBB@ HHHH #TKF/$G_'NWTKISTKF/$G_'NWTJ9;&^'^-'AGB+
M_CY;ZUCQ=*V/$7_'RWUK'BZ5R/<^VI?PT24444BPH/2B@]* &)_K!7<>&/\
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MA7MFG_\ 'JM %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@".X_X]Y/\
M=-?-OQ1_X^9/J:^DIR! ^?[IKYM^*1!N9,>IH \GM_OFK=5+?[YJW0 4444
M%5I/]8/K5FJTG^L'UH ]/^'_ /KHZ^B-&_X]4^E?._P__P!='7T1HW_'JGTH
M U:*** "BBB@ HHHH @NO]4:\J\9]'KU6Z_U1KRKQGT>LY['I9?_ !#RB?\
MU[4V$D7*GWIT_P#KV^M$8Q*#7*?8=#V7P'=[$0$UZ9&^]0:\4\)7GEL@S7KV
MF3>;".>U=4'H?(9A3M4;+]%%%:'F!1110 4444 %%%% !1110 4444 %%%%
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M]*CMO^/Q?K0/HSW3P!_J$^E=_7 > /\ 4)]*[^NR&Q\5C?XS"BBBJ.,****
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M1Y)KV*T_X]UH 9?KN@;Z5X;\0H2HD./6O>I$WKBO(OB?8A(9"!V- 'SK.?\
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MZQ_A7MFG_P#'JM>)^!F&8_PKVS3^;5: +=%%% !1110 4444 %%%% !1110
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MHHHH AD^\*['PC_KD^M<=)]X5V/A'_7)]:J.YCB?X3/;M'_X]U^E:M96C_\
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M?]:_UKSN;[YKT3QC_K7^M>=S??-<D]S[+!?PT,6EI%I:@[0HHHH 0]*CMO\
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ML[CR[M.>] 'T_P" KCS88^>U>A5Y/\,KCS(X\GTKUB@ HHHH **** "BBB@
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MFJTG^L'UH ]/^'_^NCKZ(T;_ (]4^E?._P /_P#71U]$:-_QZI]* -6BBB@
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MV):'Q%>?--L****9B%%%% '/^(/^/=OI7AGB?_CX;ZU[GX@_X]V^E>&>)_\
MCX;ZUA4/H<JW.?BJ6HHJEK ^@>X4444""HQ_K!4E1C_6"@:.Q\-?ZQ:]ET'_
M %*_2O&O#7^L6O9=!_U*_2NBF?-YGN;E%%%;'A!1110 4444 %%%% !1110
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M/&/^M?ZUYW-]\UR3W/LL%_#0Q:6D6EJ#M"BBB@!#TJ.V_P"/Q?K4AZ5';?\
M'XOUH'T9[IX _P!0GTKOZX#P!_J$^E=_79#8^*QO\9A1115'&%%%% !1110
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MN* /JFP;?9HU6:S-"F$VFQG/:M.@ HHHH **** "BBB@ HHHH **** "N/\
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M?F( - 'V';7*7,892*GKR?PEXWC:)%>0?G7I%EJL-XH*L.: -"BBB@ HHHH
M**** "BBB@ HZ53N]0AM =Y'%<[JOC.UMX6"NH/UH WKS5K>T0EF&1[UY7XU
M\:*J.L<GY&N>\3^-VD+B.3]:\JU779;N4AF)S0 _6->DO;A@S$Y-9UI8/=W
MV@G)HM+%[V<;5)R:]7\&^#6E:-GC/Y4 6/!'A R-&[Q^G:O=-&TU+&!0%QQ5
M;0M$CL8%^4# K> P,"@ HHHH **** "BBB@ HHHH *CFB$L94]ZDHH \U\8>
M%$N8G=4Y^E> >)- ELKAL(0 :^PKFV2XB*L.M>9>+O!JW2NR1\_2@#YI63R_
ME-3 [AFN@\0>%)[*5FV$ 'TKFF8P':PYH FHIJON%.H C4E)0PKN/"OB5[&9
M!OP![UQ17-)%,T,@(- 'UEX6\317D"JS@Y'K78HZR*&4Y%?*OACQ5):2H"Y
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M@OPT(M+#.G:N!^)MLEO(P48H \M1LFI*JP'+FK5 !1110 56D_U@^M6:KO\
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M \AD:2+]* ,3PAX'9F1WC_2O;=#T**Q@7Y "!5O3-(@LH% 09K4  &!0 @
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M.ZE@<%"174:)XGN+=UW2' ]Z /K6VNDN4W*14]>(Z)\1%@10\OZUU4/Q(MY
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M -H7+==U'GR-U!J7*YU4<(J6Q*@Q3ZK^8_H:/-?T-2=-F6**K^:_H:/-?T-
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MJ9_^>/Z5]#;1Z"C:/04 ?//_  J=_P#GC^E+_P *HD_YY'\J^A=H]!1M'H*
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M*** "BBB@ HHHH **** "C&>M%% $$]G#.I#H.:X[7/"$5V&VQCGVKN** /
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M!2TU%(PK8NI6^(0=*6BBK.,*0\@TM% '">)_#!U-F(3.:XU?APP<GROTKVW
M]*3 ]!4."9Z%+'U:<>6)XQ_PKMO^>7Z4?\*[;_GE^E>SX'H*,#T%+V:+_M.L
M>,_\*\?_ )Y?I2_\*]?_ )YG\J]EP/048'H*/9H/[3K'C7_"O9/^>9_*C_A7
MLG_/,_E7LN!Z"C ]!1[-!_:=8\:_X5[)_P \S^5'_"O9/^>9_*O9<#T%&!Z"
MCV:#^TZQXU_PKV3_ )YG\J/^%>R?\\S^5>RX'H*,#T%'LT']IUCQG_A7C_\
M/+]*/^%=O_SR_2O9L#T%&!Z"CV:#^TZQXQ_PKMO^>7Z4Q_ARS?\ ++]*]JP/
M048'H*/9H?\ :=8\MT;P0UG*K>7C'M7H>G6OV>(+CI5_ ]!2U2BD<E;$SK?$
M%%%%4<P5%<)YD#+ZBI:* 6AY?XA\%MJ$S,(\Y]JPX_ARRC_5?I7M>!Z48'H*
MS=-,]&&8UH1Y4>,?\*[;_GE^E'_"NV_YY?I7L^!Z"C ]!1[-%?VG6/&?^%>/
M_P \OTI?^%>R?\\_TKV7 ]!1@>@H]F@_M.L>-?\ "O9/^>9_*C_A7LG_ #S/
MY5[+@>@HP/04>S0?VG6/&O\ A7LG_/,_E1_PKV3_ )YG\J]EP/048'H*/9H/
M[3K'C7_"O9/^>9_*C_A7K_\ /,_E7LN!Z"C ]!1[-!_:=8\9_P"%>/\ \\OT
MI/\ A7;?\\OTKV? ]!1@>@H]F@_M.L>,?\*[;_GE^E,/PY;>#Y7Z5[5@>@HP
M/04>S0_[3K'GN@>$S8.I*8Q7>QQ[;8)[8J; ]**M*QQ5J\JKO(\]\3>%#J;L
M0F<URL?PX923Y7Z5[9@>E)@>@J7!,Z:>85:<>5'C'_"NV_YY?I2_\*[?_GE^
ME>S8'H*,#T%+V:+_ +3K'C/_  KQ_P#GG^E+_P *]D_YYG\J]EP/048'H*/9
MH/[3K'C7_"O9/^>9_*C_ (5[)_SS/Y5[+@>@HP/04>S0?VG6/&O^%>R?\\S^
M5'_"O9/^>9_*O9<#T%&!Z"CV:#^TZQXU_P *]D_YYG\J/^%>O_SS_2O9<#T%
M&!Z"CV:#^TZQXS_PKQ_^>7Z4G_"NV_YY?I7L^!Z"C ]!1[-!_:=8\7/PZ;_G
ME^E2P_#UD8'ROTKV/ ]!1@>@H]F@_M.L<=H'AXV!7Y<8KL5&% I<"BK2L<-6
MK*H[R"BBBF9!1110 48S110!F:IID=Y"?E&:\YUOP:69F$?Z5ZS4%U$DD#;E
M!XJ913.NAB9TGH?/%_H#6S'Y>E8LT/EG%>J^)845GPHKS740!(:YI*Q]1AJS
MJ+4S<\TM-[TZH.T*,444 )M%&T>E+10 T@"IH(!*P&*@>M+30#*N:8I.RN:-
MEX>-R1A:ZG3/!+%E8Q_I6IX;AC;9E17I%G#&D"E5&:VC!,^?Q6.J0=D8NB:#
M'9J-R=*Z(*%& ,4M%;)6/#G-S=V%%%%,@AN8_,B*UQFM>&C>EODSFNYHP/2D
MU<VI5I4W>)XQ/\/&>0GRC^5(/AVP'^J_2O9\#T%&!Z"H]FCM_M.L>,?\*[;_
M )Y?I2_\*\?_ )Y?I7LV!Z"C ]!1[-!_:=8\9_X5Z_\ SS/Y4O\ PKV3_GF?
MRKV7 ]!1@>@H]F@_M.L>-?\ "O9/^>9_*C_A7LG_ #S/Y5[+@>@HP/04>S0?
MVG6/&O\ A7LG_/,_E1_PKV3_ )YG\J]EP/048'H*/9H/[3K'C7_"O9/^>?Z4
MG_"O7_YY_I7LV!Z"C ]!1[-!_:=8\9_X5V__ #R_2D_X5VW_ #R_2O9\#T%&
M!Z"CV:#^TZQXQ_PKMO\ GE^E(/AVP/\ JOTKVC ]!1@>@H]F@_M.L>7Z5X*:
MUE5O+QCVKT/3+;[-;A,=JNX'H*6J44CEK8F=;X@HHHJCF"N9\2Z,=2C8!<YK
MIJ,4FKFE.;A+F1XI+\.6><MY7?TIX^';8_U7Z5[/@>@HP/05'LT>A_:=8\8_
MX5VW_/+]*/\ A7;?\\OTKV? ]!1@>@H]FA?VG6/&?^%>/_SR_2E_X5[)_P \
MS^5>RX'H*,#T%'LT']IUCQK_ (5[)_SS/Y4?\*]D_P">9_*O9<#T%&!Z"CV:
M#^TZQXU_PKV3_GF?RH_X5[)_SS/Y5[+@>@HP/04>S0?VG6/&O^%>R?\ /,_E
M1_PKV3_GG^E>RX'H*,#T%'LT']IUCQG_ (5XY_Y9?I2?\*[;_GE^E>SX'H*,
M#T%'LT']IUCQC_A7;?\ /+]*/^%=M_SR_2O9\#T%&!Z"CV:#^TZQXQ_PKMO^
1>7Z45[/@>@HH]F@_M.L?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '<!S8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2FFG4TU+$
MQ*6DI:D2 TTTZFFF:H;24M&*HH!3Q313JH3%%+24M(R8AI*4TE22**6D%+2&
M@[44M)04% HH%,8M!HH-4B6(:2@T4R!*2EHK&0T%+24M0D6A12TT4[-:H844
M458@HHHI@!I*6FF@8N::32$TW-, -,(YI]!%939G(CIK5(:8:Y)LQ9$12 <U
M(:!6-]2;#D%6%%1)BIEKKIF\4*1Q3"*DIIQ6DB[$6.:44XTE<[W%8<*<*8"*
M>"*UBRD##BJ\BFK.::P!K=,&5-IS4R"G;12CBJYC-BBES29IC'%2V(DS29J+
M?3P<UC)EI@:04IIHK*VI9**#2+0:VB@&TX4WO3A2:$+11122 2DIV*2NB)8"
MG"FBG"J$QW:DHSQ1FI("BDHJ1BFDHHI %%%%,84444 ***!2TQ"4TTZDQ3 2
MBC%% "T444""DHHH 3O12XHIHEB4TTIII-4A#A3Q48J04F6AC5&14K4PBE<T
M&@5(M(!3P*39+ TPT\U&37/)F<A*0TF:,UG<S84\4P&G@U<6)(D%.J,-2EQ6
MZ9JA^:6H?,%*)!3;+)*:U&\&D+"LI2!D;"F8J0D4W(K)R,6**>*8#3@::D-$
ME-:@&E-:)FA"PI5%.(H JKB'#I2&E[4TFHD,2FM3J1A7-,315G^Z:P[PX)K<
MN/NFN>OVP37GU#GD9LC?-4D+<U1EE^:I()>161F;MNW2M6 ]*PK:3I6Q;MD"
MMX,I&G&>*F%5XC5@5WTSHB.HHHKJB4PI:04M:($+2TT4N:90'I3#3J3%9L0E
M%+BC%" !10!1BM4 HHH I<4 )12XI*S8"44M)BLQB448I<4 %.%)2U2 444"
MBK **3-&: %I*** "BBC% !2&EI#0 AHI:,4T 4HI*!5 +1110 HHHHI %)2
MTE2 4444@$H-%%4F E%%%4 4444F,44445# **** "BBB@0M%%%(84E+25:
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M T@HJ1CJ*2E-!(E)2TE0P04445G88444HJD@"BBBM$(*2EI#6@"9HS24"ID
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MN!L@5UQ8RUFD+8IN>*B9JV3);)MU124BM3\9H<A7*I!S4J<4XIBHGD""L93
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M(R&FBQ+=JV2!F.JM05:MH:>?2D-@?2K2)*=DK;Q78:6#@5B6MEM8<5TEA%L
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M:UH)=V*WA5'S%W=13 >**Z><=RW1117IEA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 &FFG4E "4=J**&.X4@IU)63 ****S8PHH
MHH$ HHHK1"8AI*":;FMDC)L=FD)I,TUFP*I(R<B&63:*HO=@'K2WTVT'FN;N
M+[#]:UY3%S.FAN=YZUH1G(S7*6%YO8<UT]N^Z,5+149%D&C-,)I0:S:.B,AX
MI0:;2%JBQLB3-)30:=3L(2B@T46&@HHHI6&+11118 I:2EIB"D-+2&@!I-)F
M@TE1)B8&JEW]PU;-5;H?(:XZNQE+8Y+5.IKGI/OUT>IKR:P)%^>O,J'.Q$Z5
M-']ZFHHQ4L>-U<G4DV=/ZBNGM?N"N9T\C(KI;9AL'-=U%FT"X#2YJ/>!WI/,
M'K7I1G8U;)@:7-0B5?6G>:OK6JJ B0U$SXICSJ!UJG-= =ZQG.Y98>8"JLMP
M #S5*6['K5.6ZR#S7'.0F)?77!YKG+J?<QYJ]>2ELUD."S5R25R&*@WM5^"V
MSCBH[2 L1Q6]:VO XK'V=R&AEI:=.*W+6WP!Q3+>WQCBM.*, 5U4J144"IM%
M+WIY'%,QS79R6+8U^5K'OH\@UM,.*S;Q>#6<HDLY.[CPQJ@3@UK7PP36)*V&
MKBJ$,L(0:L*<5G1RX-6EDS6"W$7%EJ:,%S52%2QK:LK8G'%=E-%H(+3=VK0B
ML!CI5RWM@ .*O+& .E=T(#L91L!CI3#8CTK:V"F[!Z5IR"L9<=F%/2KL4>RI
M]@IIXK.2L,7=@55N9=JT^23 K*O;CY3S7+.0-F??W6,\US\]SN8\U9OIB2>:
MR&8EZPYA%E<N:T;2 DCBJEG%N(KI+&UZ<5<0)[2VX'%;$4  Z4V" *!Q5Q1B
MNJ$2D,$0%2!<4[%+BNN,!V$Z4X-3349-;)#)PU&:@#4\-3:*3"09%9MS%D&M
M,\BH)(\URU(B.:N;8G/%8UU 5SQ79RVV>U8FHVN >*XY*Q+.8\PHW6M&SNN1
MS67=J4<TEK*0PYK/F,VSMK2XR!S6K%-GO7*6EQ@#FMBWN,XYK6$BDS>1LBG5
M4@DW8JV.E=29J----.-,:E)D,KS'BL:][UL3'@UCW?.:\^LS"1S]V.364Z_-
M6O=CK6/,V&KSY,R+MF!N%=/I^,"N1M9L,*Z/3Y^G-*,M1HZ:(\586J,$P('-
M6T<'O7HTIG3 E IX%-4BGY%=T9&R0M!;%-9P!UJK-<!>]7SV!EHR@=Z8TZCO
M63+>@9YJA-J6.])U2&S:N+I0IP:Y^^O.O-5)]2+ \UF37!D/6N><[F9'=3EF
M/-554N:D,9<U:M[8DCBL&KBL+;6^2.*V;:UZ<4MI:=.*V8+8 #BFH!89:V^,
M<5K0I@5''%CM5E1@5V4X&L4.[4QJ?3#6TEH4RI<CY#7+:H.375W'W#7*ZIWK
MSJJU.>1RUSPYJ)7Q4ESRYJ%5)KBDC,LI(<U<ARV*I11DFMBRM]Q%.$=2D6[2
MW+$<5OVEIP.*BL;3 '%;4,04=*]*G WBB-;4 =*=Y ':K/04QF%=/(6R,1@=
MJD %,W4X&FJ8D*4!%5+BW# \5=!IKC-*=/0;.8O;'.>*P+JSVD\5W5Q"&!XK
MG]0MP >*\ZK&Q@SE678:=%)AJ?=KM8U31OFKF(-^TFQCFM^TGR!S7)6TA&*W
M+.;IS6T"D=-$V15A:H6KY J^O2NVFC1"]J#2TN*ZDBAO:J-VN5-:!'%5YDW"
MJ<!G,7-N68\4EO9?,.*VGMLGI4D-J >E8N QEM:8 XJ^D(7M4D<845)BFH#L
M, Q1NQ3R*8PJU EB;J7.:810#0XBN#H&%4+JV#*>*T<\5'(N0:YJD!,Y"^L^
M3Q6-);;3TKLKR$$'BL*ZAP3Q7(XV),M/DJW;SX8<U3F^6HHY</23&=?8SYQS
M6["V5KDM.ER1S746IR@KIA($RT332:6FFM6QL0FJT[84U8-5;D?(:PDR&85]
M-C/-<[=RY8\UL:DV,USL[9>N64A7);<;G%=+IL72N>LERPKK--08%5%W&C:@
M3"BK'2F1C"BG&NN"T+6@N:4&FXIP%;*(7$/2JDZ;LU=Q3&CS5\@S$EMLGI1#
M:X/2M<P GI2K  >E"B4-MHMHJWT%(J@"@FM-A@33":,TA-9R9#&LV!5&XFP#
M4\SX!K*NINO-<=29FV4+ZX//-<[=R%F-:MV^<UD2+EJXG+45RH$+-6K96Y)'
M%0P0;F'%;]A:].*VIZC+=C:\#BMV"(*HXJ"VA"@<5=Z"NVG$I$@(%!-0%Z ^
M:ZTBKDV:*:IS3Z=A!44BY%2TTUC-%&/=P9SQ6!=P8)XKKYH]P-8M[;<'BN"H
MK&;.6D&TTP3;3UJU=Q[2:RI&PU<$V3<VK2Y.1S71V,NX"N-LV.X5U&GOTJH3
M"YT"GBBHD?*T5UJH4F:5%%%>^;!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4E+24""BBB@844E%0T II*6DK-C"BBBD 4AI:0UI
M%$L::93VIE;Q.>3$-032;14S'BLR]FV@\UI%'-.1F:I<X4\UR-U<GS#S6KJ=
MUG/-<U,^YS6]CG<C=TRY^<<UVMA< H.:\VLIMCCFNNTV\R ,U$D7&1U@;=4B
MU4MI-X%7!6+.N#'&F&E)H S46.A,5:?2 4ZD6)24IH- Q****8PI:2E%( I:
M2BDR1:0T45#8#2*3%*329J&P U5NON&K1JI=?<-<M78B6QRNIG&:YV5\/6_J
MG4US,^=YKS*IRR)O.P*:+K#=:JMG%5F+;JY.I!TME? $<UO6^I *.:X>U9\B
MM>)WV]ZZZ3-8G3/JH'\51'51ZUSTCR>]0[W]Z[%(U.H&J>]/.J<=:YA7?WI^
MY\=Z.8$;LFJ>]49=2SWK,;>?6HBCD]Z>K-$7S>ECUI!,6JI' Y/0U>AMF/:L
MW$&0R*7J-+4ENE:Z69/:K4-CSTK/D)*ME9].*W;>VP!Q2VUJ%QQ6BD8 K2-,
M+$<<6*L**3&*4&NF$+%+04BFA>:?2@5O89&PXK+O3@&M:3A36)?OP:PJ(31S
MU]R36).O)K8NCEC5"2/(->95,69F2IJY;G<15>5,-5NQ3+BN>.XC:L;;=CBN
MCL[;:!Q5+38!M'%;:*%%>C1B7$E10!3J8&%.!S7HP15Q:0T[%--:- (34;]*
M=FFOT-<E01GW,FT&L&]GZ\UK7SX!KFKR7DUY=20C/N6W$U35?FJT_P U,"?-
M646,T].3)%==81#:*Y;3QAA76V'W17930R^%P*7-+VIG>O0IQ&2@T^HUIXKI
M2&(13"M2TE4AD.VGA:?@4O%58+" 4A%/I#7/-%)$;*,5CZG&-AXK:;I67J R
MAKAJHF1P>HQX<UGQ95ZVM1B^8UD[,-7!)G.S1@FV@5J6UQR.:P5?:*M6TWS#
MFM(2'%G96<N<5K(<J*YW3I<XKH(CE17;!FR8\U&U/-,:KD*15FZ&LB[[UKS=
M#61=]Z\ZL82,&[[UB7'4UM79ZUC3C)KSY&1%"Q#5MV4Y7'-8T:<UHP*0*E+4
MI'0Q7VT=:G75 .]8!+ <5"SN/6NZDC>)U8U<?WJ<-8']ZN0\V3WI1+)[UVQN
M;)G52:N"/O50FU3/\589>0^M1G>3WIZ@S2EORW>J,URS=Z187:I!:,>U0[F;
M*F]F-68(2]68K YZ5J6MCC'%*S)*<-D3CBM&WL<8XK1@LP .*NQVP':K4"DB
M"WM=O:KZ1 "G)&%J3%=$8%6$ Q3J0TF:WBK#'9I#24M$@*US]PUR6JGK76W/
M^K-<CJO4UYU7<PD<S,,N:?%%D4V3[]7+=>!7(T9#H8>16[81#CBL^)!FMFQ7
M!%:TXEQ-VUC 45<' JM;_=%6<\5Z5-:'1'8:QJ,\T^E"UTI R,+3PM/ %'%:
M)#0 4$4N:*F:T&R%QQ6)J*<&MU^E8VI#Y37F5T8S.-OQ\QK.4?-6I?#+&J*+
M\U<#1D31<5JV;\BLY%XJ]:\,*T@4CI[%L@5K)T%8UAT%;"?=%=],U0^GK4?>
MI%KM@BD*1497-2&FULT4,\H$T\1@4X4ZLFBAO04TM2M4+&I$2ALTO6HEJ44T
MT(85II%2D4A6FR6B,4,,T_%(:YYBL4;B/(-8-ZF,UT5Q]TUS^H-UKAJ-"9S=
MX<$U01_GJW>MR:HQ<R5S7U).ETLY(KK[/_5BN0TH<BNPM!^[%=5,$6#32:<:
M8:W:&V%5[G[AJ>H;C_5FN>:T);T.2U0X)KFIF^>NEU;O7*SG#FN.1)J6##(K
MK=.88%<192885U6GSXQS3@QIG5(?E%.S5*&<%>M6!)FNV$RKDXIX%1H:D!KL
M@T6A:**3-:7*' "G8%,!I2>*+E)@33#2%J!0P#%1R-@5*:K7!PIKGJ.QG+0S
MKN?;GFL6YN<D\U8U"4C-8,TQ+'FO/J2,6Q\\V<U1,GS4Z1B157)WUR7U V[$
M!F%=18PC:.*Y;3,EA79V*?NQ792*1<1<"E8<4\"C%>E'0TL5RO-.5:EVBEQ6
MR:"P@&*7=2&F$&FY(!Q>DW4S!HP:QE(5QY&15*[B!0U>%07(S&:Y*BT';0XW
M4EVDUSTI^>NDU88)KF9/]97DU=&9,O69Y%=#928 KF[5L8K7@FQWJ(R)N=)'
M/\M%9*W6!UHK?F"YVM%%%?5G6%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%%  :2E---,044F:7-!(44E J&.XM%%+6;18E%+10D E(
M:6DK6*,V,:F&GFHG.!6J.6;&2OM4USVIW& >:U;J?:IYKEM3N,YYKHA$XYR,
M._GRQYK++9-2W<F6-4S)@5M8YG(F678W6MS2[SYAS7*238:M#3;DB0<TG$N,
MCU33)MRCFM@'BN4T:YRJ\UTL<@8"N:43LIS),\U*M0CK4@-9LZXR):*:#3NU
M0S9"&DI:*10E%%%,84HI*44 %%%%2Q!2&EIK5FQ$9:DW4I6DQ6<@8[-5KG[A
MJQ5:Y/R&N6IL9RV.6U-<YKGI8\L:Z'4FY-8+L-]>=4.:1%]GR*9]DR>E74((
MJ5 ":Y>I RTL,D<5MPZ;E1Q18HI(KH;>)=HXKJI(UB8#Z7D=*A_LKGI76&%2
M.E-,"^E=:3-K',+I?M4@TOCI71B!?2GB)?2J40L<U_9/M2C2/]FNG$2^E/$*
M^E=$8%HYN/2<?PU;CT[;VK<$2CM1L [5?LRK&6MF!VJ5+<#M5[:*3%3[,FQ&
MB!:DHQ15J%@&$TW-/(INVJ2 <IIX-,"T\"AE#)3\IK!OR>:W91\M8]['G-<U
M1D,YJ<?,:@8<5=N8\$U1<XKS:IFRE,F6JWI\?SBH2-S5H6,>&%80W(.ITX80
M5H,V!6=9'"BKY&17JT46A%;FK*<U71.:LIP*]""*0[%-84I:DSFKD4,Q3'^Z
M:E-03-A37!5"QAZDV :Y6[?YC71ZF_6N6NF^<UX]5B&J<T]5R:@C;FK<2Y(K
M.#U T;$885U5C]T5SME'R*Z2S7 %>E2 T0,BC;2J.*=7IP15A *.E!I":U ,
MTFZDI,5-RAVZC=2;:7;6B8QP:C-(!164ACCTK/O5RIK0/2J-Y]TUPU=B9;')
M:A'R:Q9$P:Z&_')K$E7DUY4WJ<DBDYQ3[>3YQ4<W%,@/SU=-A$Z_2WSBNH@.
M4%<CI)Y%=9;_ '!7?!FJ9/33TI:0UN]BFRM,.#6->=ZVINE8U[T-<-5&$CGK
MSJ:R)>6K6O.IK(D/S5PRB9DT"9-;%M;;@.*R[3DBNFL(P0*48%(8MAN'2D.E
MD]JZ&&!=HXJRMNOI7H4H'1%'+#2">U/&C_[-=6($]*<(4]*[53-4CDCH_P#L
MTG]D<_=KKC"GI3# OI3Y 9S4>EX[5.NFX[5O")1VI?+'I2]F9M&,E@!VJU%;
M!>U7]@]*4(*%3$D1QQ@=JF"TH6E(P*U5,T2&DXI,TUC30:T40'YHI0*7;18$
M(*6C%(:RDQE>Y^X:Y+51R:ZRY/R&N5U3O7!4>ISS.8EX>K-LW2JMQP]2VIR1
M7.9&U;C)%;EFG2LFQ3=BN@M8L 5K N)H0# JQVJ"/@5,*]"F;Q#%'2G4A%="
M&QA;%,+TYA3"IJTQH<K5(#FHE4U*!BE)C&OTK(U$?*:V'Z5DZ@/E-<%9&,T<
MA>K\QJD@YK0OAAC6>IPU<$D9%I!5RV7YA5*,YK1M1R*(EHWK$<"MA.@K*LAT
MK60<5W4S1"XIPHQ25W0+L.S3: :7%;7* &G9S3<4HK&3&!&:85J2BLG(=B,+
MBG@TA-,9P.]1SB9)FC-5&G [U$UV!WH]H27BPJ-W [UGO>X[U5EO^#S6$YB;
M+=S.,'FN>OY@<\T^YO\ (/-8]Q<[B>:XJDC-E&[.2:K0CYZFE.XTD*_/7.GJ
M0SHM*'(KKK7_ %8KDM,X(KJK4_(*]"B"99---/I,5V.-P8RH;C_5FK.*AG'R
M&L9PT$]CD=67K7*7*G>:['5$SFN8GA)<\5YU2(BO;94BMRSN-N.:R%C*U*DI
M0UBM!G7VUWD#FM"*X![UR%M=^]:D5Y@=:VC,:.FCG'K5A9@>]<M_:.WO4T6I
MY/6NJ-4M,Z<.#WI<UCPWP;O5Q+@'O6RJEIES-!-1+(#WI^[-6J@[B&E%+25I
MS#'$U4NON&K)-5;H_(:PJ/0SEL<OJ1Y-8+G+ULZH^":YYY?GKSJC.=EG;E:@
M*?/3UERM,+_-7/U&F;6F !A78V;+Y8K@[.XV$5OVVI;5ZUW431'4[QZTTR*.
M]8!U3WIC:I[UW<QI<Z S*.]--P/6N=.IY[T#4">]0Z@7.C$P/>G[@>]<XNHX
M[T[^U<=Z7M&,Z#</6C(]:Y\:J,]:D&IY'6CF$;NX#O5>YE4(>:R'U3 ZUGW.
MK9R,UG-Z";(M58,37,S#YZT[FZ\S/-9DN2:\NJC)CX7Q5V.8^M9BD@U:BR:Q
MBB6: G..M%0!3BBMB3U2BBBOKSN"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ ---.IIIH0E%-- -,0ZEI!3JE@)1FFFFYYJ&BD29
MI:8#3J:0-A332FFDUHD8R8AJK</M6K#' K,OYPJ'FM8*[.6HS(U&[V@\URM]
M=[B>:NZM=<MS7,3S%FZUV1B<$V)/)DFJCM4IR14++S6RB<LI%9\DU:LWV,*C
MV9H)V5JJ=R/:6.STG4 F!FNQL;P2*.:\DL[XHXYKMM$O]^W)KGJTK'13JG>(
M<BG$U5MI=\8-6,YK@:LSTH3NB134H-0+4H-9M'5"0^FDTN>*8QJ+'0F+FC-1
M[J<#3+L/S1FFYHS3%8?FBF9IPI-$L**6DK-HD,4TBG4AJ)(!AJI=?ZLU;-5+
MK[AKCJ[&<]CD]3/)KGI"=]='J:\FN?D7YZ\VH<[0Z-CBK$;?,*@0<5-']ZN7
MJ38W-//(KI;;E!7-:<.173VH^6N^C$W@BQ28IV* *[U V&XI<4_%+MJE =A@
MIX-&VE K:*'8=36-.I"*U2&1]Z=2[:,4^4FPVC%.Q1BIL*PF*-M+12&)BBC-
M)FLY#N-?I6;=@8-:3GBLJ\? -<M1DLP[P#FL>;K6I=ODFLR09->95,V0I]ZM
M:S'(K*7AJU;(\BLH;DV.@M!P*TT'%4+-<@5I*,"O6HE)#E6G$8%(#3C7I1V+
M(F- -#"D HF.P\]*IW1PIJV>E4KO[IKS:S$SFM2?K7,W+?,:Z'4^]<U.<N:\
M>J]2+CH>36E;KR*S[=<FM. 8Q6=-ZBN;5DHXKH;4<"N>LFY%=!:MP*]6BRTR
M\.E+30:6O3@RP-)BGXHK5C2& 4X+12YJ2K"[:-M&:7-4 TBFXIYI#6<F T]*
MHW?W35UNE4;L\&N*J1,YR_ZFL28\FMJ^ZFL*<\FO,J+4Y)%.<U' /GI93FG6
MX^<4H: CIM)XQ75VY^05RNF#&*Z>W/R"NV#-$RSF@TE+75T*()1P:R+T<&MF
M0<5DWPX-<E4SD<Q>\9K%D/S5LW_4UB2??KC9F7K,_,*ZG3CP*Y6S^\*Z?3VZ
M545J4CI8/NBK*BJ=LV5%75Z5Z5%'3 >*7-)1FNQ&EP)IAI])MJDA#12XIV*"
M*M0)8RE%*124^0$API&Z4F:.M%BR)A0HJ3;2A:=A#E%*12"@FDT*XAJ,T\TQ
MJYJB$RK<_<-<MJ?>NIN?N&N5U0]:\JJ[,QD<S<_?-26@^85'/RYJ:V&"*Y^8
MBQTFGXXKHK?&T5S%D^,5OVLF0*Z*3NRDC36I%J./D5,!7J4UH;(44N*04M="
M10FVC8*=10-";:3&*?334R&,8<5E:A]TUK-TK)U'[IKCJF<T<AJ!PQK+#?-6
MEJ'WC68OWJX)F++D)Z5JV?45E0CI6M9]14Q>HD=#9C@5JITK*L^@K44_+7=2
M9T1'DTT\TA-*.:[(R+%44_M29Q3&D [TY3L*XXG%,,H%5I;D#O5&6] [URSJ
MBYC4:Y45$UXH[UA3:AC/-49-1.>M8.H',=*]^H[U4EU >M<XU\Q[U$UTY[TN
M8+F[)?Y[U UV3WK&$KL:LQ!F-7<5RXTS-WJ"4L15R&W+5.;'(Z4FK@<Y/NJB
M^<UT=S8X!XK(GM]I/%<U2)+,]NE+%]X42C;383\]<MM3(Z+3>HKJK3[HKEM,
M&2*ZRT7Y!7HT"DBS2XH/%"UZ,2^47;44R94U8 IKKD43C=#Y3FK^W+9XK"FL
M_FZ5VL]ON!XK,FLNO%>=5ID.)RCVVT=*H3*5-=1<6N,\5CW-H>>*Y' .4RTF
M*&K2WF!UJI-;LIZ5#AA2Y;#L7VNR3UJ6&Y;/6J$:$U<CCQ3O81KV]V1CFM.&
M]QWKG5;;3_M17O1SV%<ZN.^'K5N*[#=ZXM;\@]:T;2_R1S5QJC4CL(W#"GUE
MVET& YK15P173&H:)BDU4NS^[-6B:IWG^K-1.6A$]CD-6;DUS4C'?71ZJ.6K
MG'7YZXILYV31$D5+L)HMX\XJ_% #7/?4$RM$C"KL>\#O5R"RW=JT(M-SVKOH
MLVB8_P"\]Z8V_P!ZZ0:7QTJ-]+]JZ^AI8Y]=^>]3JKD5K#3<'I4R:?[5F(PV
M5_>H7\SWKIO[-R.E,;2L]JT4+EHYD>9GO5A"^.];?]DX[4X:9CM5\@6,"7?C
MO6?(DC-WKKVTO/:H_P"QLG[M3*!+1RT=L[=14AL6(Z5U2:2%_AJ0Z:,=*Y)T
MKD.)QPL3GI5N&R/I72?V:,]*>M@!VK-41<IAK9\=**Z 6?M16GL1<IT%%%%?
M1'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !333
MC330 PTT4XTVF(>II]1@TX&@0$4S%2TTBBP7&BG9I**=B6Q#332FHI'VJ:I&
M$F07$P0'FN=U*\^4\U=U"ZV@\UR=_=[B1FNFFK'+-F;J$Q=S6:L)=NE72/->
MKUM9YQQ79$XZAF?92%Z52GCVFNJEM-J=*P-0CVYKHBCAFS*W@5%,^13)7PU1
MELUU1B<DI!"Q$E=;HDY4KS7*Q+SFMFQG\LCFLJL+HUIR/4-/N@8P,UKH^X5P
MNFZAT&:ZJSN0ZCFO)JPLSU*50U0:>IJ%&R*E6N1H]&$B3/%-:E[4AJ#L@QE.
M%&*44&Z844M)3 !3Q313Q29+$)IN:5J94L@DI#0*#6<A##56Y^X:M&JEU]PU
MPUF1(Y?4NIKGY/OUOZEU-<_*?FKRZC,6/4\5)&?FJ 'BGQM\U<Z>I*.ATX\B
MNIM?N"N3TT\BNKM#\@KU,.=$"UCB@"G=J7%>DC:P"BBBG88M%)130"T445HA
M!11258!1114LD2@T45 "&FTZDK*0AC_=K&OCUK9?[M8U]T-<=03.>NC\QJDQ
MJY=?>-46KS:A(S^*M.Q^\*R_XJU+'J*BGN(ZFQ^Z*T .*S['[HK2'2O7H[%(
M!3J2EKOBRT-(I,4_%(:4WH,8:IW0^0U;:J\XRAKS*Q$CDM4'6N9F'SFNJU5>
MM<Q,/G->541BR6V'2M",XQ5"WXJV&Q6<%J(UK1^170V;\"N6M7^85T=B<@5Z
M5(M,V%Y%/%1Q]*E%>I3-D!.!49>G-TJ%A706AV^E#U%@TY0:+#)@:=FF**=2
M: =FFFC-)FLI(FXUCQ5&ZZ&KS51NA\IKCJ(SD<[?#K6!<=36_?=ZP+@\FO.F
MSFD4).M36P^85$_6IK4?,*S3$CI=-'2NEM_NBN<TT=*Z2 ?(*ZJ;-$3"EI!0
M:[$]"ACGBLF^/!K3D/%9-Z>#7+59#.9O^IK%?[U;=]U-8[CYJY&26K3J*Z.P
M/2N=M1R*Z*P[5<-QHZ.U/RBKZ=*S[7[HK03I7ITC>(^DS0:05UHL<*<*:*<*
MM%"TE%%:HD2FD4ZC%,:&8I0*=BEQ4E !1BEHH$---)IQIAID,,TTTM(:YJNQ
M)5N?N&N5U3O757/W#7*ZGWKQ*[U(9S4WWS4UOVJ&;[YJ6WZBN2^I)L6IY%;U
MD>E8%KU%;]GVKKH[E(VH>E6*KP]*GKVJ6Q:%I:2BMBDQ:6FTHI#0M!HH-1(L
M:W2LC41\IK6;I67J'W37)5(D<=?K\QK-5?FK7OU^8UF@?-7!,YY$\0K3M#R*
MSHZOVIY%9K<E'1V9X%:B?=K)LCTK63[M=M,Z8!BG#@4M1NV!71S6-&-DD"BL
M^XN]N>:+JXV@\US]Y>8SS6,YF4F6KB_QGFLN:^))YJA/=DD\U6WLYKDE(R;+
M4ETS=ZC5F<TZ.W9^U:%M8DD<4*[&F00VS/VJZNGL1TK7L[ <<5K1V: =*WC!
MFB.733B.U6XK(J>E=#]D0=J:;<#H*V41LI6\&.U75B!'2G+'BGC@4["*5S;@
MJ>*YR_A"YXKJIV&TUS>I,.:PJDR9RUUP34-N<N*FN^6-16R_.*X'N97.GTH<
MK76VH^05RNEC[M=7:_<%=U UB3-TI%IY'%(!7I0-K#@:,TTTW-:M: /(!%5Y
M801TJPIH9<US5(7$T8\UMGM5&6PW=JZ%HLFD\A3VKE<!6..N-+SGY:S9=,*G
MI7H#6BL.E4;G3UP>*S=,&CAOLY0]*7I6]<V.">*SGLVSTK&4#)F>S&H'8UI-
M:'TJO);D=JYI(R;,_>0:MV\Y4]:A>/!J/.VH0)G3V5]C'-;]M<[P.:X.UG(8
M<UTVG3$XYKIBS5,Z53D57NQF,U-"<H*;<C,9K1ZH;U1QFJKR:YUQ\]=/JJ\M
M7-R+\]83B82+%OQBM.W89%9<7 JY"^"*Y^74@Z.S .*W;>)=HXKG=/?)%=+:
M_<%=U&)TTRP(QCI3&C7TJ7M3&-=SCH;RL0&)<]*<J+Z4I-**A1U,AX0>E/$:
MGM3 :<":ZX0-$'E+Z4GDKZ5**6M>0HB$2CM2^6OI3Z0UFX ,*"FE!3S3:R<$
M2[#-@]*/+'I3Z<!0J:)(_+%%2XHK3V8[$E%%%=A04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %--.I* &&FT\BDQ3 ;3A1BEQ3)8
MN:0F@G%,)H);'44@-+00V,<X%9MW<;5/-6[F0*IKF]1N\ \UK%&$F9VIW><\
MUS4SF1ZMWUP78\U6@B,CBNB.ASR)[.V+,.*Z"VMMJCBF:=9\ XK6:,1QUO"1
MQU#+NE"H:Y34QR:Z74)@ 1FN7OGW9KNIHX*C.=G'S&HEJW,F34&W%=2..0Y#
MBI4GVGK4!.!5=W(-9S+@SI]/O\,.:[+2[_('->6VUP58<UU>DWQ!7FO/J1N>
MA3D>G6L^X#FKZFN:TRZW!>:Z&%PRBO/J1L>G2D6!130:=6)W1D%+244F;J0M
M%***5R[@*=249J6Q#6I,4\BDQ4W$**0TM--928##56Y^X:MFJUP/D-<%4B2.
M5U(<FN?E'S&NCU$<FN?E'S&O,J&+1$!Q2I]X4N.*$^]7-?4FQNZ:>176V9^0
M5R.F]1766?W!7IX=FT"^#Q2TT'BEKU(LW%I**,5JA"BBBBF 4445H@"BBBJ$
M%%%)4,04E+25 @I***SD Q_NUC7PX-;+]#61>C@UR5!,YNZ'S&J+"M&Z'S&J
M+BO-J$D ^]6I8]169CYJT['[PK.GN(ZJQ^Z*T1TK-L?NBM(=*]BCL6A:**2N
MM,I#Z:U**1JF3&R(U%*,J:FICCY37'45S-G,:HG!KEKA,.:[+4H\@URUW'AS
M7FU(F3*\1Q4N_FH!\M-+\UG&(C7LVRPKJK 945R.GMEA77Z?]T5VTT4C57@4
M\&HL\4@?FO0@S9,GQFD*9H4U)72F6F1>73@F*DI":T0QN,4TFE9JC8TQ7#-*
M#4=.!K*1#8\]*HW?"FKI/%4+YL(:XJVQ,F<WJ#X)KGYWRQK6U*3DUA2/EJ\>
MJ]3G8QN35JU7YA4"KFK]I'\PK.((W].7I70P_=%8FGIC%;L0^45V4]S1(DI#
M2T&NU;%,K2GBLB\/!K6FZ&L>\/6N2H9LP+SDFLEQ\U:UUU-9CCYJY6R2>U'(
MKHK =*Y^U'(KH; =*T@4CH+7H*OITJC;=!5Y*].B;Q'TF*6C%=98"G4E%"8Q
M:3-&:3-6I$L=124M5<:%HI,TN:5QA11FDIW 0TPTXTTT[F;&FD-.IIKFJL16
MN/N&N6U/O74W/W#7+:GU->-6W)9S4WWZEMQS4<WWZEMZY+:DFM:CD5OV?:L*
MUZBMZS[5V45J-&O#TJQ4$/05.*]BEL6@HHHK884HI*44%(=24O:D-0RAK=*R
MK_[IK4;I65?GY37)5,YG+7WWC6;GYJOW[?,:S-WS5PS,)%M#6A:]16;$<UJ6
M@Y%9+<E&]9=JUD/%95H.!6HO2NNF=$&/+8JI<28!J61L5GW4G!JY2+;,V^GZ
M\US5Y,23S6O?/UK N2237/*1FRMN+-6C:6^\CBL^%<O70Z=&"161DR_:6&0.
M*UH+$+CBI;2,!!Q5]0,5UTH7*B1Q1!!4X.*:3BHR]=RA8TO8FW4F:BWTX-FD
MT+F'4US@4[-,?D5E(90NI"%-<Y?N3FNCN8\J:Y^^BQFN*HR)'.7 R31;##BG
MW*X)J*!L/7'U,CJ=,[5U-K]P5R.FOR*ZJT;*"NZBS:#+U+BF@TX&O3@S>XUA
M49%3FHV%;B!:?4.[%+OK.07'FDH!S163B*XM,=0PH)Q3=])Q"Y3FM0W:JK6
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M-R%8=2&@MBHGD J'(8_/-.%5O-&:E60>M3S D344S<**KG'8DHHHKI$%%%%
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M+95[5.$"TZJ5,5B,(!VIX%&*45M&-A"@4N*!2UJD4@I,4M)FJ0Q12FDS1FJ
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MHS*OK3#,OK6$JB%=$N:,U7,ZCO3&N1ZUE[1"N6MU(7%4FNAZU$UV/6CV@7-
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M'I3N9,ZV/4?E'-%8J;P**@7,>B4445F>F%%%% !1110 4444 %%%% !1110
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MHF%*9*86S6J9SR0QJC-2GFF[:K<@A(I0O-2[*-N*.4=P48I&Z4$XI-V:+#1
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M+"7&.:Z&WG!4<U>YDRVW-5YHP5-3!\TC_=--:&$SF-3AX/%<A?1D,:[Z_BW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*,444@#%&***5@#%&***+ &*2EHH 2BEHH 2DQ2T4K -Q2TM%*P"4M%%%@"B
MBB@84444K %%%%%@$HI33":+"%I*3-&:EHD0J#3#&#4M%0T!7, /:HS:@]JN
M4E0XA8HFS![5&;!3VK2I*FP&9_9RGM0=,7'2M/BEJ;#L<]<:< #@5E36A4\"
MNPEC#"J$EF&/2BPK',K P/2K"1L*V?L'M2_8O:J2 RAN%/#L*OM9^U1-:D=J
MM(" 2D5*LY]::8".U((B*T0BY'/[U:CFK-52*G0D52 U4EJ99 :S$D(J9)35
MH"_NS2U!&V:G%,84HI*44 %%%%!0M)2TE( HHHH *#10:8#310:*8F+29HI"
M::)%I*3-+5$,3%&*6BF2T%4-0YC-7ZJ7:;D--"9Y_K$1+&L%5VR<UV.J6V<G
M%<K<PE'/%42:^GW"ICFNDM;]0!S7 13NAK2@OG ZFJ)L=P;]<=:@>^'K7,B^
M?'6FF\<]Z86.E^WCUI1? GK7,BZ<]ZECG8D4!8ZZVN-Q'-7B_P E<[82,2*V
M]Q\JI8TC+U*YV \UQVH3F1B,UT6K$\US#Q,\M-":(K:U\R0'%=9I-CC'%4=-
MLLD$BNKL;<(!Q0V%BU%;@(.*:]L">E6QP*:3S4W"Q4%D#VJ062@=*LKTJ2DV
M4HG/ZI:@1GBN%U&#$IXKTG4ES&:X?4H"7/%6F38S]-.R05W.F3?(!FN+M(66
M0<5U6G94"AA8Z/?E:SKU<J:L(_RU!<\J:E T<?JBX)K \S;)73:I$3GBN7GB
M82'BM4S-HZ#2[H CFNJMKU=@YKSZS=D(K:BO&"]:9-CJGOE]:JRWXQUKGWO7
M/>H'N6/>C0+&K/J.,\UC7MZT@(S44CLU,6!I#4E6,F2%I9,XK8TJS97!Q5ZU
MTK>0=M=!9Z7LP<4FQI%W2U*H!6JPRIJO;P>6!Q5D]*ANY5C"U&VW@\5R5_:E
M&)Q7H4T.]:Y_4K'() JDPL<8L[1-UK3L]1((&:HWMHR,<"J<0=&JKBL=]8Z@
M"!DUL1WJ8Y->?VUTZ <U?&I,!UJ6@L=A+J"*.HK-N-47GYJYB?5'/>J+WSL>
MM7%$M&[=7@DSS6)<Q>:32Q2-(:OPVY?M5W)L<^^G9.<45UBV&1THIW%8[G%.
M%+BEQ7 >H)BE I:* "BBFDT *332::3247$*>:81FG@4H6H; @V&I$7%2;12
M'BLW(8X=*#49D J-KA1WK-S%<F-,9@*JR7JJ.M49]14=ZQE(3+\ER%[U2EU$
M+WK'N=2'.#65/?DDX-9\P7.@FU8#/S50FU7/\5<_)<NQZTP%V]:ALDTIKXOG
MFL^:5W-21PLQZ5:CLBW:DK@9)5R>]6+=7#"M9=.]JFCT_!Z5T0 EL W%=-9@
MX%95G:;2.*W;>/:M=<6%B<CY:S;R/(-:9Z54G3<#6ER6CDKZ'D\5DNNUJZF\
MM\YXK!NH=I/%6F9M#+>?:PK9M;O('-<PSE&JU;7>".:UBS&2.SAFW=ZM=16!
M9W>0.:UHIP0.:T,)()H=PK(NK,'/%;X(:H98 PK2$['-.)Q-Y:8SQ6#=0X)X
MKO+VRR#Q7.WE@<GBN^G-,XIQ.1E7!J+'-;%Q9$$\52>V*]JZHLY91*A%1/5E
MT(JNXKHBSGE$K/47>IG%1XYK9,Q<1R+FITBS3(\"K*.!5-BY1ABXJM*-M76D
M&*H7#CFN><C:$"K))BEA)9JA;+&K]C;EG'%<LY'9"!K:;:&0CBNVTK3< '%9
M>BV.=O%=W86@5!Q7GU9GH4HDEG!Y:CBM-&J(1[1Q3EX-<4G<]*FK$QY%1%:D
M'-+MK"1V1&HO-3CI3 ,4X,*Q9LAU)1FEHL,2BEHIH3$HHHJR0HHHIB"BBBD,
M*6BB@8M%%%,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML!NVDVT^F,P%0Y !(%,,@%0RS =ZI2W6,\UDY :#3@=ZA>Y'K63+>X[U1EU
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?-/HH CV4\#%+13 *,9HHH$)MHVTZBF W%%.HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>prph-20241107.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa2N+bP9z5Z8mekhvWB/bdnaPyctqrCpQCMIR172EZMI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:PRPH="http://prophaselabs.com/20241107" elementFormDefault="qualified" targetNamespace="http://prophaselabs.com/20241107">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://prophaselabs.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="prph-20241107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="prph-20241107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>prph-20241107_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>prph-20241107_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://prophaselabs.com/role/Cover" xlink:href="prph-20241107.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://prophaselabs.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @  8UL6:K$(A8S 0  (@(
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  !C6Q999!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  8UL69E<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  !C6Q9-@6[LV0$   @$0  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  8UL69^@&_"Q @
MX@P   T              ( !J P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  !C6Q9EXJ[',     3 @  "P              @ &$#P  7W)E;',O+G)E
M;'-02P$"% ,4    "  !C6Q9JL0B%C,!   B @  #P              @ %M
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @  8UL620>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @  8UL6660>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001493152-24-044891-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-044891-xbrl.zip
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MC08?M_-R5=$O4[&LIH$E.ASTK5&P)X,^]%<YJ#AP6+Z&I^(X',I /* -_QG
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MY;8_6_Z_P4:!5^<ENZA_6^+J^=9M_H<U]SOW^IQ())8GNQUTC=[*$;-<57!
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MX3!&)[$ZG\?%T@/+M,\[<_X&;**7:<X@I%A=W=VC^)-G=OL^@ SUD%MZQ)^
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M@SPCC2AVR#33A7"[_<"8+*ZU.YKW3D^+C6,I]*KAX(9T_DE.TMY-@)/[1C+
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M]&YN4F]@F19T"[FODRM$"33>;,!E?1#MX<##:*>R"(PKT@(? FR$M"^8+42
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M$8HFOU4T#.AGJ-""@Y^0/7:MRP!D!]LPAB/%543KUO+[PHWIF"_:Q%/X+C0
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M%0F-A[VN4ZM&W]5FM9^4RUMNFGE<C9Q)#(_&YC^:ES=,7R8D^>W$:D66OG;
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MJ,GN<I@J1V3-C[[.;+I79]P"2]<?.68<ZL#=[%MIL+=H+Q&K%W4V-120FNS
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M.'KY$GZ"&8R7+0RF0<X)Y=]ZL0$I!+W&=UP!N+W#19ES7V4.;65Q!;",><I
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M37[%3?RNAA-51_]1@(D/>Q G'+]#9>N?1?F!52T:A[^Q6KTJ<I1TI&G-Z-9
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M-10G2LR IYO+6A@>O>XYG7ZJ (FZ\L,$%08!\N61 ]\,R('K1 Y\,R '!N3
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M7 8[&H_LT15C!-Z3S-E[6C69.+.4,C*FTJ#)A;A1N"!RW&%0L021A%!(T%8
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MZW@\$F^9"4]_;TQ\+W)!4856K4G^62[YML8I:ES3#/?>Y9M.*BD%BCQ?CB_
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M4RPK*5_,MA9H_>F70# QK'T).%<FJTG=.Q/[B->LTT&Q'GBO"1JE\SJJX:<
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MA:@F= +#Z*L-]"[3>BJE4UQ%*E?;"-H,-ACCC?,\M7075%KXG,<!WYYGQ<I
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MIHHC63:&+1"ODO$('H>3;?81[SAW>CWYZHG7KDP5R;:;KF4V,%GN!B\\.!S
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M'OBO5*E*?B=*@1/0>\_Q):%_X0MY314@*4^6T#S--LSD23W@RPY4OL<_MN:
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M++8C6HSB)\H-Z?6)FZ1%E[1-0FS?S)Y%(6UQ;O;2LSVZTC3ND;M)E-N!@TZ
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MISIA&4/%$??4N':U0'05PB:HEHDH>,SOV U@A7W G= *$LYC; \=(>QF1G5
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M6K382"UB!(/NU<OL+%5U;+.:F)!N$B-NR$1 D '\7?'N\1N'.WW# R8V&_C
M90/?V+"[;QVQ]Y&DZW;\KW;*#VX?DG!_EJ]0V-E#\#4D!/=P_Z_ZT,,)@/_1
M(?@[NZL+OOXM^UQ4KP8+YGQD0BIG_AD#E@..CH!*XJ"A'SBTX8/#_W+9'A](
M*.=_%DN75-62 A*14CWP[_XQ^[4BG@E^1]3XAI@X&NZ@QNHP)?1Q2:7J&7>:
M$QI$RFY$E*?1>\V(S&]A/!A=5)8Z#BOX$>KM0B7N=:X=Y^WDE1@F;E!A9I),
M'$(W96&BU!<.=$&=9M5I[G!(W</0G$I3_ 9K>/#-G0D#/QG!2804ZPUA\K(D
MV&:RDA"R2NRWGH)DBN5P^0(3QK3NGF:L>]P"')\'_>(D 4;V$HT$$XX^AQW'
MA^J<;#0#'>8%\,@[VTLF;N;7FQNCUYRK&1C,?CR*2.DQ![80U.ZN'5(^I@!]
MK8PJ81?&=7%\?#[%;$-';CQDN=  V8/;=UU4$,::%[B"WSHN5).ORY<.U!DQ
M.^,'*^G"Q2>('6V!EG9.C:A[D/=3"01Z/L?\B1*_X]ND<F5=%RO"8.NK,35M
MVFA%D&5/(QR/E5CN=PW"L7'BALSK[(RRQ?K  B&A!_?">\!W4U]46,['.0M+
M$8L+\@?\:[&7\+DK)+44MH(0S!0?2![^MDX.[D^2\SRK<8R@*$H#&'PND3Q7
M"/(,WA_&'G -2I6C7OJ-1U@&&@=\JX5<7KKD&E (;_F4X01>@$N5!8<-6B&-
M)A*<@3PW$F@\:HL@'-G!8;CP%B<I\1@[5B:NM@/FUJJ[MC]KF*>#N(? N>1.
M<5F'P*8OOM4ODF)4OH_>7'R^;/+>A+R/7/.=VV*'A*Y5.5>&2;](4B609ZY*
MH$>@.X@''"+DY2%90[PLL&HL"[*D>XJ!B#*]#TRWKM:(A @RPH7W>9F>'*?O
M07 (&CA*'E!=4_V M#JE>Q+0OO;%SWMFJ $*[U=S!OXAU34=4&/KOM&!9,'A
M>6BM'2)3.F.B8(9I0T*-"TMP_$16-1G=?VKN554?4/*#]%-V9OY0XU(BN&?+
M_#@GDB@,/Q!;T'BTV-9T$5TF)%Y+R6&T8Z5DQ!72R5OI0P6GW>HSTKDD3&]/
MZE*#F[+<?;O_D"JZ=FP_'6\%JILJ\H=4315_440K'I?$DD'Z@=BHR)LM;/;A
M_?L:6O$4=C7^!HV.[?(XVQ4C89(J.F-E175#*T.N[3:&B83J@(W+<-N2$!"N
M0Y2,\"E1=W#1)@]Y9X[:TPTOB-+9;D[J:GM\DE(M:?6!"=NR)3T;P3JB8IFP
M+>O>85<2P;\T[S1$Q]?=*;P. )-O!H#)E0-,#N\,"),!83*$;UKAF[N,Y\<>
MO7U)5;0RR%Q?Y(+EP#J\$KEG,O0$Y@9D&2A.,;=[3,R.MLOC$464TH1H')VO
MJ=I=8<F*$7=ZB1TW==@]_MR-4RQ],'[ \\'\3),OL44#NZ]!.HH]'9=HPM^L
M.@JH Z.V?Y;A>OI TB5B'E3+RQ$<))>'*;JP@G<-6C:S"WO0&E3)?[9PIA;G
M2>7]K%V;HF@7LG6I(CBK+=,LK@R(SJ:U;.#5]0=*"O06I?*,M](:D5' Y!+#
M)/K6C ?IH41M?XU9YFDAOXU[N:A]R)2'T:O)[J+&*/CC>>6I]X,%XF+7[10L
M-/P<6-9YC97]>7TJKC&LR*SU-2XJU^8MOJ* *CY[BOH[1ILWL[HZXPI6VQ.A
M13!@GK.;D+G'V>60E+VO&Q^L8+Y)XD] 3YBM7A]*@NO,*\M%C^Z<,HFN#UNX
M>.[F+%_"[P\.[TXH0()(*OS""J372<NCCUJA-2X4W'.^+QF*PD._*&H8CJ?3
MKHBH?%L6S-6-Z5KE*XB,;)O-;K3*M"KA4E)U/NUY1>[Q%H63*XF-G"M]24<(
M^7+34-I=>(:A>QV/G/^O^^Z'DX O6!;-27LT4:@RFY\631X@^&DON*3#/P_=
M*[C[RZI$N@@XPEOTS>;;G.N(7(EO@L+;A *32J3Y[5:81!:PCU";M-K%71LS
M.< ]7F?\0 [X8V^7$@_GQ 79?3!"+T0KSJHR3]C^<PW%+8H%,2*75%F0U>>.
M]L%&J]Y;+??8=04YR+#(:,$(IGQ9G4VZHAC?/W_YYC%[K0\.#^\<'$\._CH!
M_WGPPVYX/AJ,N@=DW&&&R 4E7V,VX-83\ TU!GE-LK9[=RB^H-%_%_/V8;[V
M=O*\="UB.A4\\6D8P3;/F>UH;NLY05(Z0%5+_H:M@E)NM65- % 3OO73 G7^
MP0--8S!:LB]]<7G)]VQ"S50YD);O3"AD#>.MQ'>PN0KOWY@H%UM)D=;D'M(\
MI0XG(K.Q,8KQYZOUDMM*P9,DVOC@()M<+K3(M%/.3",6BK>W_JK12M-2@,BY
M=ECLL(--M21SH6O<9#1PKBU,P''PSV6Y%&^JJ+@.6B.,8F;'1(/DXXR4))(D
M)+>7H'%$+M.\@$.8,PJ_6!&@-;.M>T3/7LA,&B'_Z6RXBM#N' "&\<EP3IUM
M'PY?NO+"M9X?LS$&J_4A5[P?GPOFQP=%7LP8F(?/L;V'F@36'1R(C/MZP.>Q
MX!X_RBM-.0W#7;313KPM,K# ==#SKT/OR7.0P>/'A$Y B&S8E8S;F:7V7B0-
MI=%*%#[9 F&V<6?%=[O^ MQMD3-U1"PK[(Z]IG](QPL'/ZFQM[SO,.2"#7G^
M0:C@=)WZO66LW]3^1;:2@4RYOI%@K%T)H]QQ4UM>AO&QL ,FUV5[OF];3-5M
M"#E 3T<>P*$52P)LV8_PJ\9#%>(M$-HT!&->^VT5_PC\H':8H>_<U9W/='OF
M'^Y",3WAESU3[I^2;OC+D&ZX^G3#X9!N&-(-@^?1\CS (Z5<P^_),VB4]@),
M8D=^(2'G1UT4,.&^;)K!E[-0F/]WI1F>"USG5)A(F.N9S1.,N%G'I:MD5>)^
MG&\@*])$5*TUL ,!2@I;+(RL;,/@(N180 OJ!LI-!A#(QDF/:B<8$"M^6\1W
MX7:B5U646P4\<4#7M1O=%?(F'\PNE2'DVYQ5R<%==D_5A_5-$?L]548(,ET.
M(O@PP[)<[M[=\2A";00GB:]2E#;8:0,;MD$',2:<Z*VIB0PI1%2CT^2O2^8)
M!G#,S6:C/>U$X;5A=V91Q4]J(CQA42)_I)C5':!E)H.5,W#DJHD]K,J-F]RX
MJ(EQ;1JK8G0:O9NVM[@A 6>\%O00Q7.)!M,9-@9QUV_%MP^U+'A/L+C!AFYS
M&RW6A8P/VGA$D,X]TR[[&>&]-Q[]7;*.+H>_1VNPIW;4/:F\>@ZO6)6.7+@/
MP%'(QZ)\_06Z0HA^4=_$W31Z!+&-X*#UAOH55&-#X3DRC5+DW6,L<[5L@GB'
MY^7*DU6>E:+[59H>/NBO<77HD;MW$@R5R@>/E%2#(,/'2"F\(66[K!HD<EYF
MQ2H%#;4"!R-5(XY3_\)K:4@'DR#\E#O*D4;C?&JT@NU"H3UG%)J8%3P-*<I(
M)Q7E*:@1:K>(E(9@"*X9S$ND<XM<(.$Z;.X14*RHO4)3H2*9^,B:ISM>21@3
M82'$KD_8W[Z <=I>*(U-GE%E,PRIH3@NQM]W9<S1E*9PH<-[KY0$FJD"^KI%
M1MG<H!-RJ[, D<1A"E1B3/9<O_?1PD8YI(/T!*&++LBJ3O/-62XAU."!4?/R
M5+A1F*/\YW__^]^_I,G=.S__\Y^_V.Q_]RT+8G(]U^S"M/Z&B<L5?RRU&L0A
M!X=;"/'PF" M7^K*T7^MP++"'[C%B_A]/MM%2<)[@GGX/_ZBP"O/S0U)6A<D
MV)N/OB&6FSQ 4N!WP&S.85L6SJ41R2<([' ["5KDMM/W)F>R >&AG)E(J(94
M>^YG^UHFE[^5XU'7?:)"L=W7J?LV!Q>+7)N^.ZVHI3W3\'MKUC :]<AT&P^I
MSUY67" 5',<.]M,I]['>U%N6T;X'5F@!A=3[> /U?=1NF\,3>!$=ZDR)L'QT
M8@=P3I*?#O562O8%PT_#F;XX-?'7(35Q]:F)NT-J8DA-#+JGI7ON,9E)-2,V
M[R9YYHH>72_2WA()L?5(GV3.LC-%\53Q7=JV-'AUCBO6(0R6$2>C&H_H&1;]
M8"N5]>/>I\Z4)I,P-GG-?/;2U<NTC_+LF>;9J2_H+9-J#?J-<_:2OG %O)'C
M$^BUL M-CS(\4/[W]H<$ ]&TZ_E#.!&QSKE!^H%8N"QVDG)@(EJU('^3.=N4
M:03FK(\WU235:M:)K^.>H5L&C@(696A<?)G#T.KQZ$NN Q7RQL/H7X4 3!.L
MPL0SK(IY,\_7.5TS6Y<O[Q<4%[D[1;T2DQZ<<J&X9]X*[8'4%>1?%&564F='
MMR!-8A%7._U>V_[.\Y($71+8FR5O9H59P[H-1KIH<R*$OA_>AK,?$^EDP#.<
M9::EG"P0&I RY?&(-RIM#8-2=8TMG%;<I3U$70N6:EW.#*0CR+<:9)XK"2C<
M!:'0!.U+K>N/CAQG):7E07O <K :4_2-E0+692MVG\XF!$9VR$NXQLNF<M2X
MGJKE O&)J^.@A9*(4:-^5M6XN!6>72&66>6K"HSY>6;0J@25=X*V#W[H9>L,
M%E,RNY1+#%YBHT6&,:<5*\*$EBX\>A/;>;%Q(1M<#C]2DDJ"/D-XXU9RS5W,
M/,(Z" =CL6@=+\ZX=5>WP&L9/F>7F\-T5NMPZ9.TN7!!&(SF"J&J#_+,3PEY
MRSF\]EFW<9' =^-"CPV*,(7X1@49 >=&L2%2U""H&@ D [:=_@8U4J]/^TI
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M2^17JJSGKNH55IC+#W)ZLKP!:TF'*,$^3%HZ=3[>;DZJ&GX^%YWU-;1R&P[
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M#Z05Z >$YIZBA: IV" CN["H#$:A1:I5&+RX=3N+7P:XP@T_KI"0*2,<<-.
M\/;QD+JFWJNXQ@+K9CHF!KJ5COC5^'#ZF4SRY!W:C@NVUX@#K@M!.<$_-H2
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M,\U?;O8<+ZU8OM8Y*B\]'%M'3!_0@3J"#D?@SA5N6$6 !<I=!/RI=K>CVM\
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M!V%+XP\<.ADN%IP\Z2/V3?S8Q(_G$S_Z:Q(_L!_$<#?3LX6MM;ICI*"KB([
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M347=\JD/FL($X &3ASI"VAU33"2XP<A8.%&63X35Z1B)"27589)/5TO*!U#
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MV+N0(1^R"V[=S]K]7ZS=WWLE_?%XH?NG=)O^-S7\LRK]3^O_ 5!+ P04
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MIYHR+@K5VHSS# JX\R/@_N&HF;'$<)"7!M11K!1T1.G*&#9C8&RW2*5!:5V
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MR+R<O,#',.+A:_+DDAWEGH#2UM[>,RSB*&ND!BX%ED!A>1?S-=VN66*':/0
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M[ LMY.T#]C96B_OL@CO_T%'^@QWEK]3?_?KFND'_<!/_ X?^4>??4$L#!!0
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M4[7X[4J.R%;/UB?XWZ$W,AO_#U!+ P04    "   C6Q9 XEKH2P#  #O"P
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MA,6G13"_!L>Z/:(+BLXWM4 =IFIZ^1M02P,$%     @  (UL614#OCK^"@
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M(0Z!1V=DT/A)1B$55ET)\T+2-Y9N:8YY\2XYMXU,@,XM.8#--C&:*"!2[,X
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M\BW05C'FU;5S1\?,^FM=L<^^V0W('Q<<18#@3S CA5<M4@^TA4@)OZ-3J4K
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M\@]02P$"% ,4    "   C6Q9="I AZ$S 0#=' @ "0              @ $
M    97@Q+3$N:'1M4$L! A0#%     @  (UL6;J]NWGC#   IU\   D
M         ( !R#,! &5X-2TQ+FAT;5!+ 0(4 Q0    (  "-;%E)\+(61@P
M -HZ   *              "  =)  0!E>#DY+3$N:'1M4$L! A0#%     @
M (UL6:K;C\]T"P  KS,   H              ( !0$T! &5X.3DM,BYH=&U0
M2P$"% ,4    "   C6Q9H?]2_DX:   :R@  "P              @ '<6 $
M9F]R;3@M:RYH=&U02P$"% ,4    "   C6Q9 XEKH2P#  #O"P  $0
M        @ %3<P$ <')P:"TR,#(T,3$P-RYX<V102P$"% ,4    "   C6Q9
M%0.^.OX*  " A@  %0              @ &N=@$ <')P:"TR,#(T,3$P-U]L
M86(N>&UL4$L! A0#%     @  (UL62#;3@_=!P  ^%X  !4
M ( !WX$! '!R<&@M,C R-#$Q,#=?<')E+GAM;%!+!08     "  ( -P!  #O
%B0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prph-20241107.xsd" xlink:type="simple"/>
    <context id="AsOf2024-11-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000868278</identifier>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-11-07" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-11-07" id="Fact000004">0000868278</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-11-07" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-11-07" id="Fact000010">2024-11-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-11-07" id="Fact000011">PROPHASE LABS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-11-07" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-11-07" id="Fact000013">000-21617</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-11-07" id="Fact000014">23-2577138</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-11-07" id="Fact000015">711     Stewart Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-11-07" id="Fact000016">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-11-07" id="Fact000017">Garden City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-11-07" id="Fact000018">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-11-07" id="Fact000019">11530</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-11-07" id="Fact000020">(215)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-11-07" id="Fact000021">345-0919</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-11-07" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-11-07" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-11-07" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-11-07" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-11-07" id="Fact000026">Common Stock, par value     $0.0005</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-11-07" id="Fact000027">PRPH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-11-07" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-11-07" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45494899407408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  07,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-21617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROPHASE
LABS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000868278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">23-2577138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">711
    Stewart Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Garden City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(215)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">345-0919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value
    $0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRPH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://prophaselabs.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>prph-20241107.xsd</File>
    <File>prph-20241107_lab.xml</File>
    <File>prph-20241107_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>27
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "PRPH",
   "nsuri": "http://prophaselabs.com/20241107",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "prph-20241107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "prph-20241107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prph-20241107_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://prophaselabs.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-11-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://prophaselabs.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
